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Abstract 
 
Although various anticancer therapeutic tools have been launched, such as 
immunotherapy and targeted therapy, newly developed drugs with 
antiproliferative/cytotoxic effects are still in demand; hence, newly discovered 
anticancer drugs with an improved pharmacological profile are needed to overcome 
drug resistance of cancer cells. This study focused on identifying and characterising 
novel polysaccharides isolated from the common cockle (Cerastoderma edule) with 
antiproliferative activity, using the cetylpyridinium chloride precipitation method. 
Marine polysaccharides have exhibited in-vitro potent antiproliferative activity, 
leading to induced apoptotic cellular death in three cancer cell lines, which are 
chronic myelogenous leukaemia, relapsed acute lymphoblastic leukaemia and 
mesothelioma of the pleural cavity with asbestos exposure. Structural analysis has 
confirmed the presence of glycosaminoglycan-like polysaccharides in cockle extracts 
with potent antiproliferative activity, which are susceptible to three classes of 
heparinase enzymes, which has not been seen previously, but not to chondroitinase 
enzymes. Cockle polysaccharide purification using anion-exchange chromatography 
has generated six peaks (1-6); however, only fraction 5 exhibited antiproliferative 
activity, which was determined to be susceptible to heparinase enzymes. Surprisingly, 
some sequence of resistance to heparinase was observed within cockle polysaccharide 
chains; therefore, a new type of marine-derived heparan sulphate/heparin-like 
polysaccharide with potent anticancer properties was suggested, as none of the 
mammalian glycosaminoglycans exhibited antiproliferative activity on cancer cell 
lines. Overall, the final structural characterisation did confirm the presence of 
fucosylated polysaccharide, N- and O-linked glycans, in addition to HS-like 
structures. These various chains made creating the final judgment about cockle 
polysaccharide structural elucidation very challenging because of sample complexity. 
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1. General introduction 
 
A cell is an organism’s smallest functional unit. They have different shapes and 
functions, but basic cellular structure is common in all cells. Mammalian cells are composed 
of an extracellular plasma membrane that encloses the cytoplasm and cellular contents from 
the extracellular compartments. The cytoplasm contains cellular organelles, which make up 
the cells internal structure, including the nucleus, the endoplasmic reticulum, the 
mitochondria, the Golgi apparatus, and other cellular vesicles. Depending on the type of cell, 
these cellular organelles perform specific cellular functions (Figure 1). 
 
 
Figure 1. Schematic diagram shows the cell strcuture. 
  
Briefly, the cell membrane is composed of lipids and proteins, and it is essential for 
normal cellular function, as it acts as a barrier that regulates the movements of substances to 
and from cells. The nucleus is separated from the cellular cytoplasm by a lipid bilayer 
membrane known as the nuclear envelope. Inside the nucleus, there is a fine structure known 
as deoxyribonucleic acid (DNA), which carries all genetic information, as the nucleus has the 
machinery to assemble the cells ribonucleic acid (RNA), which is released through nuclear 
envelope pores, in a process called gene expression to synthesise new protein. The 
mitochondria are the energy providers for cellular functions such as cell growth and motility. 
Mitochondria have outer and inner membranes. The outer membrane is smooth and regular, 
whereas the inner membrane is folded.  
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The endoplasmic reticulum (ER) is an extended system around the nucleus that is 
found next to the nuclear membrane. The ER can be classified according to its shape into 
rough endoplasmic reticulum (rER) and smooth endoplasmic reticulum (sER). Ribosomes are 
attached to the rER, which makes it important in protein synthesis as well as the addition of 
carbohydrates to proteins. On the other hand, the sER is responsible for the synthesis of 
lipids, hormones and storing calcium. The Golgi apparatus is composed of three flattened 
membranous sacs that are involved in a carbohydrate and protein modification process known 
as glycosylation. The Golgi apparatus is composed of three main faces: cis-face, cisternae, 
and trans-face. The Golgi apparatus also has an extended ER function, where transported 
vesicles pinch off the ER and fuse in the cis-Golgi before secretion; then, the Golgi modifies 
the protein and carbohydrate in cisternae and releases them as secretory vesicles to the trans-
face to the plasma membrane. Finally, the cell membrane has bound vesicles that are 
important to cellular function, such as lysosomes and peroxisomes. Lysosomes have 
hydrolytic enzymes that recycle cellular contents or materials have been taken up by 
endocytosis. Peroxisomes contain several different enzymes involved in various metabolic 
reactions, especially in energy metabolism. In addition, a peroxisome can utilise cellular 
hydrogen peroxide in oxidation reactions or eliminate it via its enzymes (Pocock et al., 2013). 
The extracellular matrix (ECM) is a network of proteins and fibres that are critical for 
normal cellular function. The ECM has various key functions, such as mechanical support for 
cellular integrity, control of cellular proliferation, basement membrane scaffolding for tissue 
renewal, and making the boundary between the epithelium and connective tissues. The ECM 
has two basic domains: the interstitial matrix and the basement membrane. The interstitial 
matrix is the area between cells to support cellular integrity, which mainly consists of fibres, 
collagen, and proteoglycans. The basement membrane is a specialised form of ECM which is 
highly condensed and organised layer around the epithelium and other cells that can do a 
specific biological function (Bosman and Stamenkovic, 2003). 
1.1. The chemical constituents of the body 
 
Multicellular organisms consist of 70% water, and the rest is a mixture of organic 
compounds. The organic and inorganic compounds consist largely of four major elements, 
oxygen, carbon, hydrogen, and nitrogen, which are combined to make a huge number of 
various biomolecules, such as carbohydrates, proteins, fat, minerals, and nucleic acids (Figure 
2) (Pocock et al. 2013). 
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Figure 2. The distribution of biomolecules in multicellular organisms. Water contributes 
about 70% of the living organism biomolecule, followed by proteins (16.8%), fats (16.5%), 
minerals (4.5%), carbohydrates (0.7%) and nucleic acids (0.4%) (Pocock et al., 2013)  
 
1.1.1. Carbohydrates 
 
Carbohydrates are the main source of energy. Carbohydrates consist of three basic 
elements, carbon, oxygen, and hydrogen, with the empirical formula (CH2O)n. Simple 
carbohydrates can be found freely in the blood, and complex carbohydrates are found 
attached to proteins or lipids. There are three classes of carbohydrates based on its chain 
length, which are monosaccharides, oligosaccharides, and polysaccharides (Nelson, 
Lehninger and Cox, 2008). 
1.1.1.1. Monosaccharides 
 
Monosaccharides are the simplest form of carbohydrates, which can be found in linear 
or ring forms. Monosaccharides are composed of three-carbons (known as triose), four-
carbons (tetrose), five-carbons (pentose), and six-carbons (hexose). In carbohydrate 
chemistry, when a carbon atom is double-bonded with an oxygen atom, that will form a 
carbonyl group, whose location can classify monosaccharides as either aldehydes or ketones. 
In aldehydes, the carbonyl group is at one end of the monosaccharide structure; by contrast, 
in ketones, the carbonyl group is present at any other position. For instance, glucose is an 
aldehyde, and fructose is a ketone (Figure 3). In addition, monosaccharides have chiral 
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carbon, which is defined as carbon that is attached to four different atoms or functional 
groups. Monosaccharides structural configuration can be in either a dextro-rotary (D) or levo-
rotary (L) isomer. In linear form, when the hydroxyl group on the bottom of chiral carbon is 
pointing to the right side, this is the D-configuration. In contrast, if the hydroxyl group on the 
bottom of the chiral carbon is pointing to the left side, this is the L-configuration (Bertozzi 
and Rabuka, 2009).  
 
Figure 3. Monosaccharides structural differences as aldehydes (glucose) or ketones (fructose) 
are assigned in blue colour, in addition to the difference in D- and L-configuration in glucose 
as an example in red colour (Nelson, Lehninger and Cox, 2008). 
1.1.1.2. Oligosaccharides  
 
Oligosaccharides are composed of small number of monosaccharides in ring form. 
Oligosaccharides are made up of short chains of monosaccharides attached with glycosidic 
linkages. Indeed, when two monosaccharides are attached together, they will form 
disaccharides (double sugars). These two monosaccharides are attached together via 
glycosidic linkage; for instance, lactose is composed of one galactose and one glucose 
attached together via glycosidic linkage (Figure 4). According to the glycosidic linkage type, 
molecules will have different structural properties and biological functions. Glycosidic 
linkage is formed between the anomeric carbon and a hydroxyl group from the attached 
compound; this will generate either - or β-glycosidic linkages in ring form, resulting in 
pyranose or furanose forms. Pyranose is defined as a six-membered ring of five carbons and 
one oxygen, by contrast, furanose is defined as five-member ring of four carbons and one 
oxygen (Bertozzi and Rabuka, 2009; Pastrana and Jauregi, 2017). 
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Figure 4. Lactose chemical structure as an example of disaccharide. It is composed of 
galactopytanose attached to glucopyranose via β-glyosidic linkage (Nelson, Lehninger and 
Cox, 2008). 
 
1.1.1.3. Polysaccharides  
 
Polysaccharides consist of long branched or unbranched chains of up to thousands of 
monosaccharides attached together via -/β- glycosidic bonds. Polysaccharides differ from 
each other by their monosaccharide building blocks, chain length, branching point, and type 
of linkage (Figure 5). Amylose and amylopectin polysaccharides are examples that show 
some of polysaccharides’ features. Amylose is composed of a chain of unbranched polymers 
of glucose (500–20,000 units) attached together via α (1→4) glycosidic linkages. In contrast, 
amylopectin is composed of a branched glucose polymer chain (2,000–200,000 units) 
attached together via α (1→4) and α (1→6) glycosidic linkages (Nelson, Lehninger and Cox, 
2008). 
Additionally, polysaccharides can be classified according to their monosaccharide 
building blocks into homo-polysaccharides and hetero-polysaccharides, which can combine 
any other polysaccharide features such as branching or unbranching, chain length and both 
types of glycosidic linkages. Homo-polysaccharides simply consist of only one type of 
monosaccharide along the chain. One example is glycogen, which is composed of repeating 
glucose units. In contrast, hetero-polysaccharides consist of more than one type of 
monosaccharide along the chain—for example, heparan sulphate, which consists of repeating 
glucosamine and uronic acid units (Figure 6)  (Nelson, Lehninger and Cox, 2008). 
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Figure 5. Demonstrate the main features that can be found in polysaccharide chain 
 
 
Figure 6. Schematic diagram showing polysaccharides classification according to 
monosaccharide building blocks, as homo-polysaccharide chain (A) that consists of repeating 
units of only one type monosaccharide or hetero-polysaccharide chain (B), which consist of 
more than one monosaccharide along the chain. Both (A) and (B) can have different chain 
lengths, glyosidic linkages, branching or unbranching features (Nelson, Lehninger and Cox, 
2008). 
 
Polysaccharides
Monosaccharides Building 
Block
Homopolysaccharides
Heteropolysaccharides
Chain Length
Amylose 
(500-20,000 glucose units)
Amylopectin
(2000- 20,0000 glucose 
units)
Branching
Unbranched
(Amylose 1→4 only)
Branched
(Amylopectin 1→4 and 
1→6)
Linkages
α-linkage
(Starch α-D-glucose)
β-linkage
(Cellulose β-D-glucose)
7 
 
1.1.1.3.1. Glycoconjugates 
 
Glycoconjugates are a type of polysaccharides composed of more than 10 
monosaccharides covalently attached to non-carbohydrate structures such as proteins and 
lipids via glycosidic linkages. There are several monosaccharides in nature that have the 
ability to conjugate with non-carbohydrates to form glycoconjugates (Table 1). 
Glycoconjugates can be classified into different categories according to their non-
carbohydrate molecule, such as glycolipids, glycoproteins, and proteoglycans. Glycolipids 
are defined as carbohydrate chains attached to lipids. Glycoproteins are defined as 
carbohydrate chains attached to polypeptide chains. Proteoglycans are a subclass of 
glycoproteins, which a particular type of amino-sugars, known as glycosaminoglycan, is 
attached to protein chains (Bertozzi and Rabuka, 2009). 
Table 1. Most common monosaccharides that can bind to a non-carbohydrate moiety to form 
glycoconjugates (Varki and Sharon, 2009). 
Monosaccharide Structure Example 
Pentoses Five-carbon D-xylose 
Hexoses Six-carbon D-glucose 
Hexosamine Hexose with an amino group at C-
2 
Glucosamine 
Deoxyhexose Six-carbon hexose without 
hydroxyl group at C-6 
L-fucose 
Uronic acids Hexose with negatively charged 
carboxylate group at C-6 
Glucuronic acid 
Sialic acids Nine-carbon N-acetylneuraminic 
acid 
 
1.2. Glycosaminoglycans 
 
Glycosaminoglycans (GAGs) are a group of long, unbranched hetero-polysaccharides 
consisting of repeated disaccharide units of uronic acid covalently attached to hexose-sugar 
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via glycosidic bonds. GAG structures are very diverse, and their synthesis is not template 
based, like that of proteins. What is more, each monosaccharide can acquire several structural 
modifications via various enzymes, which give GAGs their vast structural heterogeneity. For 
instance, a GAG chain can be composed of long polysaccharide chain with different 
glycosidic linkages between each monosaccharide, as well as the addition of various possible 
functional groups, as sulphates at different points. All these structural modifications give 
GAGs their structural heterogeneity and wide range of biological functions (Nelson, 
Lehninger and Cox, 2008). 
GAGs can be freely released or attached to core proteins to form glycoconjugates 
known as proteoglycans (PGs), these are found in the extracellular matrix, on the cell surface, 
and intracellularly. GAGs are covalently attached to the core protein polypeptides via N- or 
O-linkages by a process known as protein glycosylation. N-linked GAGs are usually attached 
to the core protein via asparagine (Asn) residues in the consensus peptide sequence Asn-X-
Ser/Thr; where X represents any amino acid; (Ser) represent serine and (Thr) represent 
threonine. These N-linked glycans can be divided into three main classes: hybrid, complex, 
and high-mannose glycans. On the other hand, O-linked glycans are usually attached to the 
hydroxyl group of Ser or Thr residues on core protein polypeptides (Figure 7) (Esko, 1991; 
Yayon et al., 1991; Nelson, Lehninger and Cox, 2008; Sarrazin, Lamanna and Esko, 2011). 
 
Figure 7. Schematic diagram showing GAGs attached to different core proteins at different 
locations. 
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1.2.1. Glycosaminoglycan biosynthesis 
 
GAGs can be biosynthesised from different forms of monosaccharide, such as 
hexosamines and uronic acids. Hexosamine sugars consist of hexose-sugar structure with an 
amine group replacing the hydroxyl group at carbon-2, and uronic acid is composed of 
hexose-sugar, where the hydroxyl group at carbon-6 is oxidised to form a carboxylate. Both 
biosynthesis pathways are crucial for GAGs biosynthesis and are therefore it’s been discussed 
below.  
1.2.1.1. Hexosamine biosynthesis pathway  
 
Hexosamines are composed of six-carbon sugar structures with an amine group 
attached to carbon-2. They are biosynthesised in cells via breakdown of polysaccharides to 
monosaccharides to be used as precursors in GAG synthesis. Glucose (Glc) will be used as an 
example to illustrate the synthesis of glucosamine (GlcNH2) (Figure 8). Initially, Glc carbon-
6 is phosphorylated to glucose-6-phosphate by hexokinase enzyme; then, the glucose-6-
phosphate is converted to fructose-6-phosphate via phosphohexose isomerase enzyme. Next, 
the fructose-6-phosphate is converted to glucosamine-6-phosphate by a rate-limiting enzyme 
known as glutamine-fructosamine transferase; this enzyme converts glutamine, which is used 
as an amino group donor, into glutamate, resulting in the formation of glucosamine-6-
phosphate. After that, the glucosamine-6-phosphate is converted to N-acetyl-glucosamine-6-
phosphate by glucosamine-6-phosphate-N-acetyl transferase, which transfers the acetyl group 
from acetyl-CoA to glucosamine-6-phosphate C-2, resulting in N-acetyl-glucosamine-6-
phosphate. Afterwards, this N-acetyl-glucosamine-6-phosphate is converted to N-acetyl-
glucosamine-1-phosphate by phosphoacetyl-glucosamine mutase. Finally, the N-acetyl-
glucosamine-1-phosphate is converted to uridine diphosphate (UDP)-N-acetyl-glucosamine 
by UDP-N-acetylglucosamine pyrophosphorylase. This UDP-N-acetyl-glucosamine can be 
converted to UDP-N-acetyl-galactosamine by UDP-galactose-4-epimerase, which can be 
used as a precursor for synthesising GAGs, when required (Schleicher and Weigert, 2000). 
1.2.1.2. Uronic acids biosynthesis pathway 
 
Uronic acids are derived from hexose-sugars—for example, Glc, galactose (Gal), and 
mannose (Man)—where the hydroxyl group at C-6 of the hexose-sugar is oxidized to a 
carboxyl group to form uronic acids, such as glucuronic acid (GlcA), galacturonic acid 
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(GalA), or mannuronic acid (Figure 8). GlcA biosynthesis occurs in many cells, starting with 
the phosphorylation of Glc by hexokinase transferase to glucose-6-phosphate, which is then 
converted to glucose-1-phosphate by phosphoglucomutase enzyme; then, glucose-1-
phosphate is converted to UDP-glucose by UDP-glucose pyrophosphorylase. Oxidation of 
the hydroxyl group at C-6 of the UDP-glucose by UDP-glucose dehydrogenase leads to the 
formation of UDP-glucuronic acid. This UDP-glucuronic acid is used as a substrate for GAG 
synthesis (Dutton, 1966). GlcA can be further modified to L-iduronic acid (L-IdoA) by 
epimerization of glucuronic acid via D-glucuronyl C5-epimerase enzyme, which is the key 
enzyme in converting GlcA to L-IdoA (Li, 2010). 
 
Figure 8. Schematic diagram demonstrates an example of the biosynthesis pathway of 
glucosamine or glucuronic acid from glucose. 
 
1.3. Core protein glycosylation 
 
Protein glycosylation is defined as the addition of sugar molecules to the polypeptide 
sequence of the core protein in order to determine a specific cellular function. Glycosylation 
results in the attachment of different types of monosaccharides to a core protein backbone. 
The glycosylation process is non–template-driven, so the addition of a particular saccharide 
sequence to the chain is random, thus making the structure of these PGs very diverse. 
Proteins are targeted for various biological functions, so they can be modified 
according to cell function as well as extracellular secretions. The core protein is synthesised 
in the rER, then transported via vesicles to the Golgi apparatus, where glycosylation process 
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takes place (Esko et al., 1987; Stanley, Schachter and Taniguchi, 2009). However, Prydz and 
Dalen (2000) suggested that the chain could start earlier in the rER. 
Principally, protein glycosylation requires various monosaccharides to be used as 
saccharide donors, for example, hexoses, hexosamines and uronic acids. These substrates are 
synthesised in the cytosol and attached to UDP as derivative precursors such as UDP-
GlcNAc, UDP-GlcA, UDP-Xyl, and UDP-Glc. These substrates from endogenous or 
exogenous origins enter the Golgi via antiporter channels from the cytosol to be available for 
protein glycosylation (Figure 9) (Hirschberg, Robbins and Abeijon, 1998). 
 
Figure 9. Schematic diagram shows the antiporter mechanism of monosaccharides and the 
phosphate donor 3′-phosphoadenosine 5′-phosphosulphate (PAPS) precursors in Golgi 
apparatus membrane. As the transporters are functionally like antiporters, except for PAPS, 
the antiporter is unknown (Hirschberg, Robbins and Abeijon, 1998). 
 
In the Golgi, protein glycosylation takes place in three consecutive phases—chain 
initiation, chain polymerisation, and chain modification. Chain initiation starts by enzymatic 
transfer of the sugar residues to the polypeptide residues of the core protein, which results in 
either N-linked or O-linked glycans. Next, the chain is elongated by various enzymes that add 
more monosaccharides, such as hexosamines and uronic acids. Finally, the chain acquires 
multiple modifications, resulting in non–template-driven modifications that gives GAGs their 
unique structure (Figure 10). This process is highly dependent on the cell type and the type of 
GAG that is required for the biological function (Hassell, Kimura and Hascall, 1986).  
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Figure 10. Schematic diagram of protein glycosylation process: (A) Represents the core 
protein formation in the endoplasmic reticulum. (B) The initial addition of saccharides to the 
polypeptide residues of the core protein that can be added from the rER or Golgi apparatus, 
following by chain elongation (C) and chain modification (D). Finally, according to the cell-
type, the fully synthesised glycosylated core protein can be secreted to its location (Silbert, 
1966). 
 
1.3.1. N-linked glycan 
 
If a carbohydrate sequence attaches to the polypeptide residues of core protein via N-
glyosidic linkages, this conjugation is known as an N-linked glycan. This process starts in the 
rER surface via a process known as the Dolichol-phosphate pathway, followed by addition of 
the sugar sequence to the Asn residues in the core protein sequence. Afterwards, this 
glycoconjugated sequence travels to the cis-Golgi, where the first step of sequence 
modification takes place, which is known as sequence early modifications. Then this early 
modified sequence travels to the medial-Golgi where further modifications take place, which 
is known as sequence late modification. Finally, before secretion to its final destination, the 
mature sequence is able to travel to trans-Golgi for its final decorations/modifications such as 
addition of chain branches, sulphate groups and sialic acids among other decorations (Figure 
11) (Stanley, Schachter and Taniguchi, 2009). 
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Figure 11. Schematic diagram showing N-linked glycan biosynthesis following Dolichol-
phosphate pathway (Stanley, Schachter and Taniguchi, 2009). 
 
1.3.1.1. Dolichol precursor formation 
 
N-linked glycans are synthesised through the Dolichol-phosphate pathway. Dolichol is a 
poly-isoprenol lipid compound, which is composed of five-carbon isoprene units with a 
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phosphate group (Figure 12). The N-glycan synthesis process starts in the rER, where 
Dolichol-phosphate is facing the cytoplasm to allow the addition of different sugar precursors 
to Dolichol-phosphate (Dolichol-P), for instance, UDP-N-acetylglucosamine (UDP-GlcNAc).  
 
Figure 12: Dolichol-phosphate chemical structure that is composed of multiple isoprene 
monomers that can reach 19 units in mammalian cells (Stanley, Schachter and Taniguchi, 
2009). 
This step is catalysed by GlcNAc-1-phosphotransferase, which transfers GlcNAc-1-P 
from UDP-GlcNAc, resulting in an attached GlcNAc-phosphate unit to the sequence from its 
UDP precursor, as Dolichol-P-P-GlcNAc, followed by addition of another GlcNAc unit to 
become Dolichol-P-P-GlcNAc-GlcNAc. This is followed by the addition of five Man 
residues from its guanosine diphosphate (GDP) precursor, which leads to formation of the 
sequence of a Dolichol diphosphate high-mannose structure, as [Dolichol-di-phosphate-
GlcNAc(2)-Man(5)]. Afterwards, this Dolichol high-mannose structure is translocated to face 
the rER lumen by an enzyme known as flippase. 
Then, four additional Man residues, which are donated from Dolichol-P-Man, by the 
action of mannosyltransferases, and three Glc residues are donated from Dolichol-P-Glc by 
glucosyltransferases. Those Man and Glc units are formed in the cytoplasm from GDP-Man 
and UDP-glucose, respectively, transferred to Dolichol-phosphate and flipped to the rER 
lumen. Finally, after the addition of these sugar residues, Dolichol-diphosphate will be 
mature to be act as an N-glycan precursor, which acquires this formula [Dolichol-P-P-
GlcNAc(2)-Man(9)-Glc(3)] (Figure 13). 
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Figure 13: Schematic diagram showing synthesis of [Dolichol-P-P-GlcNAc(2)-Man(5)] after 
flipping to the rER lumen, followed by chain elongation by addition of 4 Man residues as 
well as 3 Glc units after several chain modifications as a result of [Dolichol-P-P-GalNAc(2)-
Man(9)-Glc(3)] (Stanley, Schachter and Taniguchi, 2009). 
 
1.3.1.2. N-glycan precursor addition to the polypeptide sequence 
 
N-glycan precursor [Dolichol-P-P-GlcNAc(2)-Man(9)-Glc(3)] is ready to be attached to 
the polypeptide region of Asn-X-Ser/Thr via N-glycosidic linkage. Oligosaccharyltransferase 
(OST) enzyme will catalyse the cleavage of the sugar sequence to release it from Dolichol-P-
P, resulting in covalent bonds between sugar complex and Asn [Asn-GlcNAc(2)-Man(9)-
Glc(3)]. 
1.3.1.3. Early-sequence modifications 
 
Early-sequence modifications start by removing most of the sugar residues from the 
polypeptide sequence and prepare the sequence to be transferred to the cis-Golgi via vesicles. 
The process begins with the removal of Glc residues by the action of α-glucosidases-I and II, 
which remove one terminal Glc (1→2) and two inner Glc (1→3), respectively. After the 
removal of glucose residues [Asn-GlcNAc(2)-Man(9)], an additional ER enzyme called -
mannosidase-I is responsible for removing one terminal Man unit (1→2) before the 
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sequence pass through cis-Golgi as [Asn-GlcNAc(2)-Man(8)]. Most N-glycans that pass 
through the cis-Golgi can be further modified. In the cis-Golgi, further removal of the 
remaining glucose and Man residues by endo-α-mannosidase (1→2) results in [Asn-
GlcNAc(2)-Man(5)], however, Man inhibitors might inhibit the removal of all mannose 
residues, which result in uncompleted chain that cannot be modified any further. At this 
stage, three types of N-glycans can be formed: oligomannose and hybrid and complex 
glycans (Figure 14). Oligomannose will not undergo further modifications, whereas hybrid 
and complex glycans will be further modified (Stanley, Schachter and Taniguchi, 2009). 
 
 
Figure 14. Schematic diagram shows three possible modified glycan structures, namely 
oligomannose, complex and hybrid (Stanley, Schachter and Taniguchi, 2009). 
 
1.3.1.4. Late-sequence modifications 
 
In the cis-Golgi, the addition of GlcNAc to the Man α(1→3) by the action of N-
acetyl-glucosaminyl transferase-I (GlcNAcT-I) catalyses the addition of GlcNAc to the 
sequence of [Asn-GlcNAc(2)-Man(5)], resulting in [Asn-GlcNAc(2)-Man(5)-GlcNAc]. This 
sequence is crucial for further modifications on the sequence in the medial-Golgi, which 
modifies the chain to form hybrid or complex glycans. In the medial-Golgi, immediately 
following this step, the majority of N-glycans containing terminal α(1→3) and α(1→6) Man 
will be trimmed by α-mannosidase-II enzyme to yield [Asn-GlcNAc(2)-Man(3)-GlcNAc]. 
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Afterwards, additional GlcNAc will be added to the sequence by N-acetyl-glucosaminyl 
transferase-II (GlcNAcT-II) to yield [Asn-GlcNAc(2)-Man(3)-GlcNAc(2)]. This final sequence 
is responsible for the formation of complex N-glycans. On the other hand, terminal (1-6) 
and (1-3) mannoses on the N-glycan sequence remain intact or incomplete action of α-
mannosidase-II will result in generating the hybrid N-glycan structure [Asn-GlcNAc(2)-
Man(4)-GlcNAc] (Stanley, Schachter and Taniguchi, 2009). 
1.3.1.5. Trans-Golgi modification 
 
In the Trans-Golgi, N-glycans will acquire various chain branches. Initially, complex 
N-glycans can acquire additional GlcNAc branches at C-4 of core Man (1→3) and at C-6 of 
core Man (1→6) by the action of N-acetyl-glucosaminyl transferase-IV (GlcNAcT-IV) and 
N-acetyl-glucosaminyl transferase-V (GlcNAcT-V), respectively. In addition to these two 
enzymes N-acetyl-glucosaminyl transferase-IX (GlcNAcT-IX), N-acetyl-glucosaminyl 
transferase-Vb (GlcNAcT-Vb) can catalyse the addition of GlcNAc to C-6 of core Man 
(1→6), and to C-6 of the core Man (1→3). Another possible branching point can be found 
in both complex and hybrid N-glycans with the addition of GlcNAc to β-Man by the action of 
GlcNAcT-III. These enzymes can result in highly branched and complex N-glycan structures, 
which can have further sequence modifications (Stanley, Schachter and Taniguchi, 2009). 
The second possible modification to the sequence can be the addition of different 
sugar residues to the sequence. For example, fucose can be added to the GlcNAc adjacent to 
the Asn. Fucosylation occurs by an enzyme fucosyl-transferase-III, which catalyse the 
addition of fucose (1→3) and/or fucosyl-transferase-VIII, which catalyses the addition of 
fucose (1→6). In plants, fucose can only be added to the α(1→3) GlcNAc adjacent to the 
Asn, in contrast, invertebrates can acquire both fucose in both linkages α(1→3) as well as 
α(1→6). Furthermore, xylose (Xyl) can be added to the sequence by the action of xylosyl-
transferase, which catalyses the addition of Xyl (1→2) to the core β-Man. Thirdly, chain 
elongation can be achieved by addition of β-linked Gal building blocks [-3 Gal 
β(1→4)GlcNAc β1-] known as N-acetyllactosamine. (Stanley, Schachter and Taniguchi, 
2009). 
Finally, the most important part of N-glycans is known as chain decorations. Chain 
decorations can be achieved by the addition of sialic acid, fucose, a sulphate group, and -
linked GalNAc. Chain decoration features α-linkages that would facilitate glycan presentation 
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and interaction with various lectins, as this feature is shared with O-linked glycans (Stanley, 
Schachter and Taniguchi, 2009). 
1.3.2. O-linked glycan 
 
O-linked glycan chains are initiated in the Golgi apparatus, in contrast to N-linked 
glycans which initiate its chain in the rER. O-linked glycans do not require Dolichol-
diphosphate to initiate its chain; in addition, there is no particular sugar sequence to be 
transferred to the amino acid residues. However, the addition of sugars to the O-linked chain 
heavily depends on the cell-type, which has the specific sugar transferase enzymes to transfer 
it to the amino acid residues.  O-glycans are linked to the core protein commonly via Ser or 
Thr residues, which make it very challenging to analyse and predict within the sequence 
(Steen et al., 1998). 
Different sugar residues can attach to the core protein to initiate the proteoglycan 
sequence. For instance, O-Xyl can be the first monosaccharide attached to the hydroxyl group 
of Ser or Thr by the action of Xyl-transferase, which catalyses the addition of a Xyl residues 
from its UDP-Xyl precursor to Ser or Thr, resulting in the first glycosylation of the core 
protein as Ser-O-β-Xyl. Then, the chain will be elongated and modified according to cell type 
and the required proteoglycan (Brockhausen, Schachter and Stanley, 2009). 
1.4. Glycosaminoglycan classification 
 
The literature has distinguished six types of GAGs based on their repeating 
disaccharide units: heparan sulphate (HS), heparin, chondroitin sulphate (CS), dermatan 
sulphate (DS), keratan sulphate (KS), and hyaluronan (Rabenstein, 2002). Hyaluronan is 
structurally linked to GAGs; however, it is not bound to a core protein as a side chain; hence, 
it is not considered a proteoglycan (Höök et al., 1984). 
1.4.1. HS 
 
HS is biosynthesised in almost all mammalian cells with molecular weight 10–70 
kDa, and it is found both on the cell surface and in the extracellular matrix. The most 
common repeating disaccharide building block is thought to be [GlcA (1→4) GlcNH2], 
chemically formulated as [→4 β-D-GlcA (1→4) α-D-GlcNAc (1→]. Although the HS chain 
can acquire different structural modifications at different position, the GlcA is usually found 
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non-sulphated, and the GlcNH2 is mainly N-acetylated. Other typical modifications include 
the epimerisation of GlcA to IdoA and the addition of the sulphate groups in a number of 
positions (Rabenstein, 2002; Köwitsch, Zhou and Groth, 2018).  
 
Figure 15.  HS common disaccharide structure. During the modification phase, GlcA can 
acquire sulphate group at C-2, while GlcNH2 can acquire sulphate group at C-3 and/or C-6 
and the amino group (C-2) can be sulphated or acetylated, depending of cell function (Höök 
et al., 1984). 
1.4.1.1. HS biosynthesis pathway 
 
The HS chain is biosynthesised in the Golgi apparatus as a long polymer (50–200 
disaccharide units) in three consecutive phases: chain initiation, chain polymerisation, and 
chain modification. The chain initiation phase starts by the addition of the basic 
tetrasaccharide linkers which are Xyl, two Gal residues, and GlcA—to the Ser/Thr residues 
of the core protein via O-linkage. Four enzymes are involved in this process, which are 
Xylose-transferase, galactose-transferase-I, galactose-transferase-II, and glucuronic-acid-
transferase-I (Figure 16) (Rabenstein, 2002). Xylose-transferase enzyme catalyses the 
addition of Xyl from UDP-Xyl to the serine residues via O-linkages; then, two Gal residues 
are added by galactose-transferase-I β(1→4) and galactose-transferase-II β(1→3); and 
finally, GlcA is added by the action of glucuronyltransferase-I enzyme β(1→3) (Prydz and 
Dalen, 2000). 
Subsequently, chain polymerisation starts with the addition of the first GlcNAc 
(1→4) by GlcNAc-transferase-I, which control HS-GAG synthesis, followed by the 
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addition of GlcA (1→4) by an exotoxin like glycosyltransferase-3 (EXTL3). Next, the chain 
is extended by the addition of various GlcA and GlcNAc from their corresponding UDP-
precursors to make the disaccharide building blocks of HS by the action of the copolymerase 
enzymes transmembrane glycosyltransferase EXT1 and EXT2. After the HS chain is 
extended, it is ready for the modification phase, which gives HS its unique structure (Lin, 
2004). 
The chain modification phase undertakes a series of adjustments and modifications to 
the whole sequence, including deacetylation, acetylation, sulphation, and epimerization. N-
deacetylase and N-sulphotransferase, which are a group of enzymes that catalyse the transfer 
of sulphate groups to their respective sites from the sulphate group universal donor PAPS, 
lead the removal of the acetyl group from GlcNAc and add a sulphate group to the free amino 
group, resulting in the generation of sulphated chain. Epimerization of GlcA by C-5 
epimerase enzyme converts GlcA to IdoA. Further sulphation can take place at different 
positions of the chain via specific sulphotransferases (Lin, 2004). 
The uronic acid can be further modified by O-sulphation at C-2 and/or C-3 as 
GlcA(2S/3S), in addition to the epimerised IdoA, which can acquire more sulphates at C-2/C-
3. On the other hand, β-D-GlcNAc can be either acetylated or N-sulphated as (GlcNS). Both 
structures can acquire 6-O-sulphate to become GlcNAc(6S) or GlcNS(6S). However, only 
GlcNS(6S) can be further modified by the addition of 3-O-Sulphate to become GlcNS(3,6S)  
(Rabenstein, 2002). 3-O-Sulphation and/or 6-O-Sulphation of the GlcNAc occur via 3-O-
Sulphotransferase and 6-O-Sulphotransferase, respectively (Blackhall et al., 2001; 
Rabenstein, 2002; Lin, 2004). 
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Figure 16. HS biosynthesis pathway in Golgi apparatus that follow HS three phases, namely 
chain initiation, chain polymerization and chain modification. HS chain starts by addition of 
tetrasaccharide linker, which is Xyl-Gal-Gal-GlcA, to Ser or Thr residues. Following chain 
polymerization, where addition of GlcA and GlcNH2 to extend the HS chain. Finally, chain 
modification, where several possible modifications can take place to give HS its unique 
structure according to cell type, for instance, epimerisation, deacetylation, sulphation for both 
the GlcA/IdoA and the GlcNH2 (Lin, 2004). 
 
Lastly, HS chain modifications are highly dependent on the cellular function, so the 
HS chain varies along the proteoglycan in terms of HS chain length and sulphation patterns. 
HS chain modifications occur in clusters, which means the chain can be divided into different 
modified domains across the proteoglycan. These domains are referred to as N-sulphated 
(NS), N-acetylated (NA), and mixed domains (NA/NS). NS-domains are characterised by 
highly sulphated saccharides on both GlcA and GlcNH2, the NA-domain is characterised by a 
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highly acetylated sequence, and NS/NA contains a mixture of variable sulphated and 
acetylated regions. All these variable domains are non–template-driven, which results in 
different HS chains, making HS chain sequencing very heterogeneous (Nelson, Lehninger 
and Cox, 2008; Esko, Kimata and Lindahl, 2009).  Following successful assembly of the 
chain in the Golgi apparatus, cells secrete HS-PG to different locations, such as the cell 
membrane. Recently identified cell membrane endosulphatases can alter the HS chain on the 
cell membrane by removing 6-O-sulphate from GlcNH2 residues (Lamanna, 2008).  
1.4.2. Heparin 
 
Heparin is biosynthesised in connective tissues in mast cells attached to a unique 
intracellular core protein known as serglycin (Volpi et al., 2014). When a mast cell is 
stimulated, it releases heparin by exocytosis, resulting in unfractionated heparin with 
molecular weight 12-15 kDa. The most common heparin disaccharide formula is [IdoA 
(1→4) GlcNH2], chemically formulated as [→4) α-L-IdoA(2S) (1→4) α-D-GlcNS (1→], 
where IdoA is mostly sulphated at C-2, and GlcNH2 is NS, with additional sulphate groups at 
C-3 and C-6 can be added to the chain (Figure 17). Hence, heparin is known to be more 
sulphated than HS and carry high negative charge along the chain (Sasisekharan and 
Venkataraman, 2000; Sasisekharan et al., 2002; Köwitsch, Zhou and Groth, 2018). 
 
Figure 17. Heparin common disaccharide building blocks structure. During modification 
phase, IdoA can acquire a sulphate group at C-2, while GlcNH2 can acquire sulphate group at 
C-3 and/or C-6, however, the amine group is more likely sulphated or to a lesser extend 
acetylated, depending on cell function (Höök et al., 1984). 
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1.4.2.1. Heparin biosynthesis pathway 
 
Heparin is biosynthesised in the Golgi apparatus in a similar biosynthesis pathway to 
that of HS, including chain initiation, chain polymerisation, and chain modification. 
However, during chain modification, the heparin chain undergoes additional modifications by 
N-deacetylation and N-sulphation of the GlcNH2, as well as more epimerisation by the C5-
epimerase enzyme, leading to conversion of about 70% of the GlcA to IdoA. Hence, the 
heparin chain has a higher frequency of sulphated IdoA than HS (Sugahara and Kitagawa, 
2002). 
1.4.2.1.1. Enzymatic degradation of HS/heparin chain 
 
HS and heparin are secreted to the ECM as fully synthesised chains. However, some 
chains are shed from the cell through proteolytic cleavage of the core protein and endocytosis 
enzymes such as heparinases. Heparinase enzymes are endoglycosidase enzymes that cleave 
the glycosidic bonds between GlcNH2 (1→4) and uronic acid in both heparin and HS chains, 
resulting in unsaturated disaccharides with double bonds between C-4 and C-5 of the uronic 
acid (Figure 18). The heparinase gene in human chromosome 4 is known as HPSE, which is 
expressed by the lacrimal gland, lens, cornea, epithelium, and other tissues. Secreted 
heparinase is 508 amino acids long, with approximately 57.7 kDa (Zhang et al., 2010). 
Heparinase was extracted from bacteria Flavobacterium heparinum, which releases 
enzymes that cleave both HS- and heparin-containing molecules. There are three classes of 
heparinase enzymes that can cleave heparin/HS (1→4) glycosidic linkage, which are 
heparinase-I, heparinase-II and heparinase-III. Heparinase-I is highly specific to this 
sequence [α-D-GlcNS (1→4) β-D-GlcA(2S)/α-L-IdoA(2S)]. Heparinase-II is thought to be 
the only enzyme that can cleave the glycosidic linkage of [α-D-GlcN(S/Ac) (1→4) 
unsulphated or sulphated uronic acid]. Heparinase-III can hydrolyse the glycosidic linkage 
between [α-D-GlcNAc/(2S) (1→4) β-D-GlcA] (Linhardt et al., 1990). 
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Figure 18. Heparinase reaction pathway. This figure shows the heparinase enzyme that 
catalase the elimination of polysaccharides containing heparin/HS α(1→4), resulting in 
unsaturated oligo- and disaccharides. 
 
1.4.3. CS 
 
CS is expressed in the cell membrane, intracellularly, and in the ECM. It can be found 
covalently bonded to the core protein to form CS-proteoglycan (CSPG). CS common 
repeating disaccharide units are composed of [GlcA (1→3) GalNH2,], with chemical formula 
[→4 β-D-GlcA (1→3) β-D-N-GalNAc (1→] (Mizumoto, Yamada and Sugahara, 2015). In 
addition, the CS chain can acquire a high negative charge, as it can acquire several sulphates 
at different positions on both GalNH2 and GlcA, in addition to the hydroxyl group on the 
GlcA (Figure 19) (Huang et al., 2003). 
25 
 
 
Figure 19. CS common disaccharide building block structure. During the modification phase, 
GlcA can acquire sulphate group at C-2, and GalNH2 can acquire sulphate group at C-4 
and/or C-6 and the amino group either can be sulphated or acetylated, depending on cell 
function (Höök et al., 1984). 
 
1.4.3.1. CS biosynthesis pathway 
 
Basically, the CS chain synthesis follows a similar synthesising pathway to HS and 
heparin; however, the CS chain is initiated by the addition of GalNAc to the tetrasaccharide 
linker region. After the addition of the tetrasaccharide linkers to the core protein sequence, 
β(1→4) N-acetylgalactosaminyltransferase-I and β(1→3) glucuronosyltransferase-II—which 
catalyse the addition of GalNAc and GlcA, respectively, from their UDP-precursors—create 
the CS backbone. Then, the CS chain undergoes polymerisations, which result in several 
forms of modified CS structures (Bülow and Hobert, 2006). 
CS has been identified to have several isomers according to the disaccharide 
posttranslational modifications. Some CS isomers are common in mammals, and others are 
rare or not found in mammalian cells (Table 2). Common CS subtypes are CS-A, CS-B, CS-
C, CS-D, and CS-E. CS-A is composed of [GlcA-GalNAc(4S)], and CS-C is composed of 
[GlcA-GalNAc(6S)]. CS-B can be distinguished from other CS isomers due to its 
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epimerization of the GlcA to IdoA [IdoA(2S)-GlaNAc(4S)/(6S)] (Lamari and Karamanos, 
2006). CS-D structurally possess a disaccharides unit [GlcA(2S)-GalNAc(6S)] (Nadanaka et 
al., 1998). Finally, CS-E has repeated disaccharide structure units [GlcA-GalNAc(4,6S)] 
(Iwata, 1969).  
The rarest CS posttranslational modifications have been identified in marine 
invertebrates, including CS-K, CS-L, and CS-M. CS-K was isolated from king crab cartilage 
(Tachypleus tridentatus), which has unique disaccharides that contain 2-O-sulphated or 3-O-
sulphated GlcA and GalNS or GalNAc(4S)  (Sugahara et al., 1996). CS-L has unique 3-O-
sulphated GlcA, and GalNH2 is acetylated with 6-O-sulphated structure [GlcA(3S)-
GalNAc(6S)]. Finally, CS-M is characterised by 3-O sulphated GlcA, and the GalNH2 is N-
acetylated with 4-O-sulphated structure [GlcA(3S)-GalNAc(4S)] (Lamari and Karamanos, 
2006). 
According to Vieira & Mourão (1988), a novel marine sourced CS chain with 
branched fucose was discovered from sea cucumber (holothurian), which was characterised 
as fucosylated-CS. Fucose is attached to the GlcA via (1→3) glycosidic linkage, which 
make CS resistant to certain CS-degrading enzymes (Pomin, 2015; Ustyuzhanina et al., 
2015). 
Table 2. Different CS isomers. 
Chondroitin sulphate subtypes Structure 
CS-A GlcA-GalNAc(4S) 
CS-B IdoA(2S)-GlaNAc(4S)/(6S) 
CS-C GlcA-GalNAc(6S) 
CS-D GlcA(2S)-GalNAc(6S) 
CS-E GlcA-GalNAc(4S,6S) 
CS-K GlcA(2S/3S)-GalN(S)/(4S) 
CS-L GlcA(3S)-GalNAc(6S) 
CS-M Glc(3S)-GalNAc(4S) 
 
1.4.4. DS 
 
DS is expressed in many cells, and it can be found in high quantities in the skin 
(Trowbridge and Gallo, 2002). The basic disaccharide building block is composed of [IdoA 
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(1→3) GalNH2], chemically formulated as [→4 -L-IdoA (1→3) β-D-GalNAc (1→] (Figure 
20) (Sugahara et al., 2003). Although 80–90% of the DS chain’s uronic acid is epimerised to 
IdoA by C-5 epimerase enzyme, DS is considered as subtype of CS. In addition, the DS chain 
can acquire sulphate group at different positions on both IdoA and GalNH2, which makes it 
highly negatively charged (Figure 20). 
 
Figure 20. DS common disaccharide building blocks structure. During the modification 
phase, IdoA can acquire a sulphate group at C-2, and GalNH2 can acquire a sulphate group at 
C-4 and/or at C-6 and the amino group (C-2) can be either acetylated or sulphated, depending 
on cell function (Höök et al., 1984). 
 
1.4.4.1. Enzymatic degradation of CS/DS 
 
Human chondroitin sulphatases are hydrolases enzymes, which are lysosomal and 
microsomal enzymes that can be found in various cells such as fibroblasts and leukocytes 
(Bond et al., 1997). These enzymes can hydrolyse CS-A, CS-B, and CS-C chains, resulting in 
the release of unsaturated disaccharides. In case of enzyme deficiency in humans, mainly CS 
and, to a lesser extent, DS and hyaluronic acid are accumulated in tissues (Linhardt et al., 
2006).  
A CS/DS degrading enzyme, known as chondroitinase-ABC, which is extracted from 
bacteria Proteus Vulgars. Chondroitinase-ABC is a broad-spectrum endoglycosidase that can 
28 
 
degrade chondroitin-4-sulphate (CS-A), dermatan sulphate (CS-B), chondroitin-6-sulphate 
(CS-C) and, to a lesser extent, hyaluronan. Chondroitinase-ABC can catalyse the elimination 
of polysaccharides containing a glycosidic linkage between [β-D-GalN (1→4) β-D-GlcA/-α-
L-IdoA], resulting in unsaturated disaccharides (Figure 21) (Salyers and O’Brien, 1980; 
Huang et al., 2003).  
 
Figure 21. Chondroitinase-ABC reaction pathway. chondroitinase-ABC enzyme catalase the 
elimination of polysaccharides containing CS/DS chain β(1→4), resulting in unsaturated 
oligo- and disaccharides. 
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Figure 22. Schematic figure shows CS/DS biosynthesis pathway. Chain starts by addition of 
O-linked tetrasaccharides to Ser residues on the core protein. According to the cell type, 
specific enzymes catalyse the synthesis of either CS or DS. 
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1.4.5. KS 
 
KS was first isolated from the cornea of a cow (Suzuki, 1939), then Meyer et al. 
(1953)  isolated KS from bovine cornea, characterising it as keratosulphate, which refers to 
both sulphated disaccharide units of KS at Carbon-6. KS is a unique GAG type, as it lacks 
uronic acid residues on its basic structure, which consists of a linear polymer of repeated 
disaccharides of Gal and GlcNH2 [→3) β-D-galactose (1→4) β-D-GlcNAc (1→] (Figure 23). 
 
Figure 23. KS common disaccharide building blocks structure. During the modification 
phase, Gal can acquire sulphate group at C-6 and/or sialic acid at C-3, and GlcNH2 can be 
capped with sialic acid at C-4, fucose at C-3 and/or sulphate group at C-4, C-6 and/or C-3 
and the amino group (C-2) can be either acetylated or sulphated, depending on cell function. 
(Meyer et al., 1953; Funderburgh, 2000; Meininger et al., 2016). 
 
1.4.5.1. KS classification and biosynthesis pathway 
 
After the initial isolation of KS from bovine cornea, keratan sulphate proteoglycan 
(KSPG) was isolated from other tissues such as cartilage, which resulted in the discovery of 
various types of KS. Hence, KS was found to bind different core proteins in both N- and O-
linked manners. As a consequence, KS was classified according to its linkages to the core 
protein into KS-I, KS-II, and KS-III (Krusius et al., 1986). 
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KS-I was first identified in the cornea as N-linked to the core protein via Asn 
residues, with molecular weight 20–25 kDa. The KS chain can acquire sulphate group on 
both GlcNAc and Gal anywhere on the chain. KS-I can be found non-sulphated, mono-
sulphated, and di-sulphated by the action of sulphotransferases that catalyse the addition of 
sulphate groups (Esko, Kimata and Lindahl, 2009). KS-II is found in bovine articular 
cartilage, which has major disulphated pattern of sulphation, which act as cell surface ligands. 
It is found linked to the core protein, where the GalNAc is O-linked to Ser/Thr residues, in 
addition, Gal C-3 is usually capped with sialic acids, but GlcNAc C-3 can also be partially 
capped with sialic acids. Finally, KS-III was found to be O-linked to the core protein in the 
brain via mannose linked to Ser/Thr residues. Therefore, KS subtypes are not tissue-specific, 
it depends on the linkage structure (Funderburgh, 2000).  
The KS chain can have variable length and sulphation patterns. Chain length is 
managed by the addition of sugar molecules to Gal and GlcNAc, resulting in chain branching 
and elongation or chain termination. This step depends on the cell type, and it is adapted in 
the trans-Golgi in addition to fucose and sialic acid as the chain’s final decoration step 
(Stanley, Schachter and Taniguchi, 2009).  
1.4.6. Hyaluronan 
 
Hyaluronan is the simplest GAG type in terms of structure and modifications. It is 
composed of long unbranched and unmodified polysaccharide structure. Hyaluronan was 
originally called hyaluronic acid (Meyer and Palmer, 1934). Its basic repeating disaccharides 
is composed of GlcA (1→3) GlcNAc, which is chemically formulated as [→4 β-D-GlcA 
(1→3) β-D-GlcNAc (1→] (Figure 24). 
Hyaluronan is not considered a PG for two reasons, firstly, it is not attached to the 
core protein as a sidechain (Almond, 2007); secondly, it is synthesised in the cytoplasm near 
the plasma membrane, which enables hyaluronan to polymerize more sugars and increase its 
mass, unlike other GAGs-related saccharides, (Fraser, Laurent and Laurent, 1997).  
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Figure 24. Hyaluronan saccharides structure, which is consist of long unbranched and 
unmodified GlcA-GlcNAc. 
 
1.4.6.1. Hyaluronan biosynthesis pathway 
 
Basically, hyaluronan is a unique type of glycan that differs from other GAGs because 
it is synthesized near the plasma membrane. Hyaluronan-synthase (HAS) is the enzyme that 
catalyses the addition of GlcNAc and GlcA from their UDP-substrates, resulting in the 
formation of hyaluronan building blocks (Figure 25). The HAS enzyme has four isoforms— 
HAS-A, HAS-B, HAS-C, and HAS-D. HAS-C is responsible for making UDP-Glc from 
glucose-1-phosphate; HAS-B encodes the hydrogenase enzyme to convert UDP-Glc to UDP-
GlcA; HAS-D generates UDP-GlcNAc from UDP-glucosamine-1-phosphate and acetyl CoA. 
Finally, HAS-A encodes the synthesis of the hyaluronan chain by catalysing GlcNAc and 
GlcA from its precursors (Magee, Nurminskaya and Linsenmayer, 2001; Hascall and Esko, 
2015).  
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Figure 25. Schematic diagram of hyaluronan biosynthesis pathway by HAS enzyme family, 
where HAS is responsible for catalysing the addition of monosaccharides from their UDP-
precursors. Then, hyaluronan is synthesized and maturated in the ECM (Hascall and Esko, 
2015). 
1.4.6.2. Hyaluronan degrading enzymes 
 
Hyaluronan can be degraded to monosaccharides by enzymes known as 
hyaluronidases. The hyaluronidase gene (HYAL) expresses three enzymes: hyal-1, hyal-2, and 
hyal-3. Hyaluronan turnover mostly depends on cell type and can last up to one day. 
Degradation of hyaluronan can be achieved by either cellular endocytosis through CD44 or 
the lymph node. Hyal-2 is present on the cell membrane and degrades the hyaluronan chain 
into smaller fractions so fragments can enter the cell via endocytosis. In the cell, hyaluronan 
fragments are directed to the lysosome, as it has hyal-1, which can degrade fragments into 
monosaccharides via exoglycosidase enzymes such as β-glucuronidase and β-N-
acetylglucosaminidase (Hascall and Esko, 2015). 
1.5. Proteoglycans (PG) 
 
Various cells can produce different types of PGs, which can be found secreted in the 
cytosol, bound to the cell membrane, on the basement membrane, or in the ECM. To date, 
serglycin is the only intracellular PG that has heparin and CS as glycoconjugates (Iozzo and 
Schaefer, 2015). Membrane-bound PGs have the ability to interact with various extracellular 
ligands. Extracellular PGs are thought to support cellular stability and function.  
34 
 
1.5.1. Secreted PG 
 
The most well-known intracellular PG is known as serglycin (Bourdon et al., 1985). 
Serglycin PG carries highly sulphated GAGs, which can be assigned as intracellular PGs as 
well as secretory PGs that can secrete their contents into the ECM and onto the cell surface. 
Serglycin PGs can be found in various cells such as endothelial cells, haemopoietic cells, and 
pancreatic cells. GAGs have been found stored in granules in the mast cells, which contain 
heparin and to a lesser extent, CS-E; however, in monocytes and macrophages, they have 
been found freely existing without attachment to a protein core (Kolset and Tveit, 2008). 
1.5.2. Basement membrane PGs  
 
The basement membrane is one of the extracellular contents, and it plays an important 
role in maintaining haemostasis, modification of growth factor activity, and angiogenesis. On 
the basement membrane, there are several PGs such as collagen-XVIII, collagen-XV, 
perlecan, and agrin. Collagen-XVIII is expressed in cartilage, which belongs to the collagen 
family, and is characterised by the N-terminal region–triple-helical collagenous and non-
collagenous domain–C-terminal region. HS can attach to collagen-XVIII via O-linked 
linkage on the non-collagenous region (Iozzo, 2005). Collagen-XV is expressed in many 
tissues except liver and brain cells. CS and HS can attach to its N-terminal non-collagenous 
domain (Amenta et al., 2005). Perlecan PG participates in cellular mitogenesis and adhesion, 
and it has HS attached via O-linkages (Iozzo, 2005). 
1.5.3. Membrane-bound PGs  
 
This type of PG comprises two large PG superfamilies—syndecan and glypican. The 
syndecan superfamily can be subdivided into four syndecan-members (1–4) characterised by 
a cytoplasmic domain, transmembrane region and an extracellular domain with G-protein 
coupled receptors that most likely have both HS and CS (Iozzo and Schaefer, 2015). 
Meanwhile, glypicans have six members (1–6) (Figure 26). According to Filmus et al. 
(2008), the glypican superfamily has the extracellular domain attached to the cell membrane 
via a glycosylphosphatidylinositol anchor (GPI) that acquires an HS chain (Sarrazin, 
Lamanna and Esko, 2011). 
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Figure 26. Schematic diagram showing membrane bound glypican PG via its GPI anchor.  
 
1.5.4. Extracellular PGs  
 
Extracellular PGs can be found in connective tissues. Their major function is to 
support the interstitial space between cells. Extracellular PGs can be subdivided into three 
superfamilies, namely lectican, leucine-rich, and testican. Lecticans can carry highly 
negatively charged GAGs such as CS and KS, and they can be subdivided into four PGs— 
aggrecan, versican, neurocan, and brevican.  
Aggrecan PG has three regions: amino-terminal, central, and carboxyl-terminal. It is 
the major PG of the cartilage, which it supports by resisting compressional force as well as by 
retaining water. Leucine-rich PGs have a small molecular weight, about 40 kDa. This type of 
PG is known to help the organisation of collagen fibres in the cornea via their KS. Leucine-
rich PGs can be subdivided into biglycan, decorin, fibromodulin, and lumican. Biglycan and 
decorin can carry two CS and DS. Fibromodulin has KS as a side chain, and it is expressed in 
tendons. Lumican can be found in the cornea and heart valves, and it carries KS (Yanagishita, 
1993). Decorin has high binding ability to growth factors such as transforming growth factor 
β, and it can keep growth factors isolated in the ECM. Testican is an extracellular 
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proteoglycan, it can be subdivided into testican (1-3). Testicans are expressed in the thalamus 
and cerebrum. They can act as metalloproteinase inhibitors (Lee et al., 2018). 
Table 3. Classification of proteoglycans based on their location (Iozzo and Schaefer, 2015). 
Proteoglycan 
Location 
Classification Predominant protein 
side chain 
Predominant 
GAG 
Intracellular Secretory granules Serglycin Hep/CS-E 
 
 
Pericellular 
 
 
Basement membrane 
 
Perlecan 
Argin 
Collagen-XVIII 
Collagen-XV 
 
HS 
HS 
HS 
CS/HS 
 
Membrane-
bound 
Transmembrane 
 
GPI-Anchored 
Syndecan (1-4) 
 
Glypican (1-6) 
HS 
 
HS 
 
 
 
 
 
Extracellular 
 
Hyalectan lectican 
 
 
 
 
Small leucine rich PGs 
 
 
 
Spock 
Aggrecan 
Versican  
Neurocan  
Bervican 
 
Biglycan 
Decorin 
Fibromodulin 
Lumican 
 
Testican 
CS/KS 
CS 
CS 
CS 
 
CS 
DS 
KS 
KS 
 
HS 
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1.6. Glycosaminoglycan roles in normal cell physiological status 
 
Generally, GAGs are known to have enormous structural heterogeneity, which can 
lead to several cellular and extracellular functions. GAGs’ biological functions depend on the 
cell type and can vary from simple cellular function to cellular morphogenesis (Edgren et al., 
1997). GAG-PGs have several structural and modulatory functions to maintain cellular 
organization, structure, and integrity. Extracellular PGs can protect polypeptides from non-
specific proteolysis enzymes, and they can block antibody binding sites, in addition to storing 
several biologically important molecules such as growth factors. For example, the GAG chain 
can store heparin-binding growth factors near the cell that needs to be stimulated, which 
protects it from degradation and increases its life span (Varki and Gagneux, 2017). 
Furthermore, GAGs can increase PGs’ affinity for extracellular ligands due to their negative 
charge and structural heterogeneity, acting as co-receptors for several soluble lectins such as 
enzymes, proteins, and growth factors (Mythreye and Blobe, 2009; Sarrazin, Lamanna and 
Esko, 2011). Stemming from this concept, GAGs can participate in various biological roles in 
cell development, adhesion, repair, wound healing, and coagulation (Wight, Heinegård and 
Hascall, 1991). 
1.6.1. GAG’s role in cellular development  
 
Physiologically, GAGs are involved in normal cell development and growth, since 
they have high affinity to a wide range of growth factors. GAGs are thought to be the coupler 
between the cell membrane and the extracellular matrix via its PGs. This could be due to their 
structural diversity, which allows them to bind specifically to various extracellular lectins 
(Bernfield et al. 1999). GAG classes as HS, CS, KS, and hyaluronan have various roles in 
cellular development. According to Ornitz (2000), HSPG has a pivotal role in cellular 
development, as it plays a key role in activating fibroblast growth factors (FGFs) and their 
fibroblast growth factor receptors (FGFRs), which are known to regulate cellular 
development (Rabenstein, 2002; Stringer, 2006). HSPG contributes to the FGF-FGFR by 
accessing the complex’s stability, sequestration, and activation (Ye et al., 2001). Yayon et al. 
(1991) clarified that FGFs essentially bind to surface HSPGs especially a specific highly 
sulphated HS sequence before binding to their FGFR to increase the complex’s affinity and 
half-life. 
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HSPG interaction with FGF is a tightly regulated process which requires a specific 
HS sequence. As a consequence, altered HSPG structure, mutated HS synthesising enzymes, 
cells treated with HS degrading enzymes, or cells pre-treated with sulphation inhibitors might 
affect the FGF signalling pathway and the FGF-FGFR complex stability (Ornitz, 2000). 
Bullock et al. (1998) observed that mice with mutated 2-O-sulphotransferase enzymes had 
defective bone and kidney development, which could be due to a defective HS-FGF 
signalling pathway.  
The literature has indicated a further role of GAGs during cellular morphogenesis, 
which is defined as the cellular developmental cascade that leads to the formation of well-
organized and functional tissue, as reported in embryogenesis (Spooncer et al., 1983). 
Multiple elements participate in embryogenesis, such as signalling molecules and growth 
factors. It has been shown via animal studies that HSPG participates in embryogenesis, while 
a lack of HS alleles would result in developmental abnormalities. For instance, in mice with 
EXT1, which is an enzyme that extends GAG sequences, a hypomorphic allele has led to the 
development of skeletal muscle abnormalities (Bishop, Schuksz and Esko, 2007). 
CS plays a key role in cellular development in conjunction with its PGs or as free 
GAG. As suggested by Shannon et al. (2003), CSPG plays an important role in supporting 
mammals’ lung branching developments by interacting with growth factors. Indeed, lung 
cells treated with chondroitinase-ABC show inhibited lung branching, which supports the 
role of CSPG in this process. In addition, CS is involved in embryonic morphogenesis, as a 
mutated CS chain would result in growth abnormalities; for instance, the glycosyltransferase-
I knockout gene in mouse oocytes has resulted in growth failure (Mikami and Kitagawa, 
2013). Moreover, CS is considered to be the richest GAG-type in the central nervous system, 
where it can act as co-receptor to various growth factors such as brain-derived neurotrophic 
factor (B-DNF). CSPG’s pattern of sulphation can affect its function, as reported in CS-A, 
which inhibits axonal regeneration after injury (Laabs et al., 2005), while CS-C appears to 
allow axonal regeneration (Mikami and Kitagawa, 2013). Thiele et al. (2004) emphasised that 
mutated chondroitin-6-sulphotransferase leads to the development of chondrodysplasia with 
spinal involvement. 
It is also worth noting that hyaluronan has an important role during cell 
morphogenesis. High levels of hyaluronan have been observed in various proliferation and 
regeneration regions, as illustrated when mesenchymal stem cells migrate from the corneal 
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stroma to form the mature cornea, in atrioventricular cushion cells leading to the formation of 
heart valves, and in the embryonic brain ECM. Interestingly, hyaluronan concentration 
decreases after cellular differentiation and proliferation (Toole, 1997). In addition, 
hyaluronan causes swelling pressure on chondrocytes during bone development, resulting in 
bone growth, while in a bone erosion zone, CD44 has been observed to promote hyaluronan 
cellular endocytosis (Pavasant, Shizari and Underhill, 1994). During embryonic development, 
the ECMs of embryonic cells have a high amount of hyaluronan, which suggests that it plays 
an important role in embryonic development (Laurent, Laurent and Fraser, 1995). 
1.6.2. GAGs’ role in cellular adhesion 
 
Cellular organisation defines a cell’s overall final structure, which results from 
cellular interaction with various adhesion molecules. Cellular adhesion to the ECM is 
regulated by interaction of the adhesion molecules to maintain normal cellular physiological 
properties. Cellular adhesion molecules’ major families are integrin, selectin, 
immunoglobulin, and cadherin. Cellular adhesion molecules’ interaction with the ECM 
allows cells to attach to the ECM, detach from it, change shape, migrate, and divide. PGs can 
participate in adhesion process via the interaction between their GAG chains and the 
adhesion molecules and the ECM to maintain a cell’s stability. For instance, the interaction 
between HSPG and the integrin can stimulate the cellular adhesion process (Wight, Kinsella 
and Qwarnström, 1992). On the other hand, Sage and Bornstein (1991) suggested that there 
are several PGs on the cell surface and on the cellular basement membrane, such as 
osteonectin and thrombospondin can interact with different extracellular elements, leading to 
release cells from the ECM and stimulating the cellular migration process. Furthermore, 
cellular migration also depends on the extracellular ligands and their interaction with the 
cellular GAGs. For example, cells upregulate their HSPG to facilitate cellular adhesion; by 
contrast, cells upregulate their surface CSPG to release cells from the ECM (Kinsella and 
Wight, 1986). In addition, hyaluronan would participate in cellular migration due to its 
physicochemical properties and its cell membrane receptor, known as receptor for hyaluronan 
mediated motility (RHAMM), which promotes cellular migration; therefore, cellular 
migration can be inhibited by hyaluronan degradation (Vigetti et al., 2014). 
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1.6.3. GAGs’ role in wound healing and tissue repair 
 
Tissue injury can be caused by trauma, heat exposure, cold exposure, or contact with 
chemical agents, amongst other factors. Wounds can be defined as damage to the normal 
physiological and anatomical structure and/or function of cells, which can be as simple as 
epithelial skin injury or as serious as bone injury. As part of the physiological process 
following tissue injury, the wound healing repair process is initiated by the surrounding cells 
to ensure that tissue regeneration occurs. The wound healing process includes cell 
proliferation, cell migration, angiogenesis, cell differentiation, and the synthesis of 
extracellular proteins and the release of growth factors and polypeptides to aid the healing 
process (Velnar, Bailey and Smrkolj, 2009). PGs can be involved in the wound healing 
process by activation of various elements such as heparin. Heparin is thought to support the 
wound healing process via the inflammation process. According to Mcpherson et al. (1988), 
heparin is released in wounds to support the healing process by increasing vascularization at 
the wound site, which can attract different types of growth factors, cytokines as well as 
extracellular proteins such as fibronectin to participate in this process, in addition to 
thrombocyte degranulation (Kratz et al. 1997). Bernfield et al. (1999) suggested that cell 
surface PGs such as syndecan can be over-expressed near the wound site, where syndecan-1 
and syndecan-4 levels increase in the wound margins of proliferating cells. Syndecan-1 is 
thought to help newly generated keratinocytes to migrate to the wound site after complete 
healing. In addition, neutrophils can release heparinase enzymes in the wound site to 
depolymerise HS chain from its PG, which is required to activate FGFs that is needed for the 
healing process. 
DSPG plays a pivotal role in skin wound healing. During skin wound injury, DSPGs 
are upregulated through their syndecan-1 and syndecan-4 in keratinocytes to stimulate 
endothelial leukocyte adhesion molecules and promote FGF-2 to enhance the repair 
mechanism. In addition, the present of high levels of DSPG as decorin or biglycan might 
associate with scarring (Trowbridge and Gallo, 2002). Hyaluronan has a very large molecular 
weight compared with other GAGs. It has various biological roles including in wound healing 
process. According to John and Giovanni (2002), hyaluronan enhances the cellular 
inflammatory response via chemotactic pro-inflammatory molecules and increases 
inflammatory cells’ infiltration to the injury site, and Sherman et al. (1994) suggested that 
hyaluronan enhances cellular migration to the wound healing site. 
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1.6.4. GAGs’ roles in coagulation 
 
The best-studied GAG-type with anticoagulant activities is heparin. Heparin’s 
anticoagulation activity was discovered by Howell & Holt (1918). This discovery has led to 
an evolution in clinical practise, especially in patients with blood disorders such as 
myocardial infarction and pulmonary embolism, amongst other disorders that require well-
maintained circulation (Shriver et al., 2012). 
When normal haemostasis condition is impaired, for instance, by blood vessel injury, 
this leads to activating primary and secondary haemostasis mechanisms to prevent 
haemorrhage. The primary haemostasis mechanism activates platelets to prevent 
haemorrhage via initiating plugging and activating the secondary haemostasis mechanism. 
The secondary haemostasis mechanism starts by activating coagulation proteins known as 
coagulation cascade that ultimately form firm blood clots by converting soluble fibrinogen to 
insoluble fibrin via activated thrombin (Hoffbrand and Moss, 2015) (Figure 27). 
 
Figure 27. Schematic diagram of the coagulation cascade (Hoffbrand and Moss, 2015). 
 
However, blood has a counter-protease that can inhibit this coagulation process 
known as antithrombin-III, which inhibits the activation of various coagulation proteins, 
especially factors II and X. Heparin with 15-19 kDa molecular weight has the capability to 
enhance antithrombin-III activities. The major area of interest in heparin’s structure is its 
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minimal, unique pentasaccharide sequence with a potent anticoagulation role, which is 
composed of [GlcNAc/S(6S) (1→4) GlcA (1→4) GlcNS(3,6S) (1→4) IdoA(2S) 
(1→4)GlcNS(6S)] (Figure 28) , however, unfractionated sequence can be as trisulphated-
(disaccharides)-pentasaccahride-disulphated(disaccahride) (Onishi et al. 2016). 
 
Figure 28. Heparin minimal pentasaccharide structure with unique anticoagulation properties. 
This heparin minimal pentasaccharide sequence is required to attach to the 
antithrombin-III, which interacts with coagulation factor X to inhibit the conversion of pro-
thrombin to thrombin. As a result, heparin aids in the deactivation of the coagulation cascade 
and prevents the formation of blood clots (Rosenberg and Lam, 1979). Furthermore, there is 
another protease that can enhance thrombin inhibitory process, known as heparin cofactor-II 
(serpin). This particular protease can inhibit the activated thrombin from activating fibrinogen 
in the present of several GAGs such as heparin, HS, CS, and DS (Wu, Monroe and Church, 
1995). 
Although heparin interaction with heparin cofactor-II can result in 1000-folds anti-
thrombin activity, oversulphated DS is considered to be a replacement for heparin therapy in 
patients with heparin side-effects such as thrombocytopenia, as DS’s unique hexasaccharides’ 
structure [(IdoA(2S)-GalNAc(4S)]3 can inhibit the coagulation process by 100-fold through 
binding to heparin cofactor-II that inhibit thrombin as well as it can inactivate thrombin 
bound to fibrin (Prabhakar and Sasisekharan, 2006). 
1.7. Normal cellular growth  
 
Normal cell division is an essential mechanism to maintain the body’s physiological 
status. Cells divide following a very tight and rigid process known as the cell cycle. The cell 
cycle is a fundamental component of normal living cells, and it consists of the consecutive 
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processes of interphase and mitosis. Interphase consists of three phases, namely growth phase 
1 (G1), synthesis phase (S), and growth phase 2 (G2). In G1 phase, cells either become 
prepared entering S phase or it can leave the cell cycle by entering G0, where cells don’t 
divide, for instance, neurones. During S phase, the most important mechanism is duplication 
of centrosomes and DNA duplication, where 23 pairs of chromosomes are duplicated 
resulting in 46 pairs of chromosomes. Then the cell enters G2 phase, where cells are prepared 
for mitosis; in this phase cells, for example, initiate microtubules that segregate 
chromosomes. 
Next, cells will enter the mitosis phase, where the cell is divided into daughter cells. 
Mitosis is divided into different phases, which are prophase, prometaphase, metaphase, 
anaphase, telophase and cytokinesis. Prophase is the first stage of mitosis, where 
chromosomes are condensed, and mitotic spindles are formed. Following this, the 
prometaphase starts by rupture of the nuclear membrane and microtubules attaching to the 
chromosomes. In the metaphase, all microtubules attached to chromosomes and it all rests in 
the middle of the cell. During the anaphase, the most important sign is separation of cellular 
chromatin into two parts. Finally, in the telophase each chromatid is separated from each 
other, which is the end of mitosis, following which cytokinesis, where the parent cell 
physically divide into two daughter cells (Park and Lee, 2003). 
1.7.1. Cell injury 
 
When cells experience physiological stress like ischemia or potential injury such as 
infection or exposure to toxins, they can undergo an adaptation process known as reversible 
injury. However, when the cell injury persists, or the injury is severe, the cellular adaptation 
mechanism is unable to adapt the physiological status, which makes this injury irreversible, 
so cell death is established. In addition, cell death can occur in normal status, as in genetic 
abnormalities of the cell cycle. 
After irreversible cellular injury occurs, cell death is proposed to occur by different 
mechanisms according to the potential cause of cell death, its intensity, and its duration. 
Rapid and severe disturbances can cause an uncontrolled cell death known as accidental cell 
death that usually caused by toxins, infections, or trauma, which is morphologically 
demonstrated as necrosis. In necrosis, all cellular contents leak out, resulting in cellular 
digestion, which cannot be avoided by cellular adaptation mechanisms, thus, this type of cell 
death promotes inflammation via the substances released from dead cells in order to start the 
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repair process. In contrast, when normal cells are forced to die or when cell injury is not 
severe, cells activate a regulated molecular pathway to facilitate the cellular death process, 
which is morphologically known as apoptosis. Typically, apoptosis occurs in healthy tissues, 
and it does not always refer to a pathological event. Cells with intrinsic abnormalities can 
induce apoptosis by activating certain enzymes that degrade their own DNA and cytoplasmic 
proteins without causing inflammation; hence, this is called programmed cell death. 
Programmed cell death can be caused through intrinsic or extrinsic pathways. Both pathways 
ultimately activate intracellular endoprotease enzymes called caspases. This caspase cascade 
process cleaves cellular proteins and nucleic acid, resulting in an altered cellular membrane 
that allows dead cells to be removed by phagocytes (Elmore, 2007). 
During the extrinsic apoptotic pathway, cells express death receptors. When cells 
express their own apoptotic receptors, which can be activated by different ligands such as 
tumour necrosis factors or T-lymphocytes then the activated receptors activate the cytoplasm 
domain, resulting in activating further caspases to induce apoptosis. Meanwhile, the intrinsic 
pathway, which is also known as the mitochondrial pathway, has several proteins that can 
induce apoptosis. In the mitochondria, there are two families of pro-apoptotic and anti-
apoptotic proteins, which are well-balanced during cellular physiological status. When 
cellular physiological status is altered, the mitochondrial membrane becomes permeable, and 
the proapoptotic proteins can leak out into the cytoplasm. For instance, cytochrome-c, which 
is a proapoptotic protein leaks out from the mitochondria into the cytosol, resulting in the 
activation of the caspase cascade mechanism and eventually apoptosis (Kumar, Abbas and 
Aster, 2017). 
1.8. Cancer progression 
 
Normal cell growth is well regulated by the cell cycle regulator mechanism via the 
action of cyclin-dependent kinase (CDK) and cell cycle checkpoints. When the cell cycle’s 
function is altered, and the cell cycle repair mechanism is suspended, cancer can develop. 
There is a wide range of cell cycle alterations that might occur—for example, cell cycle 
mutation in proto-oncogene, tumour suppressor gene or cell cycle misregulated checkpoints. 
Each one of these mutations may give rise to tumorigenesis.  
Active cyclin and kinases, which have been the subjects of many classic studies on 
normal cell cycle division and regulation, are responsible for cell cycle progression. Various 
CDK-inhibitors are released to inhibit the cell cycle progression—for example, p53, which is 
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a tumour suppressor gene. In other words, when the p53 tumour suppressor gene 
mutates/supressed, this can result in the complete absence of CDK, which alters the cell cycle 
division and leads to the progression unregulated cell division. According to Park and Lee 
(2003), the development of unregulated cellular division after a point of mutation results in 
chromosomal abnormalities that eventually increase the probability of cancer progression 
(Figure 29). 
Tumours can be divided into benign or malignant. Benign tumours are made up of 
differentiated and localised cells and are amenable to surgery without massive fear of 
metastasis. Malignant tumours are made up of undifferentiated aggressive cells, and have the 
potential to invade other tissues and spread all over the body; this type of tumour is called a 
neoplasm, which means “new growth” (Kumar, Abbas and Aster, 2017). 
 
Figure 29. Schematic diagram of cancer progression resulting from inactive tumour 
suppressor gene p53 leading to uncontrolled proliferating cells (Kumar, Abbas and Aster, 
2017). 
1.9.  Cancer epidemiology and incidence  
 
Cancer epidemiological studies have linked some risk factors to cancer progression. 
Cancer predisposing factors such as age, environment or race can participate in cancer 
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progression. For instance, cancer risk frequently increases with age, smoking cigarettes 
increases the risk of lung cancer, and food intake quality and food with less fiber contents 
might increase the risk of colon cancer. In the United Kingdom, there were over 360,000 new 
cases of cancer in 2015—that’s nearly 990 daily diagnoses with higher incidence of breast, 
prostate, lung and bowel cancer. In 2015, 8.8 million people died worldwide due to cancer. 
Leukaemia had 9,900 cases diagnosed in 2015 and 4,712 deaths in 2016. There were 2,697 
patients diagnosed with mesothelioma in 2015 and 2,496 deaths were reported in 2016 
(Cancer Research UK, 2017). 
1.10. Glycosaminoglycans’ role in cancer progression 
 
It is well-known that cancer cells’ microenvironment has a major role in stimulating 
tumour growth via interaction with ECM molecules. More recently, there has been great 
interest in PGs proangiogenic roles. HSPG has significant abilities to bind different growth 
factors and their splices that occur in the neoplastic area, such as vascular endothelial growth 
factors (VEGFs) and FGFs. As a result, it could alter the body’s physiological status in the 
case of malignancy, to promote angiogenesis and cancer metastasis (Zhang, 2010). 
A tumour’s angiogenesis process is stimulated by autocrine cancer clonal growth 
factors, which in turn stimulate tumour endothelial cell PGs to fine-tune VEGFs to induce 
tissue remodelling. Ultimately, this process leads to angiogenesis and tumour growth (Stanley 
et al. 1999). The tumour becomes moderately acidic and hypoxic, so tumour cells express 
hypoxia-inducible transcription factors (HIFs), which stimulate synthesis of VEGFs, 
especially VEGF-A to sustain continued growth by increasing the tumour’s blood supply. 
Thereafter, when the neoplastic hypoxic condition is greatly evolved, various types of growth 
factors bind to HSPGs to fine-tune tumour growth. According to Zhang (2010), when a 
tumour’s hypoxic condition progresses, neoplastic cells alter HSPG’s structure, enabling it to 
bind as much as growth factors, which eventually results in cancer metastasis (Witsch, Sela 
and Yarden, 2010). As mentioned before, HSPG has two main membrane-bound 
proteoglycan families, syndecan and glypicans, and one important basement membrane PG 
known as perlecan; thus, it modulates various functions of the neoplastic cells. For instance, 
HSPG shows a high ability to bind FGFs, as it is upregulated in angiogenic regions, 
suggesting HS’s role in cancer progression (Blackhall et al., 2001; Zhang, 2010).  
The cellular response to different pathological conditions can result in up- or down-
regulated CSPGs as it has different roles in cellular proliferation and morphogenesis. CS/DS 
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role is highly dependent on the sulphation pattern and chain length of their structure 
(Asimakopoulou et al. 2008; Kalathas et al. 2011). According to Kalathas et al. (2011), 
CSPGs’ synthesising and degrading enzymes have been found in colorectal cancer, which 
would explain the role of CS in neoplastic cells. In various cancer cells, CSPG has been 
observed to be abnormally upregulated, which enable it to interact with enormous 
intracellular and extracellular molecules. Versican and aggrecan, which are extracellular PGs 
that carry CS as a side chain, might have major roles in cancer metastasis (Asimakopoulou et 
al., 2008). 
Versican has been detected in high concentrations in prostate, brain, breast, and 
gastric cancer. High concentration of versican promotes tumour cells’ growth and metastasis 
by interaction with various growth factors, especially platelet-derived growth factors (PDGF), 
which are known to promote cellular growth and division by inducing angiogenesis. In 
addition, versican has been found upregulated in metastatic melanomas and correlated with 
poor prognosis in prostate cancer (Asimakopoulou et al., 2008). Furthermore, versican has 
been found upregulated by the action of transforming growth factor-β in osteosarcoma cells, 
which indicate a poor prognosis. High levels of CS-E were observed in ovarian 
adenocarcinoma as it is thought to modulate growth factor function (Afratis et al., 2012). 
Cancer cells’ migration processes require remodelling of the ECM, which can be 
induced by depolymerisation of the ECM to promote remodelling and cell migration. For 
example, cancer cell metastasis can be stimulated by depolymerisation of aggrecan which 
promotes cancer cell motility by binding to adhesion molecules such as selectins on the 
endothelial cells via its CS and CD44, resulting in cellular migration. Inhibition of CS 
formation by treating cells with chondroitinase would result in great inhibition of cellular 
migration. This result elucidates CS’s role in cancer metastasis (Asimakopoulou et al., 2008). 
Another extracellular GAG that can promote cancer cell invasion is hyaluronan, 
which has been found to regulate cancer cell signals during the tumour invasion process 
(Fuster and Esko, 2005). In addition, high levels of hyaluronan have been found in various 
malignancies, such as adenocarcinomas, which might indicate its role in cancer 
morphogenesis and poor prognosis (Heldin et al., 1996). 
Overall, common GAG-types have proangiogenic roles, which can promote cancer 
and cancer metastasis. This is due to their potential capabilities to bind to various lectins such 
as growth factors and adhesion molecules. Therefore, it is very important to know the role of 
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GAGs in cancer cells’ progression in order to determine the possible therapeutic targets in 
regard to GAG anticancer therapies.  
1.10.1. Cancer treatment related to GAGs’ pathological roles 
 
As previously discussed, GAGs have various physiological and pathological roles in 
cell biology. Targeting GAGs and related products can enhance cancer therapies and inhibit 
cancer progression in several ways. Firstly, directly targeting growth factors and cell surface 
receptors that are used by GAGs to promote cancer cell growth by using monoclonal 
antibodies. As illustrated in certain neoplasms, targeting a tumour’s autocrine VEGFs is 
preferred to inhibit tumour growth and metastasis. This is done by administrating 
pharmaceutically targeted antibodies against growth factors such as anti-VEGF (Hurwitz et 
al., 2004). Unfortunately, there are several drawbacks to using this type of treatment. 
Foremost, this type of specific antibody therapy has a fundamental limitation due to the 
expression of growth factor splices such as FGF-2, which have a greater capability of 
inducing tumour metastasis, and in very acidic tumours VEGFs can result in different 
variants as the tumour progresses. Additionally, antibody-based therapy increases treatment 
costs (Sandler et al., 2006; Zhang, 2010). Secondly, blocking GAGs’ proangiogenic roles, for 
example, blocking HSPG from fine-tuning growth factors to progress cancer growth and 
inhibiting heparinases activities that may finally lead to cancer metastasis (Zhang, 2010). 
Another selective cancer therapy target is the cell surface transmembrane CD44, 
which interacts with several adhesion molecules to aid cellular migration. Therefore, its 
expression is very tightly regulated in normal cells, however, it was found to be highly 
upregulated in malignant cell surface. CD44 was observed in several tumours as its levels 
would indicate tumour behaviour and it was thought to be associated with cancer stem cells 
that would lead to cancer resistance (Liu and Jiang, 2006). According to Zöller (2011), CD44 
is associated with tumour biological events such as growth and metastasis, and elevated 
levels could be related to poor prognosis, which make it a favourable target in cancer 
selective therapy. In-vitro anti-CD44 therapy has successfully inhibited tumour cells’ growth 
and induced apoptosis on undifferentiated leukemic cells, and it could inhibit their progenitor 
cells (Liu and Jiang, 2006). 
Thirdly, targeting the angiogenic factors that are released from neoplastic cells. An 
example of these tumour angiogenic factors is the epithelial HSPG. Malignant epithelial cells 
overexpress HSPG in order to increase cancer cells’ interaction with the extracellular growth 
49 
 
factor ligands to promote cell growth. Hence, HSPG has great affinity to various growth 
factors that can lead to cell morphogenesis as well as angiogenesis (Zhang, 2010). Therefore, 
blocking a tumour cell’s HSPG binding sites would decrease its growth factors’ binding 
domains, discontinuing its potential proangiogenic role. Thus, Lamanna (2008), suggested 
blocking HSPG’s proangiogenic activities by using sulphatase enzymes. Sulphatases catalyse 
the hydrolysis of sulphate groups on GAGs’ structure leading to minimising GAGs’ 
biological functions. As an illustration, there are two cell surface HS sulphatase enzymes, 
known as sulphatase-1 (Sulf-1) and Sulf-2. These sulphatases can contribute to HS structure-
activity via endolytic glucosamine 6-O-sulphate from the HSPG chain; these conformational 
changes would lead to a change in HS’s biological function. Furthermore, regarding FGF’s 
crystal structure, FGF’s binding to HSPG and its FGFR requires a specific HS sequence with 
N-sulphated and 6-O-sulphated molecules to increase complex affinity (Yayon et al., 1991). 
Hence, Sulf-1 and Sulf-2 are determined to be potential tools in cancer therapy, especially in 
metastatic neoplasms, to minimise cancer cell interaction with extracellular environment as 
well as to reduce HSPG’s angiogenic effectiveness.  
Another therapeutic intervention could be done by launching new compounds that 
have greater affinity for these growth factors than membrane-bound HSPG—for instance, 
polysulphated-HS-like with a similar sequence to that of the cell membrane HS would have 
greater affinity for various growth factors than malignant cell HSPG (Rusnati and Urbinati, 
2009). Zhang (2010) emphasised that novel compounds such as polysulphated-HS-like can 
compete with cellular HSPG for growth factors. Johnstone et al. (2010) highlighted that using 
either a polysulphated pentasaccharide or a polysulphated tetrasaccharide sequence as an HS-
imitative compound might become a potential angiogenic antagonist. 
Another proangiogenic factor is heparinase enzyme, which digests cell surface HSPG 
and releases HS unsaturated disaccharides or oligosaccharides. It is physiologically produced 
from embryonic placenta and lymphoid organs (Vlodavsky and Friedmann, 2001). According 
to Haimov-Kochman et al. (2002), heparinases are found in large amounts in placenta cells, 
where their function is thought to involve facilitating growth factors release in the ECM in 
order to support placental cell development. Contrary to heparinases’ physiological function, 
there is great evidence that suggest heparinases are produced by tumour cells, especially in 
poorly differentiated carcinomas, promoting cellular invasion and cancer metastasis. As 
revealed by Koliopanos et al. (2001), a patient's blood test with elevated heparinases would 
indicate very poor prognosis. It was suggested that after treatment with polysulphated-HS, 
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tumour cells release heparinases to cleave cell surface HSPG and the extracellular 
polysulphated-HS-rich in growth factors in order to reactivate the tumour angiogenesis 
process (Zhang, 2010). Overexpression of heparinases could lead to cleaving HS from its 
syndecan, which plays a crucial role together with VEGF-A, in facilitating the growth of 
cancer endothelial cells and accelerates the tumour’s growth by activating full-length HSPG 
activity. Indeed, inhibition of neoplastic heparinase activity would be favoured, since it could 
reactivate cancer and promote cancer metastasis (Vlodavsky and Friedmann, 2001). 
1.11.  Blood cancer 
 
Blood cells arise from pluripotent hematopoietic stem cells (HSC) situated in the bone 
marrow in long bones. HSC have immunological markers that differentiate it from other cell 
types, however, the exact phenotype is unknown (Hoffbrand and Moss, 2015). Cellular 
differentiation arises from stem cells to progenitor cells with self-renewal properties, which 
are capable of producing different blood cell linages. Progenitor cells give rise to either 
common myeloid lineage or common lymphoid lineage progenitor cells. The term myeloid 
refers to erythrocytes, megakaryocytes, mast cells, and leukocytes, where leukocytes can be 
further subdivided into neutrophils, eosinophils, and basophils. The term lymphoid refers to 
T-lymphocytes, B-lymphocytes, and natural killer cells (Figure 30) (Moore, Knight and 
Blann, 2016). 
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Figure 30. Schematic diagram represents blood cell lines from the bone marrow. Starting 
from haematopoietic stem cell that is arise from the bone marrow. The common myeloid 
progenitor cells (left side) that produce red blood cells, platelets, monocytes, neutrophils, 
eosinophils and basophils. The lymphoid stem cell (right side) can produce B-lymphocytes, 
T-lymphocytes and natural killer cells. 
 
Haematological malignancies can affect any blood cell lineage from cells situated in 
the bone marrow to the peripheral lymphoid cells, for instance, leukaemia. Leukaemia is a 
type of blood cancer, which affects about 3% of the United Kingdom population who are 
diagnosed with cancer (Cancer Research UK, 2017). The haematological cells can become 
malignant either due to genetic factors or environmental factors such as radiation and drugs. 
Genetic mutations can occur due to defects in either tumour-suppressor gene or proto-
oncogenes, which would lead to point of mutation. For instance, gain of tyrosine kinase 
function would affect the secondary messenger resulting in unregulated proliferation of blood 
cells. Genetic deletion would result in blocking of B-lymphocyte (B-cell) maturation, 
resulting in enormous number of undifferentiated B-cell clone (Vitanza et al., 2014). 
Leukaemia can be classified based on disease progression to either chronic or acute. 
Chronic leukaemia is characterised by slow development of malignant blood cells with either 
myeloid or lymphoid linage. In contrast, acute leukaemia is characterised by fast-growing 
malignant cells with either myeloid or lymphoid linage. It is necessary here to clarify what is 
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meant by lymphoma in order to differentiate it from leukaemia. Lymphoma is a malignancy 
of blood lymphocytes with lymphoid organs origin, such as lymph nodes. Lymphoma is 
diagnosed if there is a link to a primary lymphoid origin (Moore, Knight and Blann, 2016), 
however, malignant lymphocytes present in the bone marrow is considered as leukaemia. 
There is a strong possibility of differentiating between leukaemia and lymphoma by studying 
the bone marrow picture, if more than 25% of bone marrow lymphocytes are affected, it is 
considered as leukaemia (Ross et al., 2011). 
Regarding chronic leukaemia, it can be difficult to cure as it can be divided into 
chronic myeloid leukaemia (CML) or chronic lymphoid leukaemia (CLL). CML can be 
subdivided into six-types among the myeloid lineage with 742 new cases in the UK per year; 
in addition, CLL affect any lymphocytes lineage with 3709 new cases per year in the UK. 
The most common type of CML is known as CML-Philadelphia positive. This type of 
malignancy occurs due to abnormal gene translocation between chromosome 9 Abelson 
proto-oncogene (ABL) and chromosome-22 (BCR gene), resulting in a fusion protein with 
tyrosine kinase activity that cause the pluripotent stem cells to proliferate uncontrollably 
(Hoffbrand and Moss, 2015). 
Acute leukaemia is presented as bone marrow proliferation of fast-growing immature 
blood cells in the blood, which is known to be an aggressive disease, which needs immediate 
medical intervention (Rocha et al., 2001). According to which progenitor cell type is affected, 
acute leukaemia is either acute lymphoid leukaemia (ALL) or acute myeloid leukaemia 
(AML) (Bomken and Josef Vormoor, 2009). ALL incidences are more common than AML. 
In the United Kingdom, approximately 300 children are diagnosed with ALL annually 
(Bomken and Josef Vormoor, 2009). According to Raimondi et al. (1988), T-lymphocyte 
acute lymphoblastic leukaemia (T-ALL) affects about 15% of children with ALL, and it is 
believed to affect more boys than girls, with a ratio of 3:1. In comparison to T-ALL, B-
lymphocyte acute lymphoblastic leukaemia (B-ALL) affects about 85% of children. Nearly 
90 children are diagnosed with AML per year in the United Kingdom, with moderately 
higher incidence in boys than girls (Bomken and Josef Vormoor, 2009). AML incidence is 
greater during infancy and late adulthood, which affects about 25% of children (Deschler and 
Lübbert, 2006). 
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1.12. Malignant mesothelioma 
 
Mesothelium cells are composed of squamous epithelium that lines several body 
cavities, such as thoracic (pleura cavity), peritoneum (abdominal cavity) and mediastinum 
(heart sac). Malignant mesothelium cells known as mesothelioma, most frequently occur in 
the thoracic cavity with asbestos exposure. Cancer has several risk factors that can affect cell 
growth resulting in uncontrolled proliferation, while mesothelioma is type of cancer which 
has no definite cause; however, thoracic mesothelioma has a link to asbestos exposure 
(American Cancer Society, 2018). 
Mesothelioma can be divided to three types based on cell morphology as epithelioid, 
sarcomatoid and biphasic. Epithelioid mesothelioma, according to its cell-type can be 
treatable with good prognosis. Secondly, sarcomatoid mesothelioma type is uncommon, and 
is known to be the most aggressive type with poor prognosis, is characterised by spindle 
shape cells. Sarcomatoid mesothelioma can be subdivided into desmoplastic and 
lymphohistocytoid mesothelioma. Both subtypes are morphologically similar to other cancer 
cells, such as lung carcinoma (Klebe et al., 2010). Thirdly, biphasic mesothelioma is 
composed of mixed type of epithelioid mesothelioma and sarcomatoid mesothelioma, which 
makes its treatment dependent on the predominant cell type present in the tissues.   
1.13. Cancer treatment 
 
There are several types of anticancer treatments such as surgery, chemotherapy, 
radiotherapy, stem cell therapy, immunotherapy, hormone-therapy, precision medicine and 
many new approaches in clinical trials. Various new cancer treatment regimens have been 
launched due to progression of severe forms of cancer that have become more resistant to 
standard therapies. Growing evidence suggests the presence of cancer stem cells that can lead 
to drug resistance. Cancer stem cells are defined as a small cell population from a tumour’s 
lineage with self-renewal properties, leading to tumour regrowth and metastasis even after 
treatment. Therefore, the choice between different types of cancer therapies depends heavily 
on the disease’s severity and the type of malignant cells, aiming to reduce cancer cell 
resistance, which may result in treatment failure (Prieto-Vila et al., 2017). To this end, 
various anticancer drugs are used in combination therapy, which defined as using different 
type of drugs or treatments to minimise drug resistance. Although most anticancer drugs have 
several side-effects such as anaemia, diarrhoea, constipation, hair loss, infection, nausea, and 
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fatigue, commonly used anticancer treatments such as chemotherapy, radiotherapy and stem 
cell transplants have cured 50% of cases in the UK (Cancer Research UK, 2017). 
Initially, chemotherapy treatment can be defined as using chemical substances to stop 
or slow cellular growth, including that of normal and malignant cells, which can make it 
unpleasant treatment for patients; however, it is very effective. This type of therapy can be 
used solely or in combination with other therapies. Chemotherapy can be considered to be 
highly cytotoxic treatment, so its usage may require a specific treatment strategy. For 
example, treatment of acute leukaemia is largely dependent on which type of leukaemia-cell 
subtype is affected as well as disease aetiology (Greaves and Wiemels, 2003). Basically, 
chemotherapy regimens are based on combination chemotherapy, which is been effective on 
heterogeneous tumours and reduce cellular resistance in comparison to using single-drug 
(Höök et al., 1984). 
Combination therapy in treating leukaemia can be divided to induction therapy 
followed by post-remission therapy and finally maintenance therapy. Initially, induction 
therapy is considered to be first line treatment, which is an intermittent chemotherapy 
injection, as it aims to eliminate as many leukaemia cells from the patient’s circulation and 
the bone marrow. Following successful induction therapy, the post-remission therapy is 
introduced to ensure eradication of all malignant cells from the body using combination of 
high-dose chemotherapies, especially with poor prognostic patients. However, patients with 
good prognosis may receive maintenance therapy regimens instead of post-remission therapy, 
which is defined as continuous low-dose chemotherapy (Rivera et al., 1991). 
The main concern about chemotherapy combination treatment is drug cytotoxicity. 
Chemotherapy can destroy cells by halting the cell cycle of both normal and malignant cells, 
which eventually develop various side effects. For example, it would increase the risk of 
developing chronic disorders for cancer survivals, such as heart disease, renal insufficiency, 
infertility and myelosuppression (Norris and Adamson, 2012). In addition, most 
chemotherapy has a small therapeutic window that would allow giving tolerable doses for the 
shortest period of time that ensures killing of most malignant cells. Although, combination 
chemotherapy is still the drug regime of choice in childhood leukaemia, chemotherapy-
related toxicity is the main issue about this type of therapies.  
Secondly, radiotherapy that refers to using high doses of radiation on the area of solid 
tumours leading to cellular death by DNA damage via an internal or external source of 
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radiation. Radiotherapy can be used solely or in combination with other therapies; for 
example, in breast cancer post-operative care, radiotherapy is used to ensure full eradication 
of all residual malignant cells.  
Thirdly, stem cell transplantation therapy is defined as transplanting healthy stem 
cells to a patient; it can be from the same patient (autologous), from the patient’s identical 
twin (syngeneic), or from someone else (allogeneic). This type of therapy usually indirectly 
affects cancer cells, which means the newly transplanted stem cells will help the body to 
recover and produce more normal stem cells after extensive loss of stem cells due to other 
therapies, as chemotherapy. However, allogeneic stem cell therapy can have direct effects on 
cancer cells by providing the patient’s body with fully functional white blood cells that could 
attack malignant cells (Copelan, 2006). 
Uncommon anti-cancer treatments include immunotherapy and hormone therapy. 
Immunotherapy is used to treat patients with cancers by enhancing the host’s immune system, 
so it can destroy the cancer cells. Immunotherapy can be achieved either via use synthetic 
monoclonal antibodies against various cancer cell markers or boost the body’s immune 
system, so it can recognise and attack foreign cells such as malignant cells. Although 
immunotherapy appears favourable, it is not effective in every patient and it might cause 
wide-range side-effects (Schuster, Nechansky and Kircheis, 2006). 
Hormonal therapy is a type of therapy that controls hormone production to treat a 
particular cancer. Hormonal therapy is predominantly used to ease cancer symptoms; 
however, it can slow tumours’ growth. For instance, testosterone production can be 
controlled in order to treat prostate cancer. Finally, precision medicine is a type of medicine 
that is based on patient’s cancer’s genetic information, which allows oncologists to select an 
appropriate personalised therapy. This type of therapy joins several treatments according to 
disease aetiology and it could target the cause of the disease (Cancer research UK, 2017). 
Scientists are trying to overcome these issues by identifying natural products-related 
compounds with anticancer effects with improved pharmaceutical outcomes. Different 
anticancer drugs have been discovered from natural products, for instance, L-asparaginase, 
doxorubicin and cytarabine. Even though, these drugs are derived from natural products, they 
are classified as chemotherapeutics and it might share some side-effects (Nobili et al., 2009). 
Natural products play a pivotal role in biomedical research, especially in cancer 
research. Agbarya et al. (2014), over the past century nearly 28% of drugs have been 
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originally derived from natural products or their derivatives, which are widely used as 
anticancer or antimicrobial agents that are originally extracted from plants and animals 
(Cragg, Newman and Snader, 1997). Natural products are favoured over other synthetic drugs 
as they’re naturally sourced, so they could be degraded easily by the normal living cells, 
which decrease unfavourable cytotoxicity (Du and Tang, 2014). Therefore, developing novel 
anti-cancer drugs that are derived from natural products with minimal side effects would be 
preferred instead of using chemically synthesised drugs alone. Marine life has potential 
source of promising anticancer drugs, which could play an important role in anticancer 
treatments (Nobili et al., 2009).  
1.14. Polysaccharides from natural products as pharmaceutical agents 
 
Over the past several years, there has been an increased demand for new cancer 
pharmaceutical agents from natural products such as plants, bacteria and animals, including 
marine life. The main advantage of natural product–derived anticancer drugs that it has 
acceptable side-effects than of other synthetic drugs (Zhang et al., 2013). 
There are several drugs either approved by the United State Food and Drug 
Administration (US-FDA), European Medicines Agency (EMA) or in clinical trial that have 
been derived from marine sources. For instance, Cytarabin that was the first marine-derived 
chemotherapeutic drug isolated from a sponge (Tethya crypta) (Wlawick, Roberts and 
Dekker, 1959). Dolastatin which is a polypeptide product from marine mollusc (Dolabella 
auricularia) can inhibit microtubule assembly as well as tubulin polymerisation, resulting in 
cell apoptosis. Although it was not successfully approved, this drug also progressed to 
advanced phases in clinical trials and its derivatives are still being considered as anticancer 
candidates (Hearn, Shaw and Myles, 2007; Han et al., 2018).  
Halichondrin is a tubulin inhibitor, which was isolated from Japanese sponge 
(Halichondria okadai). It is synthetic, macrocyclic ketone with enhanced antitumor activities 
against breast cancer. The US-FDA has approved its synthetic analogue since 2010 (Osgood 
et al., 2017). Cyclic-peptide drug Kahalalide-F was isolated from the mollusc (Elysia 
rubefescens) has anti-lysosomal properties. It has entered phase-I clinical trials against 
prostate cancer and phase-II against hepatocellular carcinoma, non-small cell lung cancer and 
melanoma (Avendaño and Menéndez, 2008; Ning et al., 2018). Didemnin-B isolated from 
(Carribean tunicate) shows inhibition of DNA-synthase that leads to cell cycle arrest (Nobili 
et al., 2009). 
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One of the largest phyla in the animal kingdom are known as molluscs, including 
snails, bivalves, squid, octopuses, oysters, and others. Many molluscs have been used for 
dietary intake, as they have great nutritional benefits (Celik 2014). Traditionally, molluscs 
have been used as natural treatments in Chinese traditional medicine; therefore, there has 
been great interest in investigating their valuable elements to be used as pharmaceutical 
sources (Cesaretti et al., 2004). 
Generally, mollusc soft-body structural investigations have revealed high amounts of 
carbohydrates with some proteins and lipids, which makes carbohydrates a major area of 
interest from a pharmaceutical perspective (Amornrut et al., 1999). Polysaccharides from 
vertebrates and invertebrates have emerged as powerful platforms for medical utilities, as 
they have various biological activities such as immunostimulatory, antioxidant, and antitumor 
activities (Liao et al., 2013). 
Polysaccharides isolated from invertebrates have shown very different structures to 
common mammalian polysaccharides in terms of monosaccharide composition, molecular 
weight, degree of sulphation, type of glycosidic linkages, and branching points. For instance, 
a novel polysaccharide isolated from the head of a shrimp has a novel combination structure 
between heparin and HS known as a hybrid hep/HS structure (Brito et al., 2014). This 
structural diversity in polysaccharides has generated additional features for these novel 
molecules that could make them potent tools in glycobiology, especially as pharmaceutical 
agents. 
Polysaccharide (including GAGs) structural analysis is very challenging due to their 
structural heterogeneity and polysaccharide structure vary according to species, season of 
harvest, and extraction method; accordingly, all these structural differences might interrupt 
the structural analysis as well as the biological activities of these molecules (Wang et al., 
2017). In addition, carbohydrates cannot be visualized using UV or fluorescent as it lacks 
chromophore, therefore, detection usually requires a derivatization step (Rovio, Yli‐
Kauhaluoma and Sirén, 2007). For that reason, structural analysis has been heavily dependent 
on spectroscopic analysis, which is defined as the relationship between light or 
electromagnetic radiation and matter, such as nuclear magnetic resonance (NMR) and 
Fourier-transform infrared (FT-IR), in addition to chemical analytical methods in order to 
allow detection and to determine the final structure of these polysaccharides (Pomin, 2015; 
Wang et al., 2017).  
The high content of uncommon polysaccharides structures in marine organisms make 
them a favourable source of natural products with various pharmaceutical benefits, including 
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in cancer therapy. The following section reviews polysaccharides derived from vertebrates 
and invertebrates with different structures and biological and pharmaceutical properties such 
as anticoagulation and anti-neoplastic properties. 
1.14.1. Head of shrimp—Litopenaeus vannamei 
 
A GAG-like structure was isolated from head of the shrimp Litopenaeus vannamei 
with a unique structure of both heparin and HS disaccharides merged together, resulting in an 
uncommon GAG-like structure known as hybrid heparin/HS (Brito et al., 2014). This hybrid 
Heparin/HS has both heparin and HS properties in addition to their basic disaccharide 
structure of glucosamine and iduronic acid/glucuronic acid [→4)-β-D-GlcA/α-L-IdoA (1→4) 
-D-GlcNS-(1→] (Figure 31) (Pomin, 2015). The structural analysis was based on both 
disaccharides and NMR analysis, which has found a high amount of GlcA (77.6%) not 
epimerized to iduronic acid and only 22.4% IdoA; this finding suggests the influence of the 
HS chain. On the other hand, there is a high amount of sulphated GlcNS 71.5%, and GlcNAc 
represents about 22.5%. In addition, 75.5% of GlcNS was found to be GlcNS(6S), and 5% 
was found to have the rarest GlcN(3,6S) disaccharides, which simulates heparin’s structure 
(Brito et al., 2014). 
As this novel structure is related to heparin, its anticoagulation activity was examined 
and compared with that of the well-known heparin pentasaccharide. This novel structure was 
found to have anticoagulation activities lower than heparin that facilitate interaction with 
antithrombin to prolong the clotting time. Pomin (2015) suggested that this potent 
anticoagulant activity might be due to the pattern of N- and O-sulphation. More surprisingly, 
this hybrid type has very few side-effects in terms of bleeding. 
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Figure 31. Structural presentation of novel hybrid heparin-HS structure, which isolated from 
head of shrimp (Litopenaeus vannamei) (Pomin, 2015). 
1.14.2. Bivalve mollusc—Nodipecten nodosus 
 
A novel HS-like structure was isolated from a marine mollusc bivalve known as 
Nodipecten nodosus. Structural analysis has revealed a unique highly sulphated HS-like 
structure. Structural analysis using multinuclear-NMR has confirmed the presence of novel 
structural features of HS-like compound such as α-D-GlcNH2 residues and β-D-GlcA (2,3S) 
with no IdoA residues detected. The α-D-GlcNH2 residues contain 61% GlcNAc and 39% 
GlcNS. On the other hand, structural analysis has shown that 50% of the GlcA disaccharides 
are non-sulphated, 28% are 2-O-sulphated, and 22% 3-O-sulphated. According to Gomes et 
al. (2010), despite the presence of disulphated 2,3-O-sulphated GlcA, which is very rare in 
nature, an insignificant amount was determined (Figure 32). 
This unique structure suggests the presence of an HS-like structure rather than heparin 
for several reasons. First, all uronic acids were typically in the β-anomeric configuration, as 
β-D-GlcA with no resonance for α-L-IdoA. Second, high levels of -D-GlcNAc were 
detected, which indicates a more typically HS-like structure. Therefore, this suggests a novel 
HS structure that is uncommon in mammalian HS, especially with the particular pattern of 
sulphation on both the GlcA residues (Gomes et al., 2010; Pomin, 2015). Regarding its 
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pharmaceutical outcomes, this novel HS-like compound showed a six-fold decrease in 
anticoagulant activity in comparison to porcine heparin; however, this unique HS-like 
compound has potent anticoagulant activities in the presence of heparin-cofactor-II, which 
can increase the anticoagulant activities to up to 1,000 times stronger (Gomes et al., 2010). 
 
Figure 32. Structural presentation of novel HS-like structure isolated from bivalve mollusc 
(Nodipecten nodosus).  
1.14.3. Bivalve mollusc—Corbicula fluminea 
 
Corbicula fluminea is an edible bivalve mollusc originating in eastern Asia. This 
mollusc has various nutritional value, in addition to its valuable pharmacological benefits 
such as antiproliferative activities, antioxidants, and antihypertensive effects (Qiu, Dai and 
Li, 2009). Liao et al. (2013) purified three polysaccharide samples from Corbicula fluminea’s 
soft body, namely, crude extracts of CFPS and CFPS-2 with anti-tumour activities. CFPS-2 
was structurally analysed using various spectroscopic methods including FT-IR and NMR. 
The FT-IR structural analysis confirmed the presence of β-glycosidic linkages between 
polysaccharides, pyranose rings, sulphate esters, the N-acetyl functional group, the hydroxyl 
group, and the carboxyl group. Moreover, NMR structural analysis found pyranoses, β-
glucose, β-galactose, -glucose, and β-fucose. These findings suggest the presence of 
polysaccharides; however, no definite structure was determined. 
Regarding the biological activities, the purified fractions were tested against various 
human cancer cell lines such as prostate, ovarian, and gastric carcinomas to check their anti-
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proliferative activities. All three types of purified polysaccharides showed dose-dependent 
antiproliferation activities on all cancer cells. Liao et al. (2013) claimed, the presence of 
highly sulphated contents (8.1%) makes these polysaccharides water-soluble and enhances 
their anti-proliferative activities. 
1.14.4. Sea cucumber—Ludwigothurea grisea 
 
GAG-like structures were isolated from a sea cucumber known as a holothurian 
(Ludwigothurea grisea). This unique, highly sulphated structure shares the common 
mammalian CS-like structure; however, the GlcA C-3 has a branched O-linked fucose unit, 
so it’s known as fucosylated-CS. This sea cucumber’s unique structure is composed of 
sulphated -L-fucopyranose branch linked to β-D-GlcA and β-D-GalNAc [Fucp (1→3) 
GlcA β(1→3) GalNAc β(1→] (Vieira and Mourão, 1988; Pomin, 2015) (Figure 33). 
Spectroscopic structural analysis using NMR has confirmed a number of patterns of 
sulphation on the -L-fucp, as it can acquire mono-sulphate, 2,4-disulphate, and 3,4-
disulphate (Pomin, 2015); in addition, the β-D-GlcA of holothurian-CS can acquire a 3-O-
sulphate. The other disaccharides from this sea cucumber are the typical CS chains, which is 
similar to the mammalian CS in terms of structure and sulphate decorations can also be 
unsulphated, 4-O-sulphated or 6-O-sulphated (Myron, Siddiquee and Al Azad, 2014). All 
these different structures made this GAG-like polysaccharide resistant to chondroitinase 
enzymes (Vieira, Mulloy and Mourão, 1991).  
Holothurian fucosylated-CS can participate in various biological activities such as 
tumour metastasis, coagulation, cellular morphogenesis, inflammation, and angiogenesis 
(Pomin, 2015). Borsig et al. (2007) suggested that the sea cucumber’s fucosylated-CS with 
di-sulphated fucose-branch plays a role in inhibiting tumour cell metastasis via stopping 
adhesion molecules such as selectins. Furthermore, fucosylated–CS has a very potent role in 
inhibiting thrombus formation (Mourão et al., 1998). Depolymerised fucosylated-CS was 
introduced to reduce the activities of prothrombin, mainly by inhibition of coagulation factor 
X, which is responsible for conversion of prothrombin to thrombin (Wu et al., 2015). 
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Figure 33. (A) Shows CS-like disaccharides from Ludwigothurea grisea as GlcA can acquire 
3-O-sulphate group. (B) Shows CS-like disaccharide structure from marine Ludwigothurea 
grisea with fucp attached α(1→3) to GlcA making this novel fucosylated-CS, where 
fucopyranose are attached via (1→2) glycosidic linkages. 
 
1.14.5. Squid cartilage—Ommastrephes sloani pacificus 
 
A novel GAG polysaccharide was purified from squid cartilage (Ommastrephes 
sloani pacificus) (Kawai et al. 1966). Habuchi et al. (1977) reinvestigated the squid 
cartilage’s CS structure and found a large number of glucose branches linked to C-6 of the 
GalNAc moieties, which could be due to incomplete digestion of the PG residues. In 
addition, Kinoshita-Toyoda et al. (2004) purified a squid cartilage CS-like polysaccharide 
with branched hexose structure. Squid cartilage was digested with chondroitinases that 
resulted in four fractions; one of these fractions (fraction II) contains polysaccharides with 
glucose branches. Therefore, fraction II was sub-fractionated into 11 fractions. The authors 
most interesting observations were in subfractions 2 and 6 that both contained extensive 
glucose branches. 
For structural analysis, NMR data proposed two structures from fraction-II, which are 
fraction-II-2 and fraction-II-6 that have glucose branching structures. Fraction-II-2 proposed 
unique structure—[GlcA β(1→3) Glc β(1→6) GalNAc(4S)] (Figure 34)—and fraction-II-6 is 
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characterised by this unique structure—[GlcA β(1→3) Glc β(1→6) GalNAc(4S) β(1→4) 
GlcA β(1→3) GalNAc(4,6S)] (Figure 35). In addition to these glucose branches, NMR 
structural analysis detected the presence of the rare 3-O-sulphation on the GlcA residues, thus 
making this part of the CS-E novel and uncommon to the mammalian CS as [GlcA(3S) 
β(1→3) GalNAc(4,6S)]  (Kinoshita-Toyoda et al., 2004; Lamari and Karamanos, 2006).  
Regarding the biological activities of the squid cartilage CS-like polysaccharide, it has 
anticoagulation activities that are different from those of mammalian CS. CS-like 
polysaccharide can inhibit the complement pathway through inhibition of the positive 
regulator of the complement pathway, known as properdin. This anticoagulation activity is 
highly dependent on squid cartilage CS-like polysaccharide size and structure (Kinoshita et 
al. 1997). 
 
 
Figure 34. Structural presentation of squid cartilage (Ommastrephes sloani pacificus) purified 
fraction-II-2—[GlcA β(1→3) Glc β(1→6) GalNAc(4S)]. 
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Figure 35. Structural presentation of squid cartilage (Ommastrephes sloani pacificus) purified 
fraction-II-6—[GlcA β(1→3) Glc β(1→6) GalNAc(4S) β(1→4) GlcA β(1→3) 
GalNAc(4S,6S)]. 
1.14.6. King Crab Cartilage—Tachypleus tridentatus 
 
A GAG-like polysaccharide was isolated from king crab (Tachypleus tridentatus), 
which can be related to CS-like structures (Sugahara et al. 1996). Kitagawa et al. (1997) 
reinvestigated the structure of king crab CS-like structure by digesting using different 
enzymes such as hyaluronidase and chondroitinase, then fractionating using gel-filtration 
chromatography, which resulted in nine different oligosaccharides (fractions 1–9). The 
structure of each fraction was determined by NMR spectroscopy (Table 4). Most 
interestingly, king crab CS-like GAG contains 3-O-sulphated GlcA and 3-O-fucosylated-
GlcA; thus, the fucosylated-GlcA is located in an inner position as an unsulphated and 
unbranched. 
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Table 4. NMR proposed CS-like oligosaccharides isolated from king crab (Tachypleus 
tridentatus). Fractions 8 and 9 have hexasaccharides with different pattern of sulphation 
including 3-O-sulphated GlcA. Fraction 2A has pentasaccharides structure, whereas fractions 
6 and 7 have octasaccharides, all of them contain both 3-O-sulphated GlcA and 3-O-
fucosylated GlcA (Kitagawa et al., 1997). 
 
Fraction Oligosaccharides proposed structure 
Fraction 8 
 
GlcA(3S) β(1→3) GalNAc(4S) β(1→4) GlcA(3S) β(1→3) 
GalNAc(4S) β(1→4) GlcA β(1-3) GalNAc(4S) 
Fraction 9 
 
GlcA(3S) β (1→3) GalNAc(4S) β(1→4) GlcA(3S) β(1→3) 
GalNAc(4S) β(1→4) GlcA(3S) β(1→3) GalNAc(4S) 
Fraction 2A 
 
GlcA(3S) β (1→3) GalNAc(4S) β(1→4) Fuc α(1→3) GlcA β(1→3) 
GalNAc(4S) 
Fraction 6 
 
GlcA(3S) β(1→ 3) GalNAc(4S) β(1→4) Fuc α(1→3) GlcA β(1→3) 
GalNAc(4S) β(1→4) GlcA β(1→3) GalNAc(4S) 
Fraction 7 GlcA(3S) β(1→3) GalNAc(4S) β(1→4) GlcA(3S) β(1→3) 
GalNAc(4S) β(1→4) Fuc α(1→3) GlcA β(1→3) GalNAc(4S) 
 
1.14.7. African snail—Achatina fulica 
 
A novel acharan sulphate (AS), with a molecular weight 29 kDa, was first isolated 
from an African snail Achatina fulica by Kim et al (1996). NMR spectroscopic analysis has 
demonstrated the presence of a homogenous structure of IdoA and GlcNAc repeated 
disaccharides, formulated as [→4) -L-IdoA(2S) (1→4) α-D-GlcNAc (1→] (Figure 36) 
(Vieira et al., 2004; Pomin, 2015). In addition, NMR structural analysis confirmed that the 
fully epimerised IdoA has a very low pattern of sulphation. According to Pomin (2015), AS 
structure is similar to that of mammalian heparin and HS, as the IdoA can acquire 2-O-
sulphation; however, the GlcNH2 residues are acetylated, which makes it different from 
mammalian GAGs. 
AS biological activities include the successful inhibition of angiogenesis in fertilised 
chicken eggs, which represents the antiangiogenic activities of this novel molecule (Lee et al. 
2003). AS has very weak anticoagulation activities in comparison to mammalian heparin (Li 
et al., 2004). 
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Figure 36. Structural representation of the AS, isolated from African snail (Achatina fulica). 
IdoA can acquire sulphate group at C-2, whereas, the glucosamine residues are acetylated 
(Pomin, 2015). 
 
1.14.8. Sea squirt—Ascidian 
 
The ascidian is a form of marine life known as the sea squirt that is considered to be a 
rich source of polysaccharides with unique structure. Ascidians have high amounts of DS-like 
structures, which are composed of [→4 -L-IdoA (1→3) β-D-GalNAc 1→] (Figure 37). 
There are many structural variations on the patterns of sulphation within ascidian species, as 
the IdoA can be non-sulphated or 2-O-sulphated, and the GalNAc can be 4-O-sulphated 
and/or 6-O-sulphated. Nearly 70% of the ascidian DS-like disaccharides show highly 
sulphated structures such as [-IdoA(2S) (1→3) GalNAc(4S)] in comparison to mammalian 
DS, which contains lower quantities of di-sulphated disaccharides. This ascidian DS-like 
polysaccharide has been tested for various medical purposes, including anticoagulant and 
anti-metastatic agent (Pomin, 2015).  
Regardless of inter-species variations, sea squirt DS-like polysaccharides show 
anticoagulation activities. The DS-like structure [-IdoA(2S) (1→3) GalNAc(4S)] shows 
anticoagulation activities, which accelerate the activities of heparin-cofactor-II (Pavão, 2002). 
Regarding the anti-metastatic role of ascidians’ DS-like polysaccharide, two DS-like 
structures were purified from two different sea squirts known as Styela plicata and Phallusia 
nigra, which have the unique structures [IdoA(2S)-GalNAc(4S)] and [IdoA(2S)-
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GalNAc(6S)], respectively. Both structures have shown anti-metastatic activities by 
inhibiting the interaction between cancerous cells and adhesion molecules such as selectins, 
on endothelial cells (Kozlowski, Pavao and Borsig, 2011). 
 
Figure 37. Structural representation of the DS-like extracted from two different ascidian 
species (Pomin, 2015). 
1.14.9. Cuttlefish ink—Sepiella maindroni 
 
Ink from the cuttlefish ink (Sepiella maindroni) was used in Chinese traditional 
medicine, and has various haemostatic effects and immunomodulatory functions. Liu et al. 
(2008) successfully isolated and characterised a novel polysaccharide structure from Sepiella 
maindroni ink. After carbohydrate purifications, monosaccharide analysis was carried out 
using gas chromatography coupled with mass spectroscopy (GC-MS), which identified the 
presence of fucose, Man, GalNAc, and GlcA with α- and β- linkages. Afterwards, NMR 
structural analysis confirmed the presence of hexasaccharide repeating sequence within an 
inner branched GlcA α(1→3), as [→4) L-fucose β(1→4) L-fucose β(1→4) D-GalNAc 
α(1→6) D-Man α(1→4) GalNAc α(1→], where the GlcA is attached to the Man in α(1→3) 
linkages (Figure 38). 
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Sepiella maindroni’s hexasaccharide biological activities were assessed on mice with 
sarcomas using an in-vivo analysis. It was found that a combination of chemotherapy and 
polysaccharides reduced the mutagenic effects caused in the sarcoma blast cells (Liu et al. 
2008).  
 
Figure 38. Structural representation of Sepiella maindroni ink hexasaccharide repeating 
structure that is composed of [→4) L-Fucp β(1→4) L-Fucp β(1→4) D-GalNAc α(1→6) D-
Man α(1→4) GalNAc α(1→], where the GlcA is attached to the Man in α(1→3) linkages. 
1.14.10. Bivalve mollusc—Ruditapes philippinarum 
 
Ruditapes philippinarum is a bivalve edible mollusc used in Chinese traditional 
medicine. Zhang et al. (2008) isolated and purified polysaccharide from Ruditapes 
philippinarum, resulting in a crude extract; further purified using gel filtration, which resulted 
in sub-fractionated four peaks. All four fractions were assessed for biological function against 
human hepatoma cancer cell line, fraction-1 the only peak that showed antiproliferative 
activities. A further purification step was carried out on the purified extract, which 
successfully separated the PE to two peaks, namely, purified extract fraction-1 (PEF-1) and 
purified extract fraction-2 (PEF-2).  
Structural analysis was performed using FT-IR and NMR, which demonstrated the 
presence of homo-polysaccharide chains with no uronic acid residues. The PEF-1 chain 
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consists of α(1→4) glucopyranosyl residues with (1→6) branching point, while PEF-2 has 
co-existent α(1→4) and β(1→6) glucopyranosyl residues. In addition, the presence of protein 
residues has suggested the presence of protein-bound polysaccharides within the sequence. 
Only the PE has shown potent inhibitory properties against the human hepatoma cell 
line in a non-dose-dependent manner, while PEF-1 and PEF-2 have shown lower inhibitory 
effects. Zhang et al. (2008) concluded that these antiproliferative activities could be due to 
chemical composition, type of glycosidic linkage, molecular mass, degree of branching 
and/or the protein-bound polysaccharides, which could be responsible for the antiproliferative 
activities against the hepatoma cell line. 
2. Aims and objectives 
 
The aim of this study is to isolate marine polysaccharides derived from cockle 
bivalve molluscs (Cerastoderma edule), examine their antiproliferative activity on different 
cancer cell lines, then characterise their structure in order to correlate a structure-activity 
relationship. 
The main objectives of this study 
• Polysaccharide isolation from common cockle using cetylpyridinium chloride 
precipitation methods. 
• Assessment of the cockle polysaccharides antiproliferative activities on different 
cancer cell lines. 
• Application of various structural tools to determine the structure of common cockle 
polysaccharides with antiproliferative activity such as monosaccharide, disaccharide 
compositional analysis, FT-IR and NMR. 
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3. Materials and methods 
 
3.1. Outline of experimental work 
 
Common cockle (Cerastoderma edule) obtained from the Irish Sea and the British 
Isles. The extracted polysaccharide was investigated using various biochemical and structural 
tools to check its in-vitro role as an antiproliferative agent against different cancer cell lines, 
and to characterise their antiproliferative structures. Firstly, common cockle polysaccharide 
was isolated and purified from cockle’s soft body following the cetylpyridinium chloride 
precipitation method previously described (Kim et al., 1996). The resulted cockle crude 
extract (CE) polysaccharide was tested to check its antiproliferative activity using two 
leukaemia cell lines (K-562 and Molt-4) and a mesothelioma cell line (Mero-25). Next, 
various structural analysis approaches were conducted to assess the cockle CE 
polysaccharide’s structural similarities to mammalian GAGs. Secondly, the cockle CE 
polysaccharide with confirmed antiproliferative activity was purified using anion-exchange 
resin coupled with fast performance liquid chromatography system (FPLC). The anion-
exchange chromatography successfully separated the cockle CE polysaccharide into six 
fractions according to their anionic strength. Then, the cockle polysaccharide purified 
fractions’ antiproliferative activity was assessed against the three cancer cell lines to confirm 
the activity. Finally, structural analysis was conducted using various structural techniques to 
discover this novel antiproliferative structure of the CE polysaccharides as well as the 
antiproliferative activity of fraction 5 from the anion-exchange separation. 
3.2. Materials 
 
Cockles (Manchester Fish Market, UK), acetone (Sigma-Aldrich, UK), razor blade 
blender, alcalase enzyme Bacillus licheniformis (Merck, Millipore, Watford, UK), 
tricloroacetic acid (Sigma-Aldrich, UK), cold centrifuge (life sciences, Beckman coulter), 
potassium acetate (Sigma-Aldrich, UK), ethanol (Fisher Scientific, UK), sodium chloride 
(Sigma-Aldrich, UK), cetylpyridinium chloride (Sigma-Aldrich, UK), dialysis tubes 
(Scientific Laboratory Supply, UK), freeze-dryer (Scanvac coolsafe, Labogene, Denmark), 
Ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich, UK), anion exchange resin 
diethylaminoethanol-sepharose (GE Healthcare, Little shallot, UK), FPLC system 
(Pharmacia, Stockholm, Sweden), empty column XK 16/20 (GE Healthcare, Little shallot, 
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UK), sodium phosphate monobasic (Sigma-Aldrich, UK), sodium phosphate dibasic (Sigma-
Aldrich, UK), fraction collector (FRAC-100, Pharmacia, Stockholm, Sweden), PD-10 
column (GE Healthcare, Little shallot, UK), RPMI-1640 (Lonza group Ltd), DMEM (Fisher 
Scientific,UK), fetal bovine serum (Labtech International Ltd, UK), L-glutamine (Labtech 
International Ltd, UK), penicillin and streptomycin (Labtech International Ltd, UK), 
heparanase from Flavobacterium Heparinum (Grampian Enzymes, Aberdeen, UK), 
Chondritinase-ABC (Grampian enzymes, UK), -L-fucosidase (Sigma-Aldrich, UK), sodium 
acetate (Sigma-Aldrich, UK), calcium acetate (Sigma-Aldrich), bovine serum albumin 
(Thermo fisher scientific, UK), Spectrophotometer (Multiscan, Thermo Fisher, UK), Nanosep 
10 kDa spin filter (Pall Laboratory, USA), Tris-HCL (Sigma-Aldrich, UK), sodium citrate 
(Sigma-Aldrich, UK), MTT powder (Sigma-Aldrich, UK), Cisplatin (Sigma-Aldrich, UK), 
mammalian HS (Celsus, Cincinnati, OH, USA), heparin (Celsus, Cincinnati, OH, USA), CS 
(Celsus, Cincinnati, OH, USA), DS (Celsus, Cincinnati, OH, USA), 10 x phosphate buffer 
saline (Sigma-Aldrich, UK), Dimethyl sulfoxide (Fisher Scientific UK Ltd), 0.22 µM filter 
(Merck, Millipore, Watford, UK), Apoptosis assay kit (BD biosciences, UK), Flow cytometry  
(BD FACSVerse, Franklin Lakes, NJ, USA), Dionex ICS-3000 system (Sunnyvale, CA, 
USA), MilliQ water (Merck, Millipore, Watford, UK), trifluoroacetic acid (Sigma-Aldrich), 
Isopropanol (Fisher Scientific UK Ltd), Dionex CarboPac PA1 column (Thermo fisher 
scientific, uk), 4 mm x 50 guard column (Thermo fisher scientific, UK), sodium hydroxide 
(Sigma-Aldrich, UK), UV detector (Gilson USA), sodium cyanoborohydride (Sigma-
Aldrich), HS disaccharides standards (Calbiochem and Sigma-Aldrich), CS disaccharides 
standards (Oxford Glycosystems), LC/MS (Thermo-Finnigan, San Jose, CA), Dibutylamine 
(Sigma-Aldrich), C-18 reversed-phase column (0.46 cm X 25 cm, Vydac), methanol (Fisher 
Scientific, uk), FT-IR spectroscopy system (Bruker, Billerica, Massachusetts, United States), 
NMR spectroscopy 800 MHz (Bruker, Billerica, Massachusetts, United States), duterum 
oxide 99.9% (Sigma-Aldrich, UK), tetramethylsilane (Sigma-Aldrich, UK). 
3.3. Methods 
3.3.1. Extraction of sulphated polysaccharides from common cockle 
 
This extraction procedure, known as the cetylpyridinium chloride precipitation 
method, was previously used to extract GAG-like polysaccharides from invertebrate soft 
bodies (Kim et al., 1996). Initially, cockle shells were removed, and 250 g of cockle soft 
body tissue was soaked in acetone 400 mL for 72 h to ensure fat removal; the acetone was 
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changed every 24 h. Defatted tissues were left to dry for 24-48 h at room temperature then 
ground to a fine powder using a razor blade blender. The powder (50 g) was suspended in of 
0.05 M sodium carbonate (500 mL) with pH 9.2 and 25 mL of Alcalase enzyme (30 Anson 
units/g) was added, and then the mixture was incubated at 60 °C for 48 h with constant 
agitation at 200 rpm.  
The mixture was then cooled to 4 °C and 5% trichloroacetic acid (w/v) was added to 
the mixture and mixed for 10 min. Then, the precipitated peptides were removed by 
centrifugation (8000 rpm for 25 min). After centrifugation, the supernatant was transferred to 
a cylinder and three volumes of 5% (w/v) potassium acetate in ethanol were added to one 
volume of the supernatant and the mixed solution left overnight at 4 °C.  
Subsequently, the precipitated cockle polysaccharide was recovered by centrifugation 
(8000 rpm for 30 min). The recovered precipitate (about 12 g) was then dissolved in of 0.2 M 
NaCl solution (480 mL) and centrifuged (8000 rpm for 30 min) to remove any insoluble 
material. Next, cetylpyridinium chloride (6.25 mL of a 5% (w/v) solution) was added to the 
supernatant and the mixture was centrifuged (8000 rpm for 30 min). The precipitate was 
subsequently dissolved in of 2.5 M NaCl buffer (125 mL), followed by the addition of 5 
volumes of absolute ethanol. The precipitated cockle polysaccharide was recovered by 
centrifugation (10,000 rpm for 30 min); the precipitated polysaccharides were recovered and 
dissolved in water (30 mL) in order to be ready for dialysis process. 
According to cockle preparation procedure which depends heavily on their negative 
charge, the dialysis tubing’s were treated prior to adding final polysaccharide mixture to 
remove any charged particles attached to it. Initially, tubes were treated with 30 mM sodium 
bicarbonate (10 g) and 10 mM EDTA (0.146 g) in distilled water (400 mL) for 10 min. Then, 
tubes were washed with boiled distilled water for 10 min. Finally, tubes were washed with 10 
mM EDTA (0.146 g) in distilled water (250 mL) and absolute ethanol (250 mL). Afterward, 
the polysaccharide mixture, which was dissolved in water (30 mL), was added to the freshly 
prepared dialysis tubing with a molecular weight cut-off (MWCO) of 14 kDa against water 
for 72 h, as dialysis water was changed every 24 h. The dialysate was lyophilized to obtain a 
white powder containing approximately 24 mg of cockle polysaccharide that was coded as 
crude extract (CE). 
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3.3.2. Anion-exchange chromatography 
 
The cockle CE polysaccharide preparations were purified using anion-exchange resin 
coupled with the fast performance liquid chromatography (FPLC) system. The anion-
exchange column (16 X 200 mm) was packed with fast flow diethylaminoethyl-sepharose 
(DEAE-Sepharose) (10 mL) that is composed of cross-linked agarose 6% (Silva, 2006). 
Cockle CE polysaccharide was dissolved in distilled water (1 mg/mL) prior to injection into 
the FPLC system. The column was pre-washed with 1 column volume (10 mL) of 1.5 M 
NaCl, then 1 mL of cockle CE polysaccharide mixture was injected to the FPLC system and 
the cockle CE polysaccharide was eluted using a linear gradient 0-1.5 M of NaCl (7.8 g/L) in 
50 mM sodium phosphate buffer (7.098 g/L) at pH 7.0 over 75 min at a flow rate of 1 
mL/min. Absorbance was monitored at 280 nM (Rovio, Yli‐Kauhaluoma and Sirén, 2007), 
and 1 mL fractions were collected using Pharmacia fraction collector, then pooled as 
indicated. After each run, the column was washed with 1 column volume (10 mL) of 1.5 M 
NaCl to ensure removal of any attached materials as well as to recharge the column. 
Pooled fractions corresponding to the peaks in the elution profile were dialysed 
extensively against water using a dialysis tube with MWCO 14 kDa over 3 consecutive days. 
After the dialysis process, fractions were lyophilised using freeze-drier for 3 days to obtain 
the final polysaccharide products. A further desalting step was performed to ensure samples 
are salt-free using a desalting column PD-10. The PD-10 column is a desalting column 
containing gel filtration sephadex (G-25) resin, using gravity method. The column was 
washed with of 10% ethanol (30 mL), and then 2.5 mL of the sample was applied. The first 
2.5 mL was discarded, as it was the column void volume; the next 3.5 mL was collected, 
lyophilised, and stored at -20 °C (Kitagawa et al., 1997). 
 
3.3.3. Enzymatic digestion 
 
The extracted cockle polysaccharide was digested using different enzymes, namely 
heparinase enzymes, chondroitinase-ABC and/or α-L-fucosidase, to be used for further 
analysis in order to release unsaturated disaccharides from both cockle CE or cockle purified 
fractions, as follows.  
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3.3.3.1. Heparinase dilution and working concentration 
 
Heparinases were purchased in international units (IU) as stock concentrations as 
heparinase-I (2.0 IU), heparinase-II (0.2 IU) and heparinase-III (0.5 IU) (Grampian enzymes, 
UK). Enzyme dilution was performed following the manufacturer’s recommendations, as 
follows. Initially, the enzyme concentration was adjusted to 1.0 IU/ml on the enzyme stock, 
by adding 1x heparinase buffer, which is composed of 50 mM sodium acetate and 10 mM 
calcium acetate at pH 7.0, containing bovine serum albumin (BSA) 0.2-0.4 µg/mL as a 
stabiliser. Then, the adjusted enzyme stock was split into 100 µL aliquots, in which each 100 
µL contains 1.0 IU/ml of enzyme that was stored at -80 °C. For the enzyme working 
concentration, 400 µL of 1x heparinase buffer was added to one vial (100 µL at 1.0 IU/mL) 
of enzyme stock, without BSA, to reach a final volume of 500 µL containing about 200 
mIU/mL of the enzyme. This 500 µL (200 mIU/mL) was aliquoted into 10 µL in each vial to 
obtain about 5-10 mIU. All enzyme aliquots were stored at -20 °C (Lamanna, 2008). 
For cockle polysaccharides digestion, 100 µg of polysaccharide was dissolved in 200 
µL of 1 x heparinase buffer and heparinase-I (30 mIU), heparinase-II (30 mIU), heparinase-
III (30 mIU), separately or in combination of all three enzymes. This was incubated at 30 °C 
for 24 h. The enzyme digests were monitored spectrophotometrically at 232 nM and the 
reactions were terminated by heating at 100 °C for 5 min. The samples were passed through a 
10 kDa spin filter, and then both retained materials and flow through materials were dried 
prior to further analysis. 
3.3.3.2. Chondroitinase-ABC dilution and working concentration 
 
Chondroitinase-ABC was purchased in 5 IU quantities (Grampian enzymes, UK). The 
enzyme working concentration was adjusted by reconstitution in 5 mL of 50 mM Tris-HCl 
and 50 mM sodium acetate buffer at pH 8.0 with 0.2% BSA to make 1.0 IU/mL. The enzyme 
was aliquoted at 1 mL/vial and stored at -80 ºC. Then, 1 mL stock at 1.0 IU/mL was split into 
100 µL aliquots, in which each 100 µL at 1.0 IU/mL of enzyme that was stored at -80 °C. For 
enzyme working concentration, 400 µL of 1 x condroitinase buffer was added to one vial of 
enzyme stock (100 µL at 1.0 IU/mL), without BSA, to reach a final volume of 500 µL 
containing 200 mIU/mL of the enzyme. This 500 µL (200 mIU/mL) was aliquoted into 10 µL 
in each vial to obtain about 5-10 mIU. All aliquots were stored at -20 °C. 
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For cockle polysaccharides digestion, 100 µg of cockle polysaccharides was dissolved 
in 200 µL of chondroitinase-ABC buffer and added to 30 mIU of the enzyme. Then, it was 
incubated for 24 h at 37 °C. The enzyme digests were monitored spectrophotometrically at 
232 nM and the reactions were terminated by heating at 100 ºC for 5 min. The samples were 
passed through a 10 kDa spin filter, and then both retained materials and flow through 
materials were dried prior to further analysis. 
3.3.3.3. Fucosidase enzyme dilution and working concentration 
 
-L-fucosidase enzyme is a broad-spectrum hydrolase enzyme that cleaves fucose 
from proteoglycans, extracted from bovine kidney. It has broad substrate properties that can 
cleave [-L-fucose 1→ (2,3,4,6)] from both N- or O-linked glycan (Parekh et al., 1987). 
The enzyme was purchased in 0.5 IU quantities in a 3.2 M ammonium sulphate 
solution containing 10 mM sodium phosphate monobasic and 10 mM sodium citrate. 
Initially, the ammonium sulphate was discarded by centrifugation and the pellet containing 
the enzyme was recovered. The enzyme working concentration was adjusted by 
reconstitution in 500 µL of 100 mM sodium citrate buffer at pH 5.6 (0.5 IU/500 µL). The 
enzyme was aliquot of 100 µL containing 0.1 IU been stored at 2-8 ºC. For the enzyme 
working concentration, 400 µL of 1 x enzyme buffer was added to one vial of 100 µL stock, 
as the 500 µL containing about 200 mIU/mL, then 10 µL in each vial to obtain about 5-10 
mIU. Enzyme check was determined using spectrophotometer at 400 nM. 
For cockle polysaccharide digestion, 100 µg of the cockle polysaccharide was 
dissolved in 200 µL of α-L-fucosidase buffer and 30 mIU of the enzyme was added. Then, it 
was incubated for 24 h at 37 °C. The enzyme digests were monitored spectrophotometrically 
at 400 nM and the reactions were terminated by heating at 100 ºC for 5 min. The samples 
were passed through a 10 kDa MWCO spin filter, and then both retained materials and flow 
through materials were dried before further analysis. 
3.3.4. Maintenance of cell lines 
 
Cell culture was conducted using two human leukaemia cell lines, CML-derived cell 
line K-562 and ALL-derived cell line Molt-4, and human malignant mesothelioma with 
asbestos exposure (pleural cavity) Mero-25 cell line (ECACC 09100102). The human 
leukaemia cell lines were grown in RPMI-1640 cell culture medium containing 1 g/L glucose 
76 
 
and the Mero-25 cell line was grown in a DMEM cell culture medium containing 3.7 g/L 
glucose. All culture media were supplemented with 10% (v/v) inactivated fetal bovine serum 
(FBS), 2 mM L-glutamine, 100 units/mL penicillin and 100 µg/mL streptomycin. All cell 
lines were maintained in 75 mL flasks under a sterile and humidified atmosphere of 95% air 
and 5% CO2 at 37 °C. 
3.3.5. Cell proliferation assay 
 
Cell proliferation was assessed using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) assay, which is an in-vitro colorimetric technique that is widely used to 
assess cell viability and proliferation. Physiologically viable cells’ mitochondria produce an 
enzyme known as nicotinamide adenine dinucleotide (phosphate) (NAD(P)H)-dependent 
oxidoreductase, which reduces the tetrazolium (MTT-dye) to a compound called formazan (a 
crystalline product purple in colour) (Gerlier and Thomasset, 1986). In contrast, non-viable 
cells do not catalyse the reduction of the tetrazolium to produce purple-coloured crystal 
formazan. Therefore, this assay detects the density of the colour and gives qualitative 
indications of viable and non-viable cells using half-maximal inhibitory concentration (IC50), 
which is defined as the quantity of a drug required to inhibit the biological activity by half, 
thereby illustrating anti-proliferative activity. 
Cells were seeded at a density of 5 X 103 cells per well in 96-well plates containing 
100 µL of culture medium prior to treatment with polysaccharide samples for K-562 and 
Molt-4 cell lines, however, for Mero-25 cell line, the cells were seeded in 96-well plate and 
incubated overnight, to allow cells to attach to the plate. Following that the addition of 
different drugs, such as cockle polysaccharide samples with increased dose (0, 0.78, 1.56, 
3.12, 6.25, 12.5, 25, 50 (µg/mL)), mammalian GAGs (0, 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50 
(µg/mL)), and cisplatin (0, 0.39, 0.78, 1.56, 3.12, 6.25. 12.5, 25 (µM)) that was used as 
positive control, in triplicates, then, cells were incubated for 96 h following. Following the 
incubation period, 50 µL of the MTT solution (5 mg/mL in PBS) was added to each well and 
plate was further incubated for 3 h at 37 °C, then solution was removed by aspiration. Next, 
200 µL of dimethyl sulfoxide (DMSO) was added to each well in order to dissolve the 
formazan crystal product. The amount of the MTT dye converted to formazan is directly 
proportionally to the viable cells. The plate was gently agitated until the colour reaction was 
uniform and the absorbance was measured at 570 nM using a multi-well plate reader.  
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Figure 39. MTT assay 96-well U-shaped wells for suspension cell lines or Flat-shaped wells 
for adherent cell line. Maximum drug concentration was added in the last row (H), then, drug 
was diluted until row (B). Row (A) was used for untreated control cells. Every drug 
concentration was tested in triplicates including control cells. 
3.3.5.1. Determination of IC50 values 
 
The average cell values were determined from triplicates at each data set in order to 
obtain IC50 values using GraphPad Prism 8.0 (La Jolla, CA, USA). First, the values from 
untreated cells were considered to have the maximum growth rate and the values from the 
treated cells were determined according to the untreated control values. Second, in order to 
plot a dose-response curve, all data values were normalised as the largest value was assigned 
as 100% growth, and the smallest value was assigned to 0%. Therefore, the y-axis was 
defined as the growth percentage and the x-axis was defined as the drug concentration. 
Finally, the IC50 values were determined using non-linear regression inhibitor vs normalised 
response option. 
3.3.6. Annexin-V Apoptosis Assay 
 
There are several biochemical techniques to determine the cellular death process. One 
of these techniques is to determine early apoptotic markers of cell death. One early apoptotic 
marker is known as phosphatidylserine, which is a phospholipid compound that is part of the 
inner cell membrane. During early apoptotic conditions, such as hypoxia, phosphatidylserine 
is translocated to the outer cell membrane, which makes it exposed to antibodies, for 
example. Phosphatidylserine on the outer cell membrane can bind to a binding protein known 
as Annexin-V, therefore, Annexin-V was conjugated with a fluorochrome called fluorescein 
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isothiocyanate (FITC) to visualise this reaction using flow cytometry. In order to differentiate 
between apoptosis and necrosis, cells were stained with propidium iodide (PI), which binds to 
the necrotic cells, in addition to FITC-Annexin-V. Hence, using flow cytometry as a 
quantitative technique to count FITC-Annexin-V and PI-stained cells is very useful to 
evaluate cellular death progression (Biosciences, 2011).  
To perform the apoptosis assay using FITC-Annexin-V and PI stains, cells were 
seeded into a sterile 6-well plate at 5 X 105 / mL at 37 °C. Next, cockle CE polysaccharide or 
cockle purified active fraction was added to the cells and left for 24 h. Afterwards, treated 
and untreated cells were washed twice with cold PBS and centrifuged at 2000 X g for 5 min, 
followed by resuspension in 1 x binding buffer (0.1 M HEPES buffer, 1.4 M NaCl and 25 
mM calcium chloride) at a concentration of 1 X 106 cells/mL. Cells (100 µL) were then 
stained with Annexin V-FITC (5 µL) and PI (5 µL). Stained cells were gently vortexed and 
incubated in the dark for 15 min at room temperature 25 °C. After incubation, 400 µL of 1 x 
binding buffer was added to cells prior to analysis using a flow cytometer.  
3.3.7. Monosaccharide composition analysis 
 
Monosaccharide composition analysis was conducted using high-pH anion-exchange 
chromatography coupled with pulsed amperometric detection (HPAEC-PAD) using a Dionex 
ICS-3000 system (Hardy, Townsend and Lee, 1988). This method was favoured for 
monosaccharides composition analysis as it does not require sample derivatisation, which 
makes it advantageous for an unknown polysaccharide sample. Because polysaccharides lack 
a chromophore, an electrochemical detector was chosen which has several advantages. For 
instance, it has the ability to discriminate between monosaccharides and the mobile phase, 
and is a qualitative, quantitative, sensitive and non-destructive detector. 
For cockle monosaccharide composition analysis, 50 µg of cockle CE polysaccharide 
or 50 µg of each purified fraction was dissolved in 200 µL MilliQ water. The mixture was 
then incubated with 1 mL of 4M trifluoroacetic acid at 100 °C for 6 h to ensure the release of 
both monosaccharides and uronic acids. Then the sample was centrifuged at 2000 rpm for 2 
min, followed by the removal of acid using a dry nitrogen flush and 50 µL of 50% (v/v) 
aqueous isopropyl alcohol as a co-evaporative to remove the remaining acid until the sample 
was completely dry.  
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For monosaccharide analysis, 20 µg of the hydrolysed polysaccharide sample was 
suspended in 100 µL MilliQ water. Then, 50 µL of the sample was injected into a Dionex 
CarboPac PA1 column (4 mm x 250 mm, 4μm, with 4 mm x 50 mm guard column) at a flow 
rate of 1 mL/min. Monosaccharides were eluted using gradient elution under strong alkaline 
conditions formed from three solvents: high purity H2O as solvent (A); 100 mM sodium 
hydroxide (NaOH) with 5 mM sodium acetate (NaOAc) as solvent (B); and 100 mM NaOH 
with 250 mM NaOAc as solvent (C) (Table 5). Peaks were detected using a pulsed 
amperometric detector with standard quad waveform for carbohydrates and evaluated 
according to a standard profile. 
Table 5: HPAEC solvent gradient setting for monosaccharides and organic acids analysis 
Time (minutes) Solvent A% Solvent B% Solvent C% 
0 84 16 0 
20 84 16 0 
21 79 16 5 
50 0 16 84 
65 0 16 84 
66 84 16 0 
80 84 16 0 
 
3.3.8. Disaccharides analysis 
 
Cockle CE polysaccharide (5 g) or cockle purified fraction (5 g) were incubated 
with a mixture of 30 mIU for each of heparinases I, II and III in 200 µL heparinase buffer or 
they were incubated with 30 mIU of chondroitinase-ABC in 200 µL of chondroitinase buffer. 
Samples were incubated overnight at 37 °C and the reaction was terminated by heating to 100 
°C for 5 min. The samples were passed through a 10 kDa spin filter then dried before further 
analysis. 
Glycan reductive isotope labelling (GRIL) using isotopic aniline tagging was used for 
composition analysis and mass detection of disaccharide yields from heparinase- or 
chondroitinase-treated cockle polysaccharides (Lawrence et al., 2008). 15 µL (165 µmol) of 
labelled aniline tagging added to 5 µg of dried heparinase- or chondroitinase-derived 
disaccharides, then 15 µL of 1M sodium cyanoborohydride, freshly prepared in DMSO/acetic 
acid (7:3, v/v), were added to the sample. Reactions were carried out at 37 °C for 16 h, and 
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then dried using centrifugal evaporator, then the sample was spiked with [13C6] of 5 µL (8 
pmol) of unsaturated disaccharide standards tagged. The dried samples were prepared for 
liquid chromatography coupled with mass spectrum (LC-MS) analysis by suspension in a 
running buffer (8 mM acetic acid, 5 mM in ion-pairing agent dibutylamine (DBA)), then 
disaccharides were separated on a C18 reversed-phase column (0.46 cm X 25 cm). 
The solvent system for eluting the samples was 100% buffer (A) (8 mM acetic acid, 5 
mM DBA) for 10 min, 17% buffer (B) (70%, methanol 8 mM acetic acid 5 mM DBA) for 15 
min, 32% buffer (B) for 15 min, 40% buffer (B) for 15 min, 60% buffer (B) for 15 min, 
100% buffer (B) for 10 min and 100% buffer (A). Ions of interest were detected in negative 
ion mode and the capillary temperature and spray voltage were kept at 140 °C and 4.75 kilo-
volt, respectively, with UV detection set at 232 nM, data shown in appendix XII and XIII. 
3.3.9. FT-IR 
 
FT-IR is a type of spectroscopic technique that principally uses the infrared spectrum. 
It is simple, non-destructive, fast technique that can indicate the functional groups present 
within a sample and can aid in understanding the chemical structure of that sample. The main 
principle of the technique is the detection of the bonds between atoms, which can undergo 
stretching, bendingn or wagging rotation. IR radiation can pass through the sample and 
transmit light to the detector or it can be absorbed by the molecule. Therefore, the IR 
spectrum can be represented with an x-axis (wave number cm-1) and it’s corresponding y-
axis (transmittance%) (Movasaghi, Rehman and ur Rehman, 2008). 
For the analysis of cockle CE polysaccharide, the sample platform was cleaned using 
70% ethanol, followed by 16 scans to resolve any noise prior use. Then, 500 µg of dried 
cockle CE polysaccharide was placed on the sample platform and full infrared scan was 
determined in 16 scans. Data was analysed using OMNIC software. 
3.3.10.  NMR 
 
NMR is a powerful spectroscopic technique that allows identifying the presence of 
certain physical and chemical properties of a molecule. As a result, it is excellent for 
providing the structural properties of an unknown molecule. The NMR instruments interacts 
with the nucleus by applying an external magnetic field. It has the ability to identify more 
than one nucleus at a time known as multi-dimensional NMR spectroscopy. This technique 
gathers more information about the presence of selected atoms. For instance, two-
81 
 
dimensioned NMR can detect the resonance of both 1H and 13C at the same time, resulting in 
a correlation between the bonds of these two atoms (Friebolin and Becconsall, 1993). 
For cockle polysaccharide analysis, one and two-dimensional (2D) 1H and 13C spectra 
of the cockle polysaccharides were recorded using Bruker 800 MHz machine with a triple 
resonance probe, and the spectra were analysed using TopSpin software. Approximately 5 mg 
of the cockle CE polysaccharide or its purified fraction 5 were dissolved in 0.5 mL of 99.9% 
deuterium oxide. All spectra were recorded at 56 ºC in water peak suppression mode. All 
chemical shifts were relative to the internal reference tetramethylsilane (TMS) (5 µL). 
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4. Results—Cockle CE polysaccharide biological and structural analysis  
 
Cockle CE polysaccharide was extracted from marine-source cockle (Cerastoderma 
edule) using a typical cetylpyridinium chloride precipitation method, which resulted in about 
(24 mg) white fluffy material. Several biological and structural analyses tools were 
performed on cockle CE polysaccharide in order to assess its role as an antiproliferative agent 
as well as to assess its related structure. Firstly, cockle’s CE polysaccharide pharmaceutical 
outcome as antiproliferative agent was assessed against two leukaemia cell lines (K-562 and 
Molt-4) and a mesothelioma (Mero-25) cancer cell line using a cell proliferation assay 
(MTT), this was followed by an apoptosis assay to determine its role in mediating cell death. 
Secondly, after confirming the antiproliferative activity against the cancer cell lines, several 
structural techniques were implemented such as monosaccharide and disaccharide 
compositional analyses, as well as FT-IR and NMR in order to obtain more structural details 
about this potent pharmaceutical agent. 
4.1. Biological activities of cockle CE polysaccharides 
 
4.1.1. Cockle CE polysaccharides—cell proliferation assay 
 
Numerous studies have shown the potential medicinal properties of marine 
polysaccharides. In this study, marine polysaccharides isolated from cockle showed 
antiproliferative effects on cancer cell lines in-vitro. Cockle CE polysaccharides 
antiproliferative activities were assessed against leukaemia cell lines K-562 and Molt-4 and 
mesothelioma cell line Mero-25, which resulted in considerable inhibitory effects as 
determined using MTT assay (Figure 40). Some batch-to-batch variability in IC50 values was 
determined due to different cockle preparations as well as because of the complex 
heterogeneity of the polysaccharide chains present. Cisplatin was used in all assays as a 
positive control in the comparisons of different preparations. Typical IC50 values were around 
10 ± 2 g/mL, 1.2 ± 0.5 g/mL and 22 ±4 g/mL for the K-562, Molt-4 and Mero-25 cell 
lines, respectively. 
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Figure 40. The antiproliferative activity of cockle CE polysaccharides on three cancer cell 
lines. Cancer cell lines K-562 (A), Molt-4 (B) and Mero-25 (C) were treated with increasing 
doses of cockle CE polysaccharides (0, 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50 µg/mL) and cell 
viability was determined using MTT assay, as detailed in section 3.3.4. The inserts show the 
effects of cisplatin treatment on the number of viable cells. Cell viability is expressed as a 
percentage relative to the untreated control cells. All experiments were conducted in triplicate 
and the results are shown as the mean ± the SD. Cells were cultured under standard 
conditions and maintained at 37 °C in a humidified 5% CO2 atmosphere.  
 
Table 6. Present list of IC50 of cockle CE polysaccharide and cisplatin as positive control on 
all cell lines. All IC50 values were conducted in triplicate and calculated using non-linear 
regression analysis (GraphPad Prism 8.0). 
Drug 
List of IC50 on each cell line  
K-562 Molt-4 Mero-25 
Cockle CE polysaccharide (µg/mL) 9.23 (µg/mL) 1.5 (µg/mL) 19.33 (µg/mL) 
Cisplatin (µM) 0.49 (µM) 0.9 (µM) 14.67 (µM) 
85 
 
4.1.1.1.  Comparisons of cockle CE polysaccharide GAG-like antiproliferative activity 
with mammalian GAGs 
 
Further investigations confirmed that mammalian-derived GAGs (porcine) had no 
antiproliferative activity on cancer cell lines using MTT assay (Figure 41). Cell proliferation 
assay showed that no measurable IC50 could be determined for mammalian heparin, HS, CS 
and DS against cancer cell lines; however, the cockle CE polysaccharides continued to show 
significant antiproliferative activity. In fact, at low concentrations, mammalian HS showed 
slight stimulatory activity on cell growth. These results suggest that, if HS-like-GAG chains 
are involved in the antiproliferative activity of cockle CE polysaccharides, then they must 
have unique structural features not found in typical mammalian GAGs.  
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Figure 41. Comparisons between the antiproliferative activity of cockle CE polysaccharides 
and the common mammalian GAGs on cancer cell lines. The three cancer cell lines, K-562 
(A), Molt-4 (B) and Mero-25 (C), were treated with increasing doses of cockle CE 
polysaccharides (0, 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50 µg/mL) or common mammalian-
GAGs (0, 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50 µg). Cockle CE polysaccharides was the only 
agent that show antiproliferative activity on all cell lines. Cockle CE polysaccharides (●), 
mammalian-heparin (♦), mammalian-HS (■), mammalian-CS (▲) and mammalian-DS (▼). 
The data are presented as the percentage of viable cells following treatment with different 
polysaccharides, relative to the untreated control. All experiments were conducted in 
triplicate and the results are shown as the mean ± the SD. Cells were cultured and maintained 
at 37 °C in a humidified 5% CO2 atmosphere. 
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Table 7. Present list of IC50 of cockle CE polysaccharide (0, 0.78, 1.56, 3.12, 6.25, 12.5, 25, 
50 g/mL) and mammalian GAGs (0, 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50 g/mL) on all cell 
lines. IC50 was determined when a drug has inhibited the cancer cells growth by 50% at 
maximum concentration of 50 g/mL, therefore, if a drug has inhibited less than 50%, then 
the drug is considered to be inactive. All values were conducted in triplicate and the IC50 
calculated using non-linear regression analysis (GraphPad Prism 8.0). 
 
Polysaccharides as antiproliferative 
agent 
List of IC50 on each cell line  
K-562 Molt-4 Mero-25 
Cockle CE polysaccharide 12.34 (µg/mL) 1.41 (µg/mL) 27.54 (µg/mL) 
Mammalian-heparin  Inactive Inactive Inactive 
Mammalian-HS Inactive Inactive Inactive 
Mammalian-CS Inactive Inactive Inactive 
Mammalian-DS Inactive Inactive Inactive 
 
 
4.1.1.2.  Effects of enzymatic degradation on cockle CE polysaccharide 
antiproliferative activity 
 
The extraction procedure designed to enrich the content of sulphated GAGs or sulphated 
GAG-like structures that also could cause attachment of contamination from other marine 
polysaccharides. These non-GAG polysaccharides may have contributed, solely or in part, to 
the observed antiproliferative activity of the cockle CE polysaccharides. Enzymatic 
treatments of the cockle CE polysaccharides were achieved. Heparinases, chondroitinase-
ABC or fucosidase to investigate any link between typical GAG-like structures and the 
observed antiproliferative activity. After applying the 10 kDa spin filter, each sample has 
separated into two parts, flow through and retained part. The flow through part contained all 
the disaccharides, which showed no antiproliferative activity 9.8), while, the retained part has 
shown the antiproliferative activity. Figure 42 demonstrates that there was no appreciable 
change in the antiproliferative activity of the retained part when cockle CE polysaccharides 
were treated with chondroitinase-ABC and fucosidase. Heparinase digestion (individually 
and in combination), however, did lead to a significant loss of the antiproliferative activity 
within the retained part, with an approximate decrease in IC50 values for combined 
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heparinases (I, II, III) of around 4-, 8- and 2-fold for the K-562, Molt-4 and Mero-25 cell 
lines, respectively (Table 8). 
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Figure 42. The effect of heparinase (I, II, III), chondroitinase ABC and α-L-fucosidase 
enzymatic digestion on cockle CE polysaccharide antiproliferative activity. The sensitivity of 
the cockle CE polysaccharide’s antiproliferative activity to the enzymatic degradation was 
determined using MTT assay. The figure shows the antiproliferative activity of cockle 
polysaccharides retained part of the 10 kDa spin filter on the K-562 (A), Molt-4 (B) and 
Mero-25 (C) cell lines, with and without enzymes, as cockle CE polysaccharides (●), cockle 
CE treated with heparinase-I (■), cockle CE treated with heparinase-II (▲), cockle CE 
treated with heparinase-III (▼), cockle CE with heparinase-I, II, III treated (♦), cockle CE 
treated with chondroitinase-ABC (○) and cockle CE treated with fucosidase (□).  The data are 
presented as the percentage of viable cells following treatment with cockle polysaccharides, 
relative to the untreated control. Cockle CE showed high sensitivity to heparinase enzymes 
(solely and in combination), while chondroitinase-ABC and fucosidase showed no effect on 
the antiproliferative activity. All experiments were conducted in triplicate and the results are 
shown as the mean ± the SD. Cells were cultured in suspension and maintained at 37 °C in a 
humidified 5% CO2 atmosphere. 
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Table 8. Present list of IC50 of cockle CE polysaccharide (0, 0.78, 1.56, 3.12, 6.25, 12.5, 25, 
50 g/mL) and its digested chains by the action of heparinases, chondroitinase-ABC or 
fucosidase on cancer cell lines. All IC50 values were conducted in triplicate and calculated 
using non‐linear regression analysis (GraphPad Prism 8.0). 
Polysaccharide 
as antiproliferative agent 
List of IC50 on each cell line 
(µg/mL) 
K-562 Molt-4 Mero-25 
Cockle CE polysaccharide 8.18 0.5 23.5 
Cockle CE polysaccharide with heparinase-I 26.43 5.7 48 
Cockle CE polysaccharide with heparinase-II 24.52 6.6 32.04 
Cockle CE polysaccharide with heparinase-III 25.52 4.33 43.7 
Cockle CE polysaccharide with heparinase-I, II and III 38.06 4.7 50 
Cockle CE polysaccharide with chondroitinase-ABC 11.07 0.6 21.4 
Cockle CE polysaccharide with α-L-fucosidase 9.5 1.4 19 
 
4.1.2. Apoptosis detection assay—Annexin V 
 
Cell apoptosis detection assay using Annexin-V FITC/PI staining, followed by flow 
cytometry was used to investigate the mechanism of cell death following treatment with 
cockle CE polysaccharides. Cell death mechanism of all cell lines treated with cockle CE 
polysaccharides was potentially mediated via apoptosis. K-562 and Molt-4 cell lines showed 
a small increase in the late apoptotic phase, Mero-25 cell line did not show any late apoptotic 
markers (Annexin V+/PI+), when cells were treated with cockle CE polysaccharide. 
However, early apoptosis (Annexin V+/PI−) showed the biggest change in all cell 
populations after 24 h incubation. Necrotic cells (Annexin V−/PI+) showed little change over 
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untreated controls. The results shown in Figure 43 clearly implicate apoptosis as the most 
likely cause of cellular cytotoxicity following treatment by cockle CE polysaccharides. 
However, primary necrosis cannot be ruled out.  
 
Figure 43. Apoptosis assay Annexin-V FITC/PI.  K-562 (A), Molt-4 (B) and Mero-25 (C) 
cell lines were treated with cockle CE polysaccharides (50 g) for 24 hours, then cells were 
stained with Annexin V-FITC and PI stains, in addition to staining the untreated cells, which 
left as control. A: K-562 scatter plot of Annexin V-FITC/PI stained control cells (left) and 
scatter plot of cells treated with cockle CE polysaccharides (right). B: Molt-4 scatter plot of 
Annexin V-FITC/PI stained control cells (left) and scatter plot of cells treated with cockle CE 
polysaccharides (right). C: Mero-25 scatter plot of Annexin V-FITC/PI stained control cells 
(left) and scatter plot of cells treated with cockle CE polysaccharides (right). 
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4.2. Structural analysis of cockle CE polysaccharides 
 
4.2.1. Disaccharide analysis of cockle CE polysaccharides 
 
Disaccharide analysis was used in the first instance to confirm the presence of typical 
unsaturated HS/heparin and CS/DS disaccharides residues following treatment of the cockle 
CE polysaccharide with heparinase I, II and III or chondroitinase-ABC. Primary analysis of 
the HS/heparin unsaturated disaccharide compositions, which were released after digestion of 
the cockle CE polysaccharides with combined heparinases (I, II, III), showed that susceptible 
chains within the cockle CE polysaccharide sequence did contain the major disaccharide 
types found in mammalian HS/heparin. However, the combined digestion of heparinases (I,II 
and III) is suggested to be incomplete, according to the proliferation activity (Figure 42). 
The key differences between cockle CE unsaturated disaccharides and mammalian HS 
unsaturated disaccharides were the low levels of unsulphated disaccharide of [ΔHexA‐
GlcNAc] and the high levels of the disulphated disaccharide [ΔHexA‐GlcNS(6S)] released 
from the cockle polysaccharides (Table 9). On the other hand, other unsaturated disaccharides 
were at similar levels to those seen with typical mammalian HS types. As heparinases 
treatment of the cockle polysaccharides failed to generate high quantities of this highly 
sulphated disaccharide [ΔHexA(2S)-GlcNS(6S)], which could indicate the presence of HS-
like structure within cockle CE polysaccharides is much closer to mammalian HS than 
heparin.  
Despite the fact that the chondroitinase-ABC treatment of cockle CE polysaccharides 
failed to show any significant loss of antiproliferative activity, CS/DS disaccharide analysis 
was performed. The principle unsaturated disaccharides were produced by chondroitinase-
ABC digestion as [ΔHexA-GalNAc(4S)], [ΔHexA-GalNAc(6S)] and [ΔHexA-
GalNAc(4,6S)]. The results undoubtedly show that CS/DS-like chains also exist within the 
cockle CE polysaccharide preparations. 
Overall, information gathered from the disaccharide analysis data support the initial 
suggestion that the reduction in the antiproliferative activity, following by treatment of cockle 
CE polysaccharides with heparinases, was due to breakdown of HS/Heparin-like chain. Since 
it resulted in the release of unsaturated disaccharides that are found in mammalian 
HS/heparin types. The presence of heparinase resistant fragments as well as the lack of 
antiproliferative activity of the mammalian GAGs suggested the presence of an uncommon 
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HS-like structure, which suggested that active HS-like could be different from the 
mammalian HS. 
Table 9. Disaccharide composition analysis of cockle CE polysaccharide, mammalian 
HS/heparin and mammalian CS/DS. Data are presented as a percentage of the moles of 
HS/Heparin1 and CS/DS2 unsaturated disaccharides produced by heparinase (I, II, III) and 
chondroitinase-ABC digestion. 
HS/Heparin 
Disaccharides 
Cockle CE disaccharides 
produced (mole %) 
Standard HS 
disaccharides produced 
(mole %) 
ΔHexA-GlcNAc 26.6 61.5 
ΔHexA(2S)-GlcNAc 0.0 1.9 
ΔHexA(2S)-GlcNH2 0.0 0.01 
ΔHexA-GlcNAc(6S) 4.1 1.9 
ΔHexA(2S)-GlcNAc(6S) 4.0 0 
ΔHexA-GlcNS 25.5 17.8 
ΔHexA(2S)-GlcNS 9.5 11.5 
ΔHexA-GlcNS(6S) 24.7 0.8 
ΔHexA-GlcNH2(6S) 0.0 0 
ΔHexA(2S)-GlcNS(6S) 5.6 4.6 
ΔHexA(2S)-GlcNH2(6S) 0.0 0 
Total 100% 100% 
Type of sulphation Sulphate % Sulphate % 
Unsulphated 26.61 61.51 
N-SO3- 65.23 34.67 
2-O-SO3- 19.06 18.04 
6-O-SO3- 38.47 7.32 
Number of Sulphates Mole % Mole % 
0-SO3- 26.61  61.51 
1-SO3- 29.60 21.55 
2-SO3- 38.20 12.35 
3-SO3- 5.58 4.59 
Total GAG disaccharides 
produced by heparinase 
digestion (µg) 
0.06 0.61 
Average sulphate per 
disaccharides 
1.23 0.60 
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CS/DS Disaccharides2  Cockle CE 
disaccharides produced 
(mole %) 
CS standards 
disaccharides produced 
(mole %) 
ΔHexA-GalNAc 3.2 5.08 
ΔHexA-GalNAc(4S) 33.5 56.05 
ΔHexA-GalNAc(6S) 17.2 37.94 
ΔHexA(2S)-GalNAc(4S) 0 0.21 
ΔHexA(2S)-GalNAc(6S) 0.7 0.02 
ΔHexA-GalNAc(4S)(6S) 45.4 0.7 
ΔHexA(2S)-
GalNAc(4S)(6S) 
0 0 
Total 100% 100% 
Type of sulphation Sulphates % Sulphates % 
Unsulphated 3.22 5.0 
2-O-SO3- 0.68 0.23 
4-O-SO3- 78.87 56.9 
6-O-SO3- 63.29 38.67 
Number of Sulphates Mole % Mole % 
0-SO3- 3.22 5.0 
1-SO3- 50.73 93.99 
2-SO3- 46.05 0.94 
3-SO3- 0.00 0.00 
Total GAG disaccharides 
produced by 
chondroitinase-ABC 
digestion (µg) 
0.12 1.1 
Average sulphate per 
disaccharides 
1.43 0.96 
 
4.2.2. Monosaccharide compositional analysis 
 
The disaccharide analysis employed in this study did not provide adequate 
information about the identity of the uronic acid as well as missing some information about 
the non-GAG compounds that could be linked to the cockle CE polysaccharide sequence. 
These two major issues were resolved by monosaccharide analysis of the cockle CE 
polysaccharides. Analysis of the cockle CE polysaccharide preparations revealed the 
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presence of significant quantities of the monosaccharides GalNH2, GlcNH2 and GlcA, which 
are typically found following acid hydrolysis of mammalian and marine GAG chains (Table 
10). Interestingly, the lack of an IdoA component would suggest the presence of HS-like 
chains, rather than heparin. The neutral sugars such as Glc and Gal were by far the most 
predominant monosaccharides present in the cockle CE polysaccharide preparations, which 
are components typically found in marine N- and O-linked glycans, with about 10% fucose 
residues that can be derived from the original N-linked sequence preparations or fucosylated 
glycan. The data support the presence of GAG-like chain, as was indicated by both the 
susceptibility of cockle CE polysaccharides to heparinase/chondroitinase ABC digestion and 
the production of a range of unsaturated disaccharides typically found in mammalian GAG 
chains.  
 
Table 10. Monosaccharide composition analysis of the cockle CE polysaccharide. 50 µg of 
sample was degraded with trifluoroacetic acid prior to HPAEC-PAD analysis. The peaks 
observed were identified by comparison with the elution positions of known monosaccharide 
standards. Data are presented as a percentage of the moles of monosaccharide produced by 
acid hydrolysis. 
Monosaccharide Cockle CE polysaccharide (mole %) 
Fucose 11.1 
GalNH2 16.7 
GlcNH2 9.9 
Gal 19.1 
Glc 35.2 
Man 3.7 
GlcA 4.3 
IdoA 0 
Total 100 
 
4.2.3. FT-IR 
 
FT-IR spectroscopic analysis of cockle CE polysaccharides and qualitative analysis of 
functional groups were carried out. Cockle CE polysaccharide’s spectrum is illustrated in 
Table 11. The table shows peaks ranging from 814.02 to 3351.09 cm-1. Major peaks are at 
814.02, 1043.39, 1223.17, 1417.02, 1644.69, 2927.87 and 3351.09 cm-1. Interestingly, a lack 
of signals around 1700 cm-1 confirm the absence of IdoA (Zhang et al., 2008). 
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Figure 44. FT-IR spectra of cockle CE polysaccharide with wave number (cm-1). 
 
Table 11. Peak assignment of FT-IR spectrum for cockle CE polysaccharide and standard 
heparin (bovine).   
Wavelength (cm-1) Assignments  Reference 
Standard 
heparin 
Cockle CE 
polysaccharide 
1020  ≈ 1043.39 C-O-C pyranose ring (stretching 
vibration). 
(Charles, 
Huang 
and 
Chang, 
2008; 
Liao et 
al., 2013). 
1220.11 ≈ 1223.02 S=O sulfonate stretching vibration. (Cabassi, 
Casu and 
Perlin, 
1978). 
1417.4 1417.02 Carboxylate stretching of uronic 
acid at C-6. 
(Liao et 
al., 2013). 
1604.44  ≈ 1644.69 Antisymmetric vibration of 
carboxylate of uronic acid C-6. 
2944.95 ≈ 2927.87 C-H stretching of hexosamine. (Zhang et 
al., 2013). 
3404.74 ≈ 3351.09 Hydroxyl O-H stretching. 
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4.2.4. NMR spectroscopy 
 
Although NMR is a potent structural technique, especially for carbohydrates, it was 
unable to provide useful structural information about cockle CE polysaccharides. It was clear 
from disaccharide and monosaccharide analysis that there was considerable heterogeneity in 
the types of marine polysaccharides in the cockle CE as well as high structural diversity 
within each polysaccharide. Therefore, the cockle CE polysaccharides with the 
antiproliferative activity were fractionated according to their anionic charges, by anion-
exchange chromatography, in order to allow a more focused structural analysis, while 
separating the contamination from the antiproliferative activity, which could help in 
determining the nature of cockle polysaccharides with GAG-like properties. 
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5. Results—Cockle GAGs purification and polysaccharides fractions analysis 
 
Cockle polysaccharide heterogeneous nature has limited the ability to identify the 
final structure with antiproliferative activity on cancer cell lines. Therefore, cockle CE 
polysaccharides were purified using anion-exchange chromatography in order to determine 
structures and to correlate the structures to the novel antiproliferative activity from the 
purified fractions. After successful isolation of 6 purified fractions from the anion-exchange 
chromatography (Figure 45), biological activity was assessed using the cell proliferation 
assay (MTT assay), followed by an apoptosis assay (for active fractions only), on the K-562, 
Molt-4 and Mero-25 cell lines. Thereafter, additional structural determinations were to be 
performed to evaluate the active fraction structure.  
 
 
Figure 45. Anion-exchange chromatography of cockle CE polysaccharides. The cockle CE 
polysaccharide sample was injected to the FPLC system using anion-exchange DEAE-
Sepharose resin and it was eluted using linear gradient of 0–1.5 M NaCl over 75 min. Peaks 
were pooled, as indicated by the bars shown, then, desalted, lyophilised and stored at -20 °C 
for further analysis. 
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5.1. Anion-exchange chromatography 
 
Accordingly, cockle CE polysaccharide was purified based on their anionic charge 
using anion-exchange chromatography as described in section (3.3.2) (Habuchi, Habuchi and 
Kimata, 1995). The eluent was monitored at 280 nM to detect the peptide fragments still 
attached to the polysaccharide chains following the initial protease digestion, which resulted 
in typical elution profile shown in (Table 12) with six generally occurring peaks. The 
absorbance measured under each peak was broadly comparable to the dry weights of 
polysaccharides obtained after desalting and lyophilisation. 
 
Table 12. Representation of the anion-exchange chromatography elution peaks of purified 
cockle CE polysaccharide in minutes and its corresponding NaCl molarity % was assessed by 
the electroconductivity on-line monitor. 
Peak number NaCl % Elution time (min) 
Peak-one 3-12 7-13 
Peak-two 36-52 23-31 
Peak-three 71-80 42-47 
Peak-four 86-92 50-55 
Peak-five 99-100 60-65 
Peak-six 44-6 70-75 
 
5.2. Biological activities of cockle polysaccharide purified fractions 
5.2.1. Cell proliferation assay—Cockle purified fractions 
 
Following the purification of cockle CE polysaccharide, all fractions were collected, 
desalted and lyophilised. Cockle polysaccharide fractions’ antiproliferative activities were 
evaluated using a cell proliferation MTT assay on the K-562, Molt-4 and Mero-25 cell lines. 
Figure 46 shows that most of the antiproliferative activity was due to fraction 5, with 
negligible antiproliferative activity observed with fractions 1–3. The elution profile from the 
anion-exchange chromatography suggests that the low levels of activity observed in fractions 
4 and 6, which could be due to cross-contamination with fraction 5. The results indicate that 
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the antiproliferative activity of fraction 5 is relatively due to minor component of the CE 
polysaccharides (approximately 1-2% of the total dry mass) 
 
 
.  
101 
 
 
Figure 46. Antiproliferative activity of cockle polysaccharide purified fractions. Assessment 
of the antiproliferative activity of the purified fractions on K-562 (A), Molt-4 (B) and Mero-
25 (C) cell lines that were achieved using MTT assay. Fraction 5 was expressed potent 
antiproliferative activity, in comparisons to other inactive fractions in terms of IC50. Fraction 
one (⚫), fraction two (◼), fraction three (▲), fraction four (▼), fraction five (♦) and fraction 
six (). The data are presented as the percentage of viable cells following treatment with 
cockle polysaccharides fractions, relative to untreated control. All experiments were 
conducted in triplicate and the results are shown as the mean ± the SD and the IC50 values 
were calculated using non-linear regression analysis (GraphPad Prism 8.0). Cells were 
cultured and maintained at 37 °C in a humidified 5% CO2 atmosphere. 
 
Table 13. Presents list of IC50 of the cockle polysaccharide purified fractions on cancer cell 
lines. IC50 was determined when drug inhibited the cancer cells growth by 50% at maximum 
concentration of 50 g/mL, therefore, if the drug has inhibited less than 50%, then the drug is 
considered to be inactive. All IC50 values were conducted in triplicate and calculated using 
non‐linear regression analysis (GraphPad Prism 8.0). 
Cockle polysaccharide 
purified fraction 
List of IC50 on each cell line (µg/mL) 
K-562 Molt-4 Mero-25 
Fraction-1 Inactive Inactive Inactive 
Fraction-2 Inactive Inactive Inactive 
Fraction-3 Inactive Inactive Inactive 
Fraction-4 Inactive Inactive Inactive 
Fraction 5 24 11.4 37 
Fraction-6 Inactive Inactive Inactive 
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5.2.2. Effects of enzymatic degradation on cockle polysaccharide Fraction 5 
antiproliferative activities 
 
Enzymatic treatment of the cockle polysaccharide purified fraction 5 using heparinases (I, II, 
III) or chondroitinase-ABC was used to investigate any link between GAG-like chains and 
the observed antiproliferative activity. Cockle polysaccharide fraction 5 treated with 
chondroitinase-ABC enzyme has shown no appreciable decrease in antiproliferative activity 
on the retained part of the 10 kDa spin filter on all cell lines. On the other hand, treatment of 
fraction 5 by heparinase enzymes (individually and in combination) on the K-562 and Mero-
25 cell lines showed a considerable reduction in the antiproliferative activities on the retained 
part of the spin filter. There was little difference between the individual heparinase enzymes 
on the Molt-4 cell line; however, in replicates heparinase-II significantly destroyed the 
antiproliferative activity, while the other heparinase treatments led to significantly loss of 
most the antiproliferative activity, as seen with heparinase-I and III, and in combination with 
all enzymes including heparinase-II. Taken together, the data suggest that HS/heparin-like-
GAG structure probably exists in the active fraction 5, and it could play an important 
contributing role to the antiproliferative activity of ion-exchange purified cockle 
polysaccharides (Figure 47).  
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Figure 47. The effect of heparinase enzymes (individually or in combination) (I, II, III) or 
chondroitinase-ABC enzymatic digestion on the antiproliferative activity of the cockle 
polysaccharide purified fraction 5. The sensitivity of the cockle polysaccharide’s purified 
fraction 5 to the enzymatic degradation on the antiproliferative activity was determined using 
MTT assay on the K-562 (A), Molt-4 (B) and Mero-25 (C) cell lines, in addition to assessing 
the antiproliferative activity of undigested fraction 5 in order to confirm the difference 
between chains activity. Cockle polysaccharides Fraction 5 (●), cockle polysaccharides 
Fraction 5 treated with heparinase-I (■), cockle polysaccharides Fraction 5 treated with 
heparinase-II treated (▲), cockle polysaccharides Fraction 5 treated with heparinase-III 
treated (▼), cockle polysaccharides Fraction 5 treated with heparinase I, II, III treated (♦) and 
cockle polysaccharides Fraction 5 treated with chondroitinase-ABC (○). The data is presented 
as the percentage of viable cells following treatment with cockle polysaccharides fraction 5 
and its digests, relative to untreated control. All experiments were conducted in triplicate, the 
results are shown as the mean ± the SD and the IC50 values were calculated using non-linear 
regression analysis (GraphPad Prism 8.0). Cells were cultured and maintained at 37 °C in 
humidified 5% CO2 atmosphere. 
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Table 14. Represents list of IC50 of cockle polysaccharide purified fractions on all cell lines. 
IC50 was determined when drug has inhibited the cancer cells growth by 50% at maximum 
concentration of 50 g/mL, therefore, if the drug has inhibited less than 50%, then the drug is 
considered to be inactive. All IC50 values were conducted in triplicate and calculated using 
non‐linear regression analysis (GraphPad Prism 8.0). 
Cockle purified fraction 5 treated 
with different GAG-related 
enzymes 
List of IC50 on each cell line (µg/mL) 
K-562 Molt-4 Mero-25 
Fraction 5 21.42 11.5 37 
Fraction 5 treated with 
heparinase-I 
Inactive 40.35 Inactive 
Fraction 5 treated with 
heparinase-II 
Inactive Inactive Inactive 
Fraction 5 treated with 
heparinase-III 
Inactive 28.60 Inactive 
Fraction 5 treated with 
heparinase-I, II and III 
Inactive 48.67 Inactive 
Fraction 5 treated with 
chondroitinase-ABC 
21 10.70 38.2 
 
5.2.3. Apoptosis detection assay Annexin-V—Cockle polysaccharide purified fraction 5 
 
The antiproliferative activity of cockle polysaccharide fraction 5 was further 
investigated on cancer cell lines using an apoptosis assay. Cancer cells were treated with 
cockle polysaccharide purified fraction 5, then, cellular apoptosis was assessed using cellular 
apoptosis targets Annexin-V FITC/PI, followed by flow cytometry. In-vitro treatment with 
fraction 5 was potentially mediated via apoptosis. Early apoptotic markers (Annexin V+/PI−) 
showed the biggest change in cell populations after 24 h incubation in all cell lines. However, 
the K-562 and Molt-4 cell lines showed small increases in the late apoptotic phase (Annexin 
V+/PI+), while, Mero-25 cell line did not show any increase in the late apoptotic phase. K-
562 necrotic cells (Annexin V−/PI+) showed little change over untreated controls. Thus, the 
results clearly implicate apoptosis as the most likely cause of the cellular cytotoxicity seen 
following treatment by cockle polysaccharide fraction 5 (Figure 48). However, primary 
necrosis cannot be ruled out. 
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Figure 48. Apoptosis assay Annexin V-FITC/PI.  K562 (A), Molt-4 (B) and Mero-25 (C) cell 
lines, were treated with 50 g/mL of cockle polysaccharide purified fraction 5 for 24 h, then 
stained using Annexin V-FITC and propidium iodide (PI). A: K562 scatter plot of Annexin 
V-FITC/PI stained control cells (left) and scatter plot of cells treated with cockle 
polysaccharide purified Fraction 5 (right). B: Molt-4 scatter plot of Annexin V-FITC/PI 
stained control cells (left) and scatter plot of cells treated with cockle polysaccharide purified 
fraction 5 (right). C: Mero-25 scatter plot of Annexin V-FITC/PI stained control cells (left) 
and scatter plot of cells treated with cockle polysaccharide fraction 5 (right). Cancer cells 
treatment with Fraction 5 has led to cellular apotosis. Results are presented as the mean ± of 
three independent experiments. 
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5.3. Structural analysis of cockle polysaccharides purified fractions 
 
5.3.1. Disaccharide analysis—anion-exchange purified fractions 
 
Disaccharide composition analysis of the cockle purified polysaccharide fractions was 
used to identify the nature of the glycan structures presented within the purified fractions in 
order to correlate its structure to the antiproliferative activity in comparisons to the known 
marine/mammalian GAGs. Table 15 shows the distribution of unsaturated disaccharides of all 
purified fractions and the amounts produced in micrograms when each fraction was treated 
with a combination of all heparinases (I, II, III). The total weight of disaccharides produced 
from each microgram of sample digested indicated that only fraction 5 produced a significant 
number of unsaturated disaccharides. Fractions 1, 2, 3 and 4 produced approximately 30-, 
150-, 30- and 6- fold less disaccharide than did fraction 5, respectively, suggesting that the 
early eluting fraction contains mainly non-HS-like chains. 
The compositions of fractions 5 and 6 showed the presence of all major disaccharides 
found within mammalian HS/heparin chains. The enrichment of the trisulphated disaccharide 
[HexA(2S)-GlcNS(6S)] and the disulphated disaccharide [HexA(2S)-GlcNS] showed 
approximately four-fold and three-fold increases, respectively, in comparison to the 
unfractionated cockle polysaccharides (Table 9). These likely contributed significantly to the 
later elution of these chains from the anion-exchange column. 
Fraction 1 appeared to generate the highest proportion of sulphates per disaccharides 
than any other fractions; however, the quantity, in micrograms of disaccharides produced was 
very small, compared to the total material digested. In fact, there is little correlation between 
the increase in the number of sulphates per disaccharide produced from heparinase digestion 
and the elution positions. This could be linked to the limited digestion of the glycan chains 
contained within them. 
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Table 15. HS disaccharide analysis of cockle polysaccharide anion-exchange purified 
fractions. Data are presented as a percentage of the moles of unsaturated disaccharides 
produced by heparinases (I, II and III) digestion of all purified fractions 1-6. 
HS Disaccharides F1 (%) F2 (%) F3 (%) F4 (%) F5 (%) F6 (%) 
∆HexA-GlcNAc 4.6 28 84.4 31.9 9.8 6.8 
∆HexA(2S)-GlcNAc 0 0 0 0 0.9 0.4 
∆HexA(2S)-GlcNH2 0 0 0 0.1 0.2 0 
∆HexA-GlcNAc(6S) 0.2 2.4 1.6 5.3 4.9 3.3 
∆HexA(2S)-GlcNAc(6S) 30.4 10.9 0 0 3.1 4.6 
∆HexA- GlcNS 0.7 8.6 12.9 28.4 10.4 5.9 
∆HexA(2S)-GlcNS 16.6 25.2 0.5 12.8 24.4 34 
∆HexA-GlcNS(6S) 4.9 10.9 0.6 15.9 19.4 16.4 
∆HexA-GlcNH2(6S) 0 0 0 0.1 0.2 0 
∆HexA2S-GlcNS(6S) 42.7 14 0 5.7 26.3 28.6 
∆HexA2S-GlcNH2(6S) 0 0 0 0 0.3 0.1 
 
Unsulphated 4.6 28 84.4 31.9 9.8 6.8 
N-SO3 64.8 58.8 14 62.6 80.5 84.8 
2-O-SO3 89.6 50.2 0.6 18.5 55.3 67.6 
6-O-SO3 78.1 38.2 2.2 27 54.2 53 
Total GAG disaccharides 
produced by heparinase 
digestion (g) 
0.01 0.002 0.01 0.05 0.29 0.06 
Average sulphate per 
disaccharide 
2.33 1.47 0.17 1.08 1.9 2.05 
 
The relative distribution of unsaturated disaccharides and the amounts produced when 
each fraction was treated exhaustively with chondroitinase-ABC enzyme are shown in Table 
16. Disaccharide analysis of each fraction also showed that early eluting fractions (1, 2 and 3) 
lack correlation between the sulphate content per disaccharides and the fractions’ elution 
positions. Again, this is likely linked to the incomplete nature of the digests, as confirmed by 
the quantity, in micrograms, of disaccharides released after digestion. The later eluting 
fractions (4, 5 and 6) produced disaccharide compositions close to those seen for the 
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unfractionated cockle polysaccharides (Table 9). The later eluting fractions, 5 and 6, contain 
a CS-like GAG chain; however, Figure 47 suggests that these chains do not contribute to the 
antiproliferative activity of Fraction 5. 
Table 16. CS/DS Disaccharide analysis of anion-exchange purified cockle polysaccharide 
fractions. Data are presented as a percentage of the moles of unsaturated disaccharides 
produced by chondroitinase-ABC digestion of the anion-exchange fractions (F1–F6). 
 
CS/DS Disaccharides F1 (%) F2 (%) F3 (%) F4 (%) F5 (%) F6 (%) 
∆HexA-GalNAc 70.6 72.36 86.446 8.75 3.5 3.6 
∆HexA-GalNAc(4S) 23.1 26.68 13.55 89.85 56.8 35 
∆HexA-GalNAc(6S) 3.8 0.18 0 1.396 3.7 4.3 
∆HexA(2S)-GalNAc(4S) 0 0 0 0 0 0 
∆HexA(2S)-GalNAc(6S) 0 0 0 0 1.8 3.9 
∆HexA-GalNAc(4,6S) 2.5 0.78 0 0 34.2 53.2 
∆HexA(2S)-GalNAc(4,6S) 0 0 0 0 0 0 
 
Unsulphated 70.6 72.4 86.4 8.8 3.5 3.6 
2-O-SO3 0.0 0.0 0.0 0.0 1.8 3.9 
4-O-SO3 25.6 27.5 13.6 89.9 91.0 88.2 
6-O-SO3 6.3 1.0 0.0 1.4 39.7 61.5 
Total GAG disaccharides 
produced by ABC-lyase 
digestion (µg) 
0.002 0.006 0.006 0.026 0.285 0.086 
Average sulphate per 
disaccharide 
0.32 0.28 0.14 0.91 1.31 1.51 
 
Taken together, the data indicate the presence of heparinases and chondrotinase-ABC 
susceptible linkages, therefore, GAG-like structures are present in the cockle purified later 
eluting fractions. The production of a significant quantity of HS disaccharides, from the 
active fraction 5 confirms the link between HS-GAG-like structures and the antiproliferative 
activity of the cockle polysaccharides. However, the retained activity of the heparinase-
resistant chains must also be considered when judging on the structure/activity relationships. 
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5.3.2. Monosaccharide composition analysis—anion-exchange purified fractions 
 
Monosaccharide analysis was carried out on each cockle purified fraction (F1-F6) 
(Table 17).  The anion-exchange purified fractions analysis showed enrichment of the GAG-
related monosaccharides such as GalNH2, GlcNH2, and GlcA in the later eluting fractions 
(Fractions 3–6). The components found in the active fraction 5 showed typical GAG-like 
contents with the highest amount of GlcA and no detectable IdoA residues, however, this 
does not, on its own, explain the unique activity of the cockle derived HS-like GAG chains. 
 
Table 17. HPAEC-PAD analysis of monosaccharides derived from anion-exchange purified 
fractions (F1–F6). Samples were hydrolysed to monosaccharides. The observed peaks were 
identified by comparison with the elution position of monosaccharide standards. Data are 
presented as a percentage of the moles of monosaccharides produced by acid hydrolysis. 
Monosaccharide F1 (%) F2 (%) F3 (%) F4 (%) F5 (%) F6 (%) 
Fucose 5.11 5.8 3.3 3.6 14.2 2.1 
GalNH2 3 4 11.7 35.6 21.8 9.5 
GlcNH2 3.9 2.1 11.9 10.4 14.5 3.6 
Galactose 2.3 3 11 14.4 20.1 8.8 
Glucose 73.49 57.4 52.8 30 10.4 50.4 
Mannose 5.06 28.1 7.4 2.7 4.9 23.5 
Glucuronic acid 1.02 0.7 1.9 3.3 14.1 2.1 
Iduronic Acid 0 0 0 0 0 0 
 
5.3.3. NMR—anion-exchange purified fractions 
 
Extensive chromatography separation of the cockle CE polysaccharides using anion-
exchange chromatography was inefficient to purify a single polysaccharide chain with 
antiproliferative activity. In fact, the disaccharide analysis of the fraction 5 indicated the 
presence of HS-like and CS-like components. In addition, the monosaccharide composition 
analysis suggested the presence of fucosylated polysaccharides, N-linked and O-linked 
glycan and HS-like polysaccharides as represented only a minority of the glycan chain. 
Therefore, in order to further characterize the structure of cockle polysaccharides with 
antiproliferative activity, an attempt was made to study fraction 5 by NMR spectroscopy. 
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A number of spectra where recorded at 800 MHz including 1H NMR, 13C NMR, 
correlation spectroscopy (COSY), total correlation spectroscopy (TOCSY) and heteronuclear 
single quantum correlation (HSQC). These spectra are shown in the appendices. It was clear 
from the spectra obtained that it would be extremely difficult to make unambiguous 
assignments of the various saccharides present due to the complexity of the resonance 
patterns observed. Consequently, it was even more difficult to obtain fine structure 
differences between mammalian-HS, which has no antiproliferative activity, and the cockle 
HS-like structures that had previously, based on heparinase activity, shown to be active at 
inhibiting the growth of cancer cells. The COSY spectrum in Figure 49, in the appendices, 
shows three of the spin systems linked to fucosylated-CS (red lines) and the GlcNAc and 
GlcNS monosaccharides of HS-like cockle glycans (green lines). However, time and complex 
signal overlap, resulting from contaminating glycan chains did not allow further assignment 
of spin systems. 
 
Figure 49. 2D 1H-1H NMR-COSY for cockle purified fraction 5. Red lines CH3 linked to 
fucopyranose at 5.2 ppm, and green lines indicate possible spin systems found in mammalian 
HS. The spectra were recorded at 56.85 °C. 
 
Further analysis of these samples might in the future provide more detail regarding 
the structural attributes of the cockle GAG-like active structure. However, it is clear that the 
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analysis would benefit from further purification of the active fraction from other 
contaminating molecules, such as fucosylated-CS and other N- and O-linked glycans. 
Problems with further purification system from the relative abundance of fraction 5 in the 
crude cockle GAG mixture, as it is a very minor component (Figure 45). Other methods for 
chromatography such as size-exclusion might be useful in removing smaller contaminating 
N- and O- linked glycan changes but are unlikely to enable separation between HS, CS and 
fucosylated polysaccharides. Different stationary phases and function groups might be 
employed along with further ion-exchange chromatography but might be ineffective in the 
short term in producing samples that could be worked on more effectively by NMR analysis. 
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6. Discussion 
 
Typical mammalian GAGs chains are composed of long unbranched polysaccharides 
characterised by repeating disaccharide building blocks of uronic acid and hexose-sugar. 
GAGs are classified into six types according to their disaccharide building blocks—HS, 
heparin, CS, DS, KS and hyaluronate (Nelson, Lehninger and Cox, 2008). Each type can 
acquire different structural modifications on its disaccharide including chain length, type of 
glycosidic linkage, branching point, the addition of various functional groups and the addition 
of other saccharides. Chain structural modifications provide GAGs with their unique 
structures and biological functions (Vlodavsky and Friedmann, 2001). The aim of this study 
focused on the isolation, purification and characterisation of common cockle (Cerastoderma 
edule) polysaccharides with in-vitro novel antiproliferative activity against a cancer cell line. 
One of the main objectives of this study was to isolate common cockle 
polysaccharides and examine their anticancer activity. Therefore, the cockle polysaccharides 
were successfully isolated using an anionic cetylpyridinium chloride precipitation method, 
which has been used to target the anionic properties within cockle polysaccharides structure. 
The antiproliferative activity was assessed in-vitro against three cancer cell lines using cell 
proliferation assays (MTT assay), which resulted in potent antiproliferative activity on all cell 
lines used (Figure 40) and induced by programmed cell death. 
As hypothesised, the cockle polysaccharide is likely to contain GAG-like chain, on 
the basis of the isolation method used that could be linked to the antiproliferative activity. 
This antiproliferative activity of GAG-like polysaccharides was unusual given that 
mammalian GAGs, in this and other studies, failed to show any antiproliferative activities 
against cancer cell lines (Figure 41). As a consequence, structural analysis was conducted in 
order to determine cockle polysaccharides structure and to correlate it to that of typical 
members of the mammalian GAG families, in an attempt to determine the exact structural 
nature of the observed antiproliferative activity. 
Initially, an important structural and biological characteristic of the mammalian 
GAGs is the pattern of sulphation, which can influence the biological activity of a particular 
glycan chain. For instance, the highly sulphated heparin pentasaccharide sequence, with 
potent anticoagulation activity, make it able to prevent blood coagulation by binding to 
antithrombin-III to inhibit the action of factors X and II, which plays an important role in the 
coagulation cascade (Rosenberg and Lam, 1979). Besides that HS chains can acquire various 
forms of structural heterogeneity, including considerable variation in sulphated and non-
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sulphated patterns within domains; which are no doubt linked to its important physiological 
and pathological roles according to its structure (Höök et al., 1984; Yayon et al., 1991; 
Stanley et al., 1999; Ornitz, 2000). Marine glycans pattern of sulphation, are also highly 
variable across species. Liao et al. (2013) reported that polysaccharide from bivalve molluscs 
(Corbicula fluminea) with a high level of sulphation have very potent antiproliferative activity 
against human cancer cell lines, in comparison to other less-sulphated fractions. Hence, the 
initial isolation and purification methods were performed to explain the highly variable 
anionic properties of the polysaccharides, and to maximise the chances of linking structural 
differences with biological activity.  
The only clearly defined GAG sequence activity relationship to date continues to be 
the highly sulphated heparin pentasaccharide antithrombin-III binding sequence chain with 
confers on heparin its potent anticoagulant activity, as it has been used for a long time in 
clinical practice (Howell and Holt, 1918). Mammalian heparins have never previously been 
shown to have any antiproliferative activity in-vitro, however, chemical modification of 
heparin has been reported to have led to inhibitory effects that cannot destroy 50% of cancer 
cells (Yu et al. 2010). These results are consistent with the high-molecular-weight porcine 
mucosal heparin used in this study, which did not show any antiproliferative activity on 
cancer cell lines (Figure 41). Cockle CE polysaccharides show high sulphate content and it 
might be argued that this this alone is responsible for the potent antiproliferative activity 
observed, with no role for fine structural variation in polysaccharide structure. However, the 
disaccharide analysis results from the cockle purified fraction-6 has the highest overall 
sulphate content but, with significantly no antiproliferative activity than the earlier eluted 
fraction 5 and the CE samples (Table 15). 
A possible explanation for these results would therefore be that a specific sequence 
and/or type of linkage within cockle polysaccharides chain is playing a pivotal role in 
mediating their antiproliferative activity. This difference is also linked to the lack of 
antiproliferative activity seen with the mammalian GAGs in this study. 
In this study we show for the first time, that marine polysaccharides with 
antiproliferative activity are susceptible to the digestion of three different classes of 
heparinase enzymes that are typically used to cleave mammalian HS/heparin chains. After the 
treatment of cockle polysaccharides with heparinase enzymes, the potent antiproliferative 
activities were dramatically decreased on all cell lines. In other words, the cockle CE 
polysaccharide treated with combined heparinase enzymes showed an increase of up to 3 
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times in IC50 values, as shown in the K-562 and Mero-25 cell lines, and up to 9 times on the 
Molt-4 cell line compared to the untreated cockle CE polysaccharide (Figure 42). More 
surprisingly, the purified cockle polysaccharide active fraction 5 lost all its antiproliferative 
activity on both K-562 and Mero-25 cell lines, with great loss of activity on the Molt-4 cell 
line following treatment with heparinases I,II,III (Figure 47). 
Although these findings could be viewed as a direct link between the cockle 
polysaccharide’s antiproliferative activity and the presence of a GAG HS-like structure, a 
potential structural difference from mammalian-HS is still implicated by the lack of 
antiproliferative activity of the latter. Some antiproliferative activity show some resistant to 
the heparinase treatment, particularly in the cockle CE, which could be due to structural 
differences between the cockle HS-GAG-like and mammalian HS. Consequently, it was 
suggested that a new, atypical, marine polysaccharide has been identified in this study, with 
GAG-like properties that are linked, at least in part, to the antiproliferative activity observed 
in the three cell lines tested. In the future, a reductionist assessment of the structural features 
within these heparinase resistant sequences might be an attractive research approach that 
could will lead to a more thorough understanding of the precise structural features required to 
determine the antiproliferative activity seen in this study. 
The disaccharide analysis employed in this study aimed to identify compositional 
differences between mammalian GAGs and cockle-derived polysaccharides with potent 
antiproliferative activity. The cockle CE polysaccharide or the purified fractions were treated 
with a combination of heparinase enzymes (I, II and III), which resulted in the most common 
unsaturated disaccharides typically observed in mammalian HS, apart from the rarest 3-O-
sulphated disaccharide, using the method described. The most significant characteristic of the 
disaccharide analysis is related to the highest levels of the N-sulphated disaccharides 
produced after heparinase digestion. For example, cockle CE polysaccharide has about 66% 
of its glycan chain N-sulphated, and the purified fraction 5 has about 80% N-sulphated 
glycans, as opposed to the much lower amount from the porcine intestinal mucosal, which 
contains approximately 40% N-sulphated HS (Deakin and Lyon, 2008). 
Another notable finding is the differences in the levels of the disaccharides 
[ΔHexA(2S)-GlcNS] and [ΔHexA(2S)-GlcNS(6S)], which were generated by combined 
heparinase digestion of the anion-exchange purified active fraction 5, making up 24% and 
26% of the disaccharides, respectively, as opposed to the percentage of these disaccharides in 
porcine mucosal heparin (0.9% and 14.6%, respectively) (Saad et al., 2005), and porcine 
mucosal HS (11% and 4.59%, respectively). Although fraction 5 showed antiproliferative 
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activity and an increased level of these disaccharides compared to porcine mucosal HS, it 
seems unlikely that these disaccharides are solely responsible for the antiproliferative 
activity, as described in section (4.1.1.2). In fact, disaccharide analysis of cockle CE 
polysaccharide showed less abundance of these particular disaccharides (9.5% and 5.6%, 
respectively), which gives no definitive clues about the differences in the biological activity 
seen in cockle polysaccharides and mammalian GAGs (Table 9). The anion-exchange 
purified fractions (1, 2, 3, 4 and 6) with no antiproliferative activity were enriched with a 
significant amount of neutral sugars and comparatively lower GAG-like properties. These 
findings would suggest that a particular role of the GAG-like structure within the cockle 
polysaccharide would influence the antiproliferative activity. 
To date, invertebrate-derived polysaccharides with different pharmacological 
outcomes are linked to a non-GAG like structure, as they typically differ from those of 
mammalian GAGs in terms of monosaccharide composition, disaccharide composition, 
and/or structural homogeneity. The literature has distinguished various types of 
polysaccharides isolated from different invertebrates with active pharmaceutical outcomes 
such as antiproliferative, anti-metastatic and anticoagulation activities. These polysaccharides 
can differ in several ways from typical mammalian GAGs, as their most dramatic structural 
differences in the type of linkages, branching, monosaccharide compositions, disaccharides 
building blocks, chain length, chain modifications and/or homogeneity. As an illustration, a 
polysaccharide derived from the marine bivalve mollusc (Corbicula fluminea) is composed of 
neutral sugars such as fucose, glucose and galactose and demonstrates anti-tumour, 
antiproliferative and antioxidant activities; however, its final structure has not yet been 
determined, and its structural analysis did not confirm any link to mammalian GAGs 
polysaccharides (Liao et al., 2013). 
Moreover, the marine bivalve mollusc (Ruditapes philippinarum) polysaccharide-
derived chain shows antiproliferative activity against the human hepatoma cell line, but its 
structure lacks heterogeneity, as its composed of glucose-based polysaccharides with several 
branches, which means it is not structurally linked to mammalian GAGs that are known to be 
heterogeneous and unbranched (Zhang et al., 2008). In addition, the unique AS 
polysaccharides isolated from the African snail (Achatina fulica) lack structural 
heterogeneity, they are composed of IdoA and essentially GlcNAc, which make it different 
from mammalian GAGs in terms of structural heterogeneity (Vieira et al., 2004; Pomin, 
2015). Similarly, the cuttlefish ink (Sepiella maindroni) novel hexasaccharide, which is 
composed of both neutral and acidic sugars. Its structure shows the presence of the 
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unbranched β-fucose and a branched GlcA, which makes it different from mammalian GAGs 
in terms of disaccharide building blocks and branching points (Liu et al., 2008). 
The highly sulphated DS-like polysaccharide isolated from Ascidian, a fucosylated-
CS isolated from sea cucumber, hybrid heparin/HS chains isolated from head of shrimp and 
the highly sulphated GlcA-containing HS chain isolated from bivalve mollusc, have been 
suggested. However, none of these unique GAG-like polysaccharides have previously been 
reported to have any direct antiproliferative activity. 
Monosaccharide composition analysis of cockle polysaccharides showed no evidence 
of IdoA residues within the chains; therefore, the presence of the highly sulphated DS-like 
structure is unlikely to exist within the cockle polysaccharide preparation (Table 10) (Pavão, 
2002; Pomin, 2015). Secondly, regarding the novel fucosylated-CS with GAG-like structures 
extracted from sea cucumber, its CS-like structure has been reported to be insensitive to 
chondroitinase-ABC without prior removal of the attached fucose chain (Vieira and Mourão, 
1988). In contrast, the disaccharide analysis of the cockle GAG-like polysaccharide revealed 
susceptibility to chondroitinase-ABC, which resulted in the release of typical mammalian CS-
related disaccharides (Table 9). According to Vieira et al. (1991), the GlcA chain of the 
fucosylated-CS either can acquire branched 3-O-fucopyranose or 3-O-sulphate. The rarest 3-
O-sulphate was not determined within cockle GAG-like polysaccharides. Although treatment 
of the cockle GAG-like polysaccharide with chondritinase-ABC did not affect its 
antiproliferative activity, fucosylated polysaccharide was present in the cockle structure, so 
its contribution to the antiproliferative activity cannot be ruled out, however it is not known 
to be sensitive to any of the three heparinase enzymes used in this study. 
The literature has identified two marine derived polysaccharides with heparinase 
sensitive structures, namely hybrid heparin/HS isolated from the head of the shrimp 
(Litopenaeus vannamei) (Brito et al., 2014) and the highly sulphated GlcA containing-HS 
isolated from bivalve molluscs (Nodipecten nodosus) (Gomes et al., 2010). As the cockle 
polysaccharide lost some of its antiproliferative activity following heparinase digestion, its 
structure/activity can possibly be linked to the presence of a similar structure to the hybrid 
heparin/HS or GlcA-rich HS polysaccharides, although no direct link to antiproliferative data 
have been reported with these polysaccharide structures. Some activity remained after 
heparinase digestion of the cockle CE polysaccharide, which could suggest the presence of 
other uncommon GAG structures that are potentially involved in the antiproliferative activity. 
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The main findings of the monosaccharide composition analysis of cockle 
polysaccharides provided two main structural insights into the nature of the cockle 
polysaccharides. Firstly, following monosaccharide analysis of cockle CE and the purified 
fraction 5, the main monosaccharides identified were closely related to mammalian GAGs. 
Cockle CE monosaccharide composition with GAG-like structure represented about 42% of 
the chain as fucose (11%), GalNH2 (16.7%), GlcNH2 (9.9%) and GlcA (4.3%) (Table 10). 
Likewise, the purified active fraction 5 monosaccharide GAG-like composition represented 
approximately 65% as fucose (14.2%), GalNH2 (21.8%), GlcNH2 (14.5%) and GlcA (14.3%) 
(Table 17). As expected, the monosaccharide composition of the cockle polysaccharide 
represented the main N-linked and O-linked glycan building blocks found in glycan 
structures. 
Secondly, the non-derivatisation-based method used to confirm the nature of all 
monosaccharides within the sequence with minimal structural modification identified the type 
of uronic acid in all cockle monosaccharides was 100% GlcA with no detectable 
epimerisation to IdoA. However, the absence of IdoA does not on its own, explain the 
antiproliferative activity of the HS-GAG-like chain within cockle polysaccharides, 
appendices (Figure 58). Overall, the compositional details do not yet represent satisfactory 
structural evidence to confirm the final structure of the antiproliferative activity and its 
relation to the glycan structure. Therefore, detailed structural analysis was suggested to assess 
the nature of the antiproliferative activity that is linked to the cockle polysaccharides, using 
NMR spectroscopy. 
The NMR spectra recorded from the crude GAG mixtures showed the difficulties that 
would have to be met in order to determined definitive structural characterisation of all the 
glycan components. The spectra showed complex signal overlap in many key areas, making it 
impossible to determine essential structural detail on sequence composition and critically 
linkage types within different families of glycan components.  To date, the data obtained 
from the anion-exchange chromatography indicated that many of the glycan components 
might be removed from the active fraction 5.  As a result, extensive chromatography runs 
where undertaken to produce enough amount of the active fraction 5 polysaccharides for 
NMR analysis. This was a challenge as we had already shown that the active fraction 5 was 
only a minor component of the initial crude cockle polysaccharide extracts (Figure 45). 
Heteronuclear and homonuclear 2D NMR experiments were carried out and spectra 
recorded for both purified cockle Fraction 5 and commercially available porcine mucosal HS. 
Once again, analysis the spectra of cockle fraction 5 had been achieved considerable 
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challenges still remained in attributing a unique HS-like structures within fraction 5. The 
monosaccharide and disaccharide analysis did point the way to identifying a number of spin 
systems related to HS-like structures rich in GlcA and fucosylated-CS. However, at the 
present time the contaminating CS-related structures and N- and O-linked glycans that are 
clearly still present in fraction 5 and in far larger concentrations than the HS like GAG 
structures have proven to be extremely challenging for NMR assignment. It is possible that 
further study of the available spectra will yield more detailed structure/activity findings, and 
perhaps with additional NMR experiments this could allow a meaningful explanation of the 
polysaccharide activity.  However, it is likely that further purification of the active chains will 
be needed to succeed in an NMR based approach to understanding the structural differences 
between the cockle HS-like polysaccharides and typical mammalian GAGs such as HS. This 
will ultimately lead to a structure-based understanding of the structure/activity relationships 
between the antiproliferative polysaccharides isolated from cockles. 
7. Conclusion and future study 
 
This study was conducted to isolate cockle polysaccharide and assess its 
antiproliferative activity on cancer cell lines using in vitro cell proliferation assay. Cockle 
polysaccharide has exhibited potent antiproliferative activity against acute lymphoblastic 
leukaemia, chromic myeloid leukaemia and mesothelioma cell lines, where cell death was 
induced by apoptosis, which would make this polysaccharide pharmaceutically a candidate 
for cancer therapies. 
Extensive structural analysis confirmed the presence of GAG-like structures within 
cockle preparations, specifically HS-like structures. For the first time, marine polysaccharides 
antiproliferative activity was directly affected after treatment with different classes of 
heparinase enzymes, which have found to be linked to antiproliferative activity, whereas 
mammalian GAGs did not exhibit antiproliferative activity on cancer cell lines.  
This provides insights into a new marine polysaccharide with HS-like structures with 
influence on a biological activity that is structurally different from its mammalian 
counterpart, as the literature exclusively correlates the biological activity in marine 
polysaccharides with that in non-GAG glycans. 
Further structural analysis showed a number of sulphates per disaccharide. The results 
indicated that not only the highly sulphated polysaccharides’ structure would be biologically 
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active, as cockle CE and the purified fraction 5 showed a lower level of sulphation with 
potent antiproliferative activity in comparison with fraction 6, which represented a higher 
number of sulphates per disaccharide. The results of this study indicate that the level of 
sulphation is not a principal reason for biological activity, which depends on various 
structural modifications, such as chain length, type of linkages, branching points and addition 
of functional groups (Bertozzi and Rabuka, 2009). 
Structural characterisation of cockles’ antiproliferative activity, represented in the 
purified fraction 5, indicated the presence of not only HS-like structures, but also fucosylated 
polysaccharide, N- and O-linked saccharides, which made the final structural elucidation very 
difficult because of the complex nature of the sample. Indeed, further purification strategies 
may be used to remove non-glycan contaminations, followed by treatment with a 
combination of heparinase enzymes to improve structural elucidations using NMR 
spectroscopy. This study offers insight into marine polysaccharides with uncommon 
therapeutic outcomes from a marine source, as they manifested direct antiproliferative effects 
on cancer cells related to GAG-like polysaccharides. 
8. Limitations 
 
Study limitations make the creation of an overall conclusion about the cockle 
antiproliferative structure extremely difficult. The main limitation of this study was the 
evaluation of the nature of the cockle polysaccharide, which has an unknown structure and 
lacks any chromophore that affects adopting an appropriate purification step. For instance, 
size-exclusion chromatography requires a well-known molecular weight sample, and lectin 
affinity chromatography requires knowledge of the exact structure of the antiproliferative 
compound. As a result, anion-exchange chromatography was chosen according to the 
negatively charged nature of GAG-like structures, which finally resulted in a relatively small 
fraction several containing polysaccharides instead of only one purified chain. 
Also, because of a lack of a non-destructive sequencing method for polysaccharides, a 
major polysaccharide structural analysis heavily depends on NMR spectroscopy. However, 
using NMR requires a strong magnetic field to evaluate carbohydrates (over 500 MHz), high 
costs of the use of a stronger magnetic field and a sensitive probe and a highly concentrated 
sample. Finally, NMR requires a high level of expertise to interpret the NMR raw data 
(Mulloy, Hart and Stanley, 2009). 
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9. Appendices 
 
9.1. Appendix I: Extraction of polysaccharides from common cockle 
 
 
  
9.2. Appendix II: Cockle polysaccharides purification using size-exclusion 
chromatography. 
 
 Cockle CE polysaccharide was attempted to be separated using size-exclusion 
chromatography coupled with high performance liquid chromatography (HPLC). This 
chromatography is based on excluding materials larger than the designated molecular weight 
for column. Superose-12 column (GE healthcare, UK) is composed of highly cross-linked 
agarose with molecular range 1-300 kDa. 100 µg of cockle CE polysaccharide sample was 
dissolved in 200 µL of 0.2 M ammonium bicarbonate buffer (mobile phase) injected to the 
system at flow rate 0.5 ml/minutes. Depending on cockle CE polysaccharides molecular 
weight, two peaks eluted from the column, the first one has high molecular weight materials 
and the second peak was a very wide peak (Figure 50). Another size-exclusion column 
coupled with HPLC system was used known as superdex-75. It is composed of cross-linked 
agarose and dextran resin with an exclusion range of 3-70 kDa. Superdex-75 column gives 
better separation properties for lower molecular weight samples. 100 ug of intact GAG 
dissolved in 200 µL 1x PBS as column mobile phase (Figure 51). All chromatographic peaks 
recorded using on-line UV detector at 280 nM.  
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Figure 50. Cockle CE polysaccharide purification using size-exclusion chromatography, 
superpose-12 column. The figure provides two peaks eluted depending on the materials 
molecular weight. Namely, high molecular weight and low molecular weight peaks. 
 
Figure 51. Cockle CE polysaccharides purification using size-exclusion chromatography, 
superdex-75 column. The figure shows only one peak. 
 
122 
 
9.3. Appendix III: Anion-exchange optimisation. 
 
Following several unsuccessful purification attempts, cockle polysaccharides were 
purified based on its charge using anion-chromatography. Anion-exchange column was 
optimised to separate cockle polysaccharides, using gradient elution profiles ranging from 0-4 
M NaCl.  
 
Figure 52. Demonstrate cockle polysaccharide elution profile using anion-exchange 
chromatography, sephacel-DEAE resin with gradient elution of 0-0.35 M NaCl. It shows 
from the first attempt that cockle CE can be purified, as figures shows about 4 peaks. 
 
 
Figure 53. Demonstrate cockle polysaccharide elution profile using anion-exchange 
chromatography, sephacel-DEAE resin with gradient elution of 0-0.5 M NaCl. It shows better 
separation of cockle CE, which need more optimisation as still some cross-peaks 
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Figure 54. Demonstrate cockle polysaccharide elution profile using anion-exchange 
chromatography, sephacel-DEAE resin with gradient elution of 0-1 M NaCl. Improved signal 
of charged materials, however, major eluted materials seems to be eluted in two peaks only. 
 
Figure 55. Demonstrate cockle polysaccharide elution profile using anion-exchange 
chromatography, sephacel-DEAE resin with gradient elution of 0-1.5 M NaCl. It has 
separated cockle CE into 6 peaks successfully. 
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Figure 56. Demonstrate cockle polysaccharide elution profile using anion-exchange 
chromatography, sephacel-DEAE resin with gradient elution of 0-2 M NaCl. It shown high 
salts has affected the elution time that resulted in poor purification.  
 
9.4. Appendix IV: Cell proliferation assay using MTS on K-562 cell line.  
 
MTS—[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt, which is a colorimetric assay that can be used to determined cell 
viability. Cockle CE polysaccharide (◼) with IC50 8.65 (µg/mL), and cockle CE treated with 
chondroitinase-ABC (▲) with IC50 10.49(µg/mL) were tested in order to check if there are 
any differences in the IC50 results between MTS and MTT. It was shown no difference in the 
activity prolife when using MTS assay on K-562 cell line (Figure 57). 
 
Figure 57. Cell proliferation assay MTS assay. 50 µg of cockle CE polysaccharides was 
incubated with K562 to check its antiproliferative activity using MTS assay. No great 
difference in IC50 values between MTT and MTS results. 
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9.5. Appendix V: Monosaccharides cell proliferation assay. 
 
500 g of cockle CE polysaccharide dissolved in 2 mL of MilliQ water, then added 
10 mL of 4M trifluoracetic acid then sample was incubated for 6 h at 100 oC. Afterwards, 
sample was cooled on room temperature, then centrifuged at 2000 rpm for 2 minutes. Next, 
Sample was concentrated by evaporation overnight. Next day, 100 l of 50% isopropanol, 
then sample concentrated again. Finally, dried sample was diluted in 2000 L cell culture 
media, in order to check the antiproliferative activity using MTT assay using K562, Molt-4 
and Mero25 cell lines. As a result, monosaccharide sample shown to be inactive on all cell 
lines (Figure 58). 
 
 
Figure 58. Cell proliferation assay of cockle monosaccharide using K562, Molt-4 and Mero-
25 cell lines.  
 
9.6. Appendix VI: Enzymes activity checks using spectrophotometer.  
 
Each heparinase activity was assessed prior use, as 100 µg of standard mammalian 
HS was dissolved in heparinases buffer then 30 mIU of each enzyme was added. The mixture 
was incubated at 30 ○C for 30 minutes and the enzymes activity were check 
spectrophotometrically at 232 nm. For chondroitinase-ABC, the enzyme was added to 
standard mammalian CS. 
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9.7. Appendix VII: α-L-fucosidase activity.  
 
Activity was checked using spectrophotometer. α-L-fucosidase activity was assessed 
prior use, as 100 µg of cockle CE polysaccharide was dissolved in fucosidase buffer then 30 
mIU of the enzyme was added. The mixture was incubated at 30 ○C for 30 minutes and the 
enzymes activity were check spectrophotometrically at 400 nm. 
 
 
9.8. Appendix VIII: Cell proliferation assay using cockle disaccharides residues from 
the 10 kDa spin filter. 
 
Cockle CE polysaccharides treated with heparinase (individually or combination), 
chondroitinase-ABC or fucosidase in order to release disaccharide chains. After incubation 
period, cockle polysaccharide samples, including CE polysaccharide (Figure 59) and fraction 
5 (Figure 60), were filtered using 10 kDa spin filter in order to separate disaccharides. As 
disaccharides passed through the filter so it’s known as flow through (FT), which was tested 
to check its antiproliferative activity. 50 µg of each FT samples antiproliferative activity was 
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assessed using K562 cell line. As a result, the FT sample, which was enriched with 
disaccharides, it was inactive.   
 
Figure 59. Antiproliferative activity of cockle CE disaccharides on K562 cell line. All 
disaccharide samples were inactive. 
 
 
 
Figure 60. Antiproliferative activity of cockle purified fraction 5 disaccharides on K562 cell 
line. All disaccharide samples were inactive. 
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9.9. Appendix IX: Cell proliferation assay using cockle CE polysaccharides treated 
with different enzymes on Molt-4 cell line.  
 
Cockle CE polysaccharides treated with heparinase (individually or combination), 
chondroitinase-ABC or fucosidase in order to release disaccharide chains. After incubation 
period, cockle polysaccharide samples, including CE polysaccharide (Figure 61) and fraction 
5 (Figure 62) were filtered using 10 kDa spin filter in order to separate disaccharides. As 
disaccharides passed through the filter so it’s known as flow through (FT), which was tested 
to check its antiproliferative activity. 50 µg of each FT samples antiproliferative activity was 
assessed using Molt-4 cell line. As a result, the FT sample, which was enriched with 
disaccharides, it was inactive.  
 
Figure 61. Antiproliferative activity of cockle CE disaccharides on Molt-4 cell line. All 
disaccharide samples were inactive. 
 
 
Figure 62. Antiproliferative activity of cockle purified fraction 5 disaccharides on Molt-4 cell 
line. All disaccharide samples were inactive. 
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9.10. Appendix X: Cell proliferation assay using cockle CE polysaccharides treated 
with different enzymes.  
 
Cockle CE polysaccharides treated with heparinase (individually or combination), 
chondroitinase-ABC or fucosidase in order to release disaccharide chains. After incubation 
period, cockle polysaccharide samples, including CE polysaccharide (Figure 63) and fraction 
5 (Figure 64), were filtered using 10 kDa spin filter in order to separate disaccharides. As 
disaccharides passed through the filter so it’s known as flow through (FT), which was tested 
to check its antiproliferative activity. 50 µg of each FT samples antiproliferative activity was 
assessed using Mero-25 cell line. As a result, the FT sample, which was enriched with 
disaccharides, it was inactive.   
 
 
Figure 63. Antiproliferative activity of cockle CE disaccharides on Mero-25 cell line. All 
disaccharide samples were inactive. 
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Figure 64. Antiproliferative activity of cockle purified fraction 5 disaccharides on Mero-25 
cell line. All disaccharide samples were inactive. 
9.11. Appendix XI: Cell proliferation assay of purified cockle polysaccharide samples 
using 10 mL fractions.  
 
Common cockle polysaccharide was eluted using gradient elution (0-3 M) NaCl and 
samples were collected in 10 mL fractions over 70 minutes (F10-F70). Afterwards, cell 
proliferation assay was performed on K562 cell line for each fraction (Figure 65). 
Surprisingly, no antiproliferative activity was determined and all fractions were inactive. 
 
Figure 65. Cell proliferation assay of CE polysaccharides purified fractions using 10 ml 
fraction of anion-exchange column. 50 µg of cockle CE polysaccharide was incubated with 
K562 cell line, which enhanced the cancer cells growth instead of inhibiting its proliferation. 
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Table 18. Cockle CE polysaccharides purification using anion-exchange column. 10 mL 
fractions were eluted using 0-3 M gradient elution of NaCl. 
Fraction number NaCl % (0-3) M IC50 Maximum drug 
concentration 50 µg/mL 
F-10 0-0.28 (3-9%) Inactive 
F-20 0.36-1.0 (12-33%) Inactive 
F-30 1.1-1.5 (33-50%) Inactive 
F-40 1.6-2.0 (50-66.6) Inactive 
F-50 2.1-2.5 (66.6-83) Inactive 
F-60 2.58-2.9 (83-96) Inactive 
F-70 2.9-3 (96-100) Inactive 
 
 
9.12. Appendix XII: HS disaccharide mass spectrum profile.  
 
HS disaccharide analysis of mammalian HS, cockle CE polysaccharides and cockle 
purified fractions (1-6) using GRIL-LC-MS.  
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9.13. Appendix XIII: CS/DS disaccharide mass spectrum profile.  
 
CS disaccharide analysis of mammalian CS, cockle CE polysaccharides and cockle 
purified fractions (1-6) using GRIL-LC-MS.  
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9.14. Appendix XIV: Monosaccharide composition analysis using HPAEC-PAD.  
 
Monosaccharide composition analysis of mammalian HS, cockle CE polysaccharide 
and cockle purified fractions using HPAEC-PAD. All peaks were referred to the 
monosaccharide standards. 
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9.15. Appendix XV: NMR figures 
 
 
Figure 66. 2D 1H-1H NMR-TOCSY for cockle purified fraction 5. The spectrum was 
recorded at 56.85 °C. 
 
 
Figure 67. 2D 1H-1H NMR-TOCSY for Mammalian HS. The spectrum was recorded at 56.85 
°C. 
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Figure 68. 2D 1H-13C NMR-HSQC for cockle purified fraction 5. The spectrum was recorded 
at 56.85 °C. 
 
 
Figure 69. 2D 1H-13C NMR-HSQC for Mammalian HS. The spectrum was recorded at 56.85 
°C. 
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Figure 70. 2D 1H-1H-NMR-COSY for mammalian HS standard. Green lines indicate possible 
spin systems found in mammalian HS. The spectra were recorded at 56.85 °C. 
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